

# Comprehensive molecular characterization of urothelial

Nature

507, 315-322

DOI: [10.1038/nature12965](https://doi.org/10.1038/nature12965)

Citation Report

#	ARTICLE	IF	CITATIONS
1	La formalisation de la GRH dans une PME comme enjeu d'une certification RSE. Revue De Gestion Des Ressources Humaines, 2012, N° 83, 20-30.	0.2	8
2	Identification of ALK Gene Alterations in Urothelial Carcinoma. PLoS ONE, 2014, 9, e103325.	2.5	9
3	MicroRNA-99a and 100 mediated upregulation of FOXA1 in bladder cancer. Oncotarget, 2014, 5, 6375-6386.	1.8	23
4	Defining intermediate-risk non-muscle-invasive bladder cancer. Nature Reviews Urology, 2014, 11, 430-432.	3.8	0
5	Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma. Cancer Discovery, 2014, 4, 1140-1153.	9.4	506
6	Insights into cancer biology through next-generation sequencing. Clinical Medicine, 2014, 14, s71-s77.	1.9	3
7	Testing the Metal of ERCC2 in Predicting the Response to Platinum-Based Therapy. Cancer Discovery, 2014, 4, 1118-1119.	9.4	1
8	Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. BMC Cancer, 2014, 14, 966.	2.6	24
9	Epigenetic inactivation of ST6GAL1 in human bladder cancer. BMC Cancer, 2014, 14, 901.	2.6	38
10	Biobank Bootstrapping: Is Biobank Sustainability Possible Through Cost Recovery?. Biopreservation and Biobanking, 2014, 12, 374-380.	1.0	40
11	Attempt at a systemic outlook on aging and carcinogenesis. Bio-Algorithms and Med-Systems, 2014, 10, 101-115.	2.4	1
12	Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder. Cancers, 2014, 6, 2313-2329.	3.7	14
13	Independent Component Analysis Uncovers the Landscape of the Bladder Tumor Transcriptome and Reveals Insights into Luminal and Basal Subtypes. Cell Reports, 2014, 9, 1235-1245.	6.4	181
14	Copy Number Analysis of 24 Oncogenes: MDM4 Identified as a Putative Marker for Low Recurrence Risk in Non Muscle Invasive Bladder Cancer. International Journal of Molecular Sciences, 2014, 15, 12458-12468.	4.1	13
15	HERC2/USP20 coordinates CHK1 activation by modulating CLASPIN stability. Nucleic Acids Research, 2014, 42, 13074-13081.	14.5	60
16	Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer. International Journal of Molecular Sciences, 2014, 15, 20500-20517.	4.1	30
17	P53 and Cancer-Associated Sialylated Glycans Are Surrogate Markers of Cancerization of the Bladder Associated with Schistosoma haematobium Infection. PLoS Neglected Tropical Diseases, 2014, 8, e3329.	3.0	30
18	Using molecular profiled human tissue to accelerate drug discovery. Expert Opinion on Drug Discovery, 2014, 9, 1383-1387.	5.0	1

#	ARTICLE	IF	CITATIONS
19	PrimPol—A new polymerase on the block. <i>Molecular and Cellular Oncology</i> , 2014, 1, e960754.	0.7	35
20	Systems biology: unlocking the complexities of disease to enhance medicine. <i>Future Medicinal Chemistry</i> , 2014, 6, 1727-1729.	2.3	0
21	Integrated Omic Analysis of Oropharyngeal Carcinomas Reveals Human Papillomavirus (HPV)-dependent Regulation of the Activator Protein 1 (AP-1) Pathway. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 3572-3584.	3.8	19
22	Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1429-1443.	2.4	1
23	Identification of Recurrent <i>FGFR3</i> - <i>TACC3</i> Fusion Oncogenes from Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 6551-6558.	7.0	85
24	Single nucleotide variations: Biological impact and theoretical interpretation. <i>Protein Science</i> , 2014, 23, 1650-1666.	7.6	94
25	MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. <i>Nature</i> , 2014, 515, 558-562.	27.8	2,109
26	Integrated Genomic Characterization of Papillary Thyroid Carcinoma. <i>Cell</i> , 2014, 159, 676-690.	28.9	2,318
27	Hypermutation in human cancer genomes: footprints and mechanisms. <i>Nature Reviews Cancer</i> , 2014, 14, 786-800.	28.4	354
28	Up-regulation of p21 <sup>WAF1/CIP1</sup> by miRNAs and its implications in bladder cancer cells. <i>FEBS Letters</i> , 2014, 588, 4654-4664.	2.8	61
29	EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. <i>Science Translational Medicine</i> , 2014, 6, 244ra91.	12.4	304
30	Non-specific filtering of beta-distributed data. <i>BMC Bioinformatics</i> , 2014, 15, 199.	2.6	15
31	High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer. <i>BMC Cancer</i> , 2014, 14, 638.	2.6	24
32	STAG2 promotes error correction in mitosis by regulating kinetochore-microtubule attachments. <i>Journal of Cell Science</i> , 2014, 127, 4225-33.	2.0	34
33	State of the Art of Genetic Alterations in Thymic Epithelial Tumors. <i>Journal of Thoracic Oncology</i> , 2014, 9, S131-S136.	1.1	60
34	Progress made in the use of animal models for the study of high-risk, nonmuscle invasive bladder cancer. <i>Current Opinion in Urology</i> , 2014, 24, 512-516.	1.8	5
35	Variant histology. <i>Current Opinion in Urology</i> , 2014, 24, 517-523.	1.8	51
36	Noncoding RNA in bladder cancer. <i>Current Opinion in Urology</i> , 2014, 24, 506-511.	1.8	12

#	ARTICLE	IF	CITATIONS
37	Targeted therapies in urothelial carcinoma. <i>Current Opinion in Oncology</i> , 2014, 26, 305-320.	2.4	40
38	Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. <i>Journal of Clinical Oncology</i> , 2014, 32, 4172-4173.	1.6	0
39	Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden. <i>Nature Communications</i> , 2014, 5, 3756.	12.8	81
40	Whole-Exome Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of <i>UNC5C</i> and Prognostic Importance of DNA Repair Gene Mutations on Survival. <i>Clinical Cancer Research</i> , 2014, 20, 6605-6617.	7.0	77
41	Discovery and Validation of Novel Expression Signature for Postcystectomy Recurrence in High-Risk Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	46
42	Structure-based predictions broadly link transcription factor mutations to gene expression changes in cancers. <i>Nucleic Acids Research</i> , 2014, 42, 12973-12983.	14.5	5
43	Genetic studies mark change in fortune for bladder cancer. <i>Nature Reviews Urology</i> , 2014, 11, 123-123.	3.8	1
44	Cohesin in cancer: chromosome segregation and beyond. <i>Nature Reviews Cancer</i> , 2014, 14, 389-393.	28.4	210
45	Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. <i>European Journal of Cancer</i> , 2014, 50, 3145-3152.	2.8	99
46	Long-Term Survival in Bone-Predominant Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e241-e244.	1.9	6
47	Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy. <i>British Journal of Cancer</i> , 2014, 111, 2103-2113.	6.4	36
48	Optimal Treatment for Metastatic Bladder Cancer. <i>Current Oncology Reports</i> , 2014, 16, 404.	4.0	32
49	Evaluation of the Prognostic Significance of Altered Mammalian Target of Rapamycin Pathway Biomarkers in Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2014, 84, 1134-1140.	1.0	18
50	Pan-cancer patterns of DNA methylation. <i>Genome Medicine</i> , 2014, 6, 66.	8.2	149
51	Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1553-1562.	4.1	15
52	Advancing clinical oncology through genome biology and technology. <i>Genome Biology</i> , 2014, 15, 427.	8.8	9
53	Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2014, 11, 400-410.	3.8	267
54	Identification of Differentially Expressed Long Noncoding RNAs in Bladder Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5311-5321.	7.0	55

#	ARTICLE	IF	CITATIONS
55	Next-generation RNA Sequencing of Archival Formalin-fixed Paraffin-embedded Urothelial Bladder Cancer. <i>European Urology</i> , 2014, 66, 982-986.	1.9	33
56	HRAS mutations are frequent in inverted urothelial neoplasms. <i>Human Pathology</i> , 2014, 45, 1957-1965.	2.0	39
57	Lean Big Data integration in systems biology and systems pharmacology. <i>Trends in Pharmacological Sciences</i> , 2014, 35, 450-460.	8.7	85
58	Multimodal management of muscle-invasive bladder cancer. <i>Current Problems in Cancer</i> , 2014, 38, 80-108.	2.0	76
59	WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 188-200.	7.4	89
60	Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. <i>Cell</i> , 2014, 158, 929-944.	28.9	1,242
61	A new tumor suppressor role for the Notch pathway in bladder cancer. <i>Nature Medicine</i> , 2014, 20, 1199-1205.	30.7	160
62	NOTch Just a Bladder Control Problem. <i>Cancer Cell</i> , 2014, 26, 452-454.	16.8	4
63	Hedgehog Signaling Restrains Bladder Cancer Progression by Eliciting Stromal Production of Urothelial Differentiation Factors. <i>Cancer Cell</i> , 2014, 26, 521-533.	16.8	164
64	A New Way of Thinking About Bladder Cancer. <i>Urology</i> , 2014, 84, 1265-1266.	1.0	0
65	Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack. <i>Biotechnology Journal</i> , 2014, 9, 1104-1114.	3.5	43
66	<i>In Vivo</i> Disruption of an Rb-E2F-Ezh2 Signaling Loop Causes Bladder Cancer. <i>Cancer Research</i> , 2014, 74, 6565-6577.	0.9	76
67	Bladder cancers arise from distinct urothelial sub-populations. <i>Nature Cell Biology</i> , 2014, 16, 982-991.	10.3	163
68	Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. <i>Human Molecular Genetics</i> , 2014, 23, 5545-5557.	2.9	46
69	Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 465-471.	2.3	14
70	Biological significance of the CpG island methylator phenotype. <i>Biochemical and Biophysical Research Communications</i> , 2014, 455, 35-42.	2.1	86
71	Where cancer genomics should go next: a clinician's perspective. <i>Human Molecular Genetics</i> , 2014, 23, R69-R75.	2.9	13
73	Squamous Cell Carcinoma of the Oral Tongue in Young Non-Smokers Is Genomically Similar to Tumors in Older Smokers. <i>Clinical Cancer Research</i> , 2014, 20, 3842-3848.	7.0	124

#	ARTICLE	IF	CITATIONS
74	Genetic landscape of esophageal squamous cell carcinoma. <i>Nature Genetics</i> , 2014, 46, 1097-1102.	21.4	600
76	Next-generation Sequencing of Urologic Cancers: Next Is Now. <i>European Urology</i> , 2014, 66, 4-7.	1.9	10
77	Treatment of muscle invasive urinary bladders tumors: A potential role of the mTOR inhibitors. <i>Biomedicine and Aging Pathology</i> , 2014, 4, 169-178.	0.8	2
78	Does the Nonurologic Scientific Community Understand Urothelial Bladder Cancer?. <i>European Urology</i> , 2014, 66, 601-602.	1.9	4
79	Crosstalk between the nucleotide excision repair and Fanconi anemia/BRCA pathways. <i>DNA Repair</i> , 2014, 19, 130-134.	2.8	27
80	Molecular Pathways: Targeting <i>NRAS</i> in Melanoma and Acute Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2014, 20, 4186-4192.	7.0	61
81	Controversies and challenges in research on urogenital schistosomiasis-associated bladder cancer. <i>Trends in Parasitology</i> , 2014, 30, 324-332.	3.3	78
82	New Insights into Subtypes of Invasive Bladder Cancer: Considerations of the Clinician. <i>European Urology</i> , 2014, 66, 609-610.	1.9	55
83	Interleukin-4 receptor alpha overexpression in human bladder cancer correlates with the pathological grade and stage of the disease. <i>Cancer Medicine</i> , 2014, 3, 1615-1628.	2.8	48
84	Quimioterapia perioperatoria en c�ncer de vejiga: m�s evidencia que realidad. <i>Urolog�a Colombiana</i> , 2015, 24, 106-112.	0.0	0
85	Vitamin D Deficiency and Increased Risk of Bladder Carcinoma: A Meta-Analysis. <i>Cellular Physiology and Biochemistry</i> , 2015, 37, 1686-1692.	1.6	27
86	MEK and PI3K inhibition in solid tumors: rationale and evidence to date. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 170-180.	3.2	105
87	HER2 as a target in invasive urothelial carcinoma. <i>Cancer Medicine</i> , 2015, 4, 844-852.	2.8	41
88	Preclinical optimization of a broad-spectrum anti-bladder cancer tri-drug regimen via the Feedback System Control (FSC) platform. <i>Scientific Reports</i> , 2015, 5, 11464.	3.3	17
89	Dysregulation of the Keap1-Nrf2 pathway in cancer. <i>Biochemical Society Transactions</i> , 2015, 43, 645-649.	3.4	72
90	Biological determinants of bladder cancer gene expression subtypes. <i>Scientific Reports</i> , 2015, 5, 10957.	3.3	102
91	Cancer type-dependent genetic interactions between cancer driver alterations indicate plasticity of epistasis across cell types. <i>Molecular Systems Biology</i> , 2015, 11, 824.	7.2	54
92	HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1061-1064.	4.9	70

#	ARTICLE	IF	CITATIONS
93	Next-Generation Sequencing and In Silico Analysis Facilitate Prolonged Response to Pazopanib in a Patient With Metastatic Urothelial Carcinoma of the Renal Pelvis. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1181-1185.	4.9	7
94	Management of muscle-invasive bladder cancer in the elderly. Current Opinion in Urology, 2015, 25, 459-467.	1.8	14
95	The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer. European Urology Focus, 2015, 1, 94-95.	3.1	7
96	Bioinformatics analysis of thousands of TCGA tumors to determine the involvement of epigenetic regulators in human cancer. BMC Genomics, 2015, 16, S5.	2.8	29
97	Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro. BMC Cancer, 2015, 15, 927.	2.6	14
98	Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines. Journal of Experimental and Clinical Cancer Research, 2015, 34, 144.	8.6	27
99	Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer. Biology Direct, 2015, 10, 57.	4.6	64
100	Comprehensive data resources and analytical tools for pathological association of aminoacyl tRNA synthetases with cancer. Database: the Journal of Biological Databases and Curation, 2015, 2015, bav022-bav022.	3.0	4
101	A clinical and molecular review of inverted papilloma of the urinary tract: how to handle?. Apmis, 2015, 123, 920-929.	2.0	3
102	Oncogenes and tumor suppressor genes: comparative genomics and network perspectives. BMC Genomics, 2015, 16, S8.	2.8	41
103	Determining the origin of synchronous multifocal bladder cancer by exome sequencing. BMC Cancer, 2015, 15, 871.	2.6	17
104	Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients. Journal of Negative Results in BioMedicine, 2015, 14, 18.	1.4	2
105	Complexity of FGFR signalling in metastatic urothelial cancer. Journal of Hematology and Oncology, 2015, 8, 119.	17.0	28
106	Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer. Histopathology, 2015, 66, 639-649.	2.9	38
107	Toward Personalized Guidelines in Bladder Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1458-1460.	4.9	1
108	Options in metastatic urothelial cancer after first-line therapy. Current Opinion in Supportive and Palliative Care, 2015, 9, 255-260.	1.3	3
109	Genetic subtypes of invasive bladder cancer. Current Opinion in Urology, 2015, 25, 449-458.	1.8	35
110	Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer—Evidence for a Relevant Model System and Urine-Based Diagnostic Test. Molecular Cancer Research, 2015, 13, 993-1002.	3.4	117

#	ARTICLE	IF	CITATIONS
111	Mutations in <scp><i>TERT</i></scp> promoter and <scp><i>FGFR3</i></scp> and telomere length in bladder cancer. International Journal of Cancer, 2015, 137, 1621-1629.	5.1	81
112	The role of WNT signalling in urothelial cell carcinoma. Annals of the Royal College of Surgeons of England, 2015, 97, 481-486.	0.6	7
113	The Prognostic Value of Cell Cycle Gene Expression Signatures in Muscle Invasive, High-Grade Bladder Cancer. Bladder Cancer, 2015, 1, 45-63.	0.4	7
114	Reverse phase protein arrays in signaling pathways: a data integration perspective. Drug Design, Development and Therapy, 2015, 9, 3519.	4.3	40
115	Truncated Isoforms of lncRNA ANRIL Are Overexpressed in Bladder Cancer, But Do Not Contribute to Repression of INK4 Tumor Suppressors. Non-coding RNA, 2015, 1, 266-284.	2.6	20
116	TACC3 promotes stemness and is a potential therapeutic target in hepatocellular carcinoma. Oncotarget, 2015, 6, 24163-24177.	1.8	54
117	New and Promising Strategies in the Management of Bladder Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 105-112.	3.8	20
118	Clinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder. Journal of Korean Medical Science, 2015, 30, 1068.	2.5	21
119	Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma. Oncotarget, 2015, 6, 13539-13549.	1.8	64
120	Protein Interactome of Muscle Invasive Bladder Cancer. PLoS ONE, 2015, 10, e0116404.	2.5	12
121	Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Wspolczesna Onkologia, 2015, 1A, 68-77.	1.4	2,410
122	Comparison of the Prognostic Utility of the Diverse Molecular Data among lncRNA, DNA Methylation, microRNA, and mRNA across Five Human Cancers. PLoS ONE, 2015, 10, e0142433.	2.5	14
123	A Pan-Cancer Catalogue of Cancer Driver Protein Interaction Interfaces. PLoS Computational Biology, 2015, 11, e1004518.	3.2	122
124	Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma. PLoS ONE, 2015, 10, e0131245.	2.5	42
125	Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. PLoS ONE, 2015, 10, e0134346.	2.5	72
126	Comparative Gene Expression Analyses Identify Luminal and Basal Subtypes of Canine Invasive Urothelial Carcinoma That Mimic Patterns in Human Invasive Bladder Cancer. PLoS ONE, 2015, 10, e0136688.	2.5	56
127	Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets. Current Genomics, 2015, 17, 33-61.	1.6	3
128	Bladder cancer in the elderly patient: challenges and solutions. Clinical Interventions in Aging, 2015, 10, 939.	2.9	44



#	ARTICLE	IF	CITATIONS
129	Urothelial Superior Vena Cava Syndrome with Limited Response to Radiation Therapy. Case Reports in Oncological Medicine, 2015, 2015, 1-4.	0.3	0
130	A New Double Stranded RNA Suppresses Bladder Cancer Development by Upregulating p21 <sup>Waf1/CIP1</sup> Expression. BioMed Research International, 2015, 2015, 1-13.	1.9	7
131	Evolving Immunotherapy Strategies in Urothelial Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e284-e290.	3.8	3
132	The emerging complexity of gene fusions in cancer. Nature Reviews Cancer, 2015, 15, 371-381.	28.4	544
133	MicroRNA expression profiles in muscle-invasive bladder cancer: identification of a four-microRNA signature associated with patient survival. Tumor Biology, 2015, 36, 8159-8166.	1.8	24
134	NOTCH pathway inactivation promotes bladder cancer progression. Journal of Clinical Investigation, 2015, 125, 824-830.	8.2	86
135	Oncotator: Cancer Variant Annotation Tool. Human Mutation, 2015, 36, E2423-E2429.	2.5	448
136	Primary Sarcomatoid Tumor of the Bladder: A Different Entity but the Same Approach?. Clinical Genitourinary Cancer, 2015, 13, 493-498.	1.9	7
138	Molecular Biology of Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 191-203.	2.2	30
139	Potential Role for Targeted Therapy in Muscle-Invasive Bladder Cancer. Urologic Clinics of North America, 2015, 42, 201-215.	1.8	30
140	Identification of Novel Gene Targets and Putative Regulators of Arsenic-Associated DNA Methylation in Human Urothelial Cells and Bladder Cancer. Chemical Research in Toxicology, 2015, 28, 1144-1155.	3.3	26
141	Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. Molecular Cancer Therapeutics, 2015, 14, 1224-1235.	4.1	74
142	Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations. Cytokine and Growth Factor Reviews, 2015, 26, 425-449.	7.2	125
144	Progress of cancer genomics. Thoracic Cancer, 2015, 6, 557-560.	1.9	1
145	Feasibility of implementing molecularly-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma. Cancer Medicine, 2015, 4, 871-886.	2.8	26
146	Docetaxel for the treatment of bladder cancer. Expert Opinion on Investigational Drugs, 2015, 24, 1657-1664.	4.1	13
147	Primase-polymerases are a functionally diverse superfamily of replication and repair enzymes. Nucleic Acids Research, 2015, 43, 6651-6664.	14.5	79
148	Checkpoint inhibitors in bladder and renal cancers: results and perspectives. Immunotherapy, 2015, 7, 1259-1271.	2.0	22

#	ARTICLE	IF	CITATIONS
149	Why Does Infection With Some Helminths Cause Cancer?. Trends in Cancer, 2015, 1, 174-182.	7.4	104
150	Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers. Molecular and Cellular Oncology, 2015, 2, e999507.	0.7	1
151	Elevated RNA Editing Activity Is a Major Contributor to Transcriptomic Diversity in Tumors. Cell Reports, 2015, 13, 267-276.	6.4	262
152	Thyroid genomics: refining diagnosis, prognosis and treatment. International Journal of Endocrine Oncology, 2015, 2, 105-107.	0.4	0
153	Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma. Clinical Genitourinary Cancer, 2015, 13, 302-308.	1.9	6
154	CXCL5/CXCR2 axis promotes bladder cancer cell migration and invasion by activating PI3K/AKT-induced upregulation of MMP2/MMP9. International Journal of Oncology, 2015, 47, 690-700.	3.3	109
155	Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09). Oncology, 2015, 89, 70-78.	1.9	26
156	The Molecular Background of Urothelial Cancer: Ready for Action?. European Urology, 2015, 67, 202-203.	1.9	5
157	Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder. European Urology, 2015, 67, 198-201.	1.9	122
158	Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. European Journal of Cancer, 2015, 51, 45-54.	2.8	131
159	Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomena. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140042.	4.0	46
160	Molecular Profiling of Infiltrating Urothelial Carcinoma of Bladder and Nonbladder Origin. Clinical Genitourinary Cancer, 2015, 13, e37-e49.	1.9	56
161	Re: Bacillus Calmette-Guérin Strain Differences Have an Impact on Clinical Outcome in Bladder Cancer Immunotherapy. European Urology, 2015, 67, 351.	1.9	0
162	Re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New Insights into Subtypes of Invasive Bladder Cancer: Considerations of the Clinician. Eur Urol 2014;66:609-10. European Urology, 2015, 67, e73-e75.	1.9	4
163	From the genomic frontier to immunotherapeutics. Nature Reviews Urology, 2015, 12, 74-76.	3.8	4
164	Re: Whole-genome and Whole-exome Sequencing of Bladder Cancer Identifies Frequent Alterations in Genes Involved in Sister Chromatid Cohesion and Segregation. European Urology, 2015, 67, 350-351.	1.9	3
165	Reply to Mattias Aine, Fredrik Liedberg, Gottfrid Sjöndahl, and Mattias Håkglund's Letter to the Editor re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New Insights into Subtypes of Invasive Bladder Cancer: Considerations of the Clinician. Eur Urol 2014;66:609-10. European Urology, 2015, 67, e76-e78.	1.9	3
166	Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma. Clinical Genitourinary Cancer, 2015, 13, 185-192.	1.9	2

#	ARTICLE	IF	CITATIONS
167	Emerging therapeutic targets in bladder cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 170-178.	7.7	108
168	Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. <i>Annals of Oncology</i> , 2015, 26, 812-817.	1.2	246
169	Detection, Characterization, and Inhibition of FGFR&TACC Fusions in IDH Wild-type Glioma. <i>Clinical Cancer Research</i> , 2015, 21, 3307-3317.	7.0	230
170	Novel genotype-phenotype associations in human cancers enabled by advanced molecular platforms and computational analysis of whole slide images. <i>Laboratory Investigation</i> , 2015, 95, 366-376.	3.7	54
171	Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 297-311.	2.8	43
172	Whole-Exome Sequencing Studies of Parathyroid Carcinomas Reveal Novel<i>PRUNE2</i>Mutations, Distinctive Mutational Spectra Related to APOBEC-Catalyzed DNA Mutagenesis and Mutational Enrichment in Kinases Associated With Cell Migration and Invasion. <i>Journal of Clinical Endocrinology and Metabolism</i> . 2015. 100. E360-E364.	3.6	86
173	To be an ally or an adversary in bladder cancer: the NF-ÎB story has not unfolded. <i>Carcinogenesis</i> , 2015, 36, 299-306.	2.8	31
174	Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3&BAIAP2L1. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 704-712.	4.1	45
175	The Role of Genomics in the Management of Advanced Bladder Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 319.	3.0	10
176	Therapeutic opportunities within the DNA damage response. <i>Nature Reviews Cancer</i> , 2015, 15, 166-180.	28.4	442
177	The lncRNA <i>DRAIC</i>/<i>PCAT29</i> Locus Constitutes a Tumor-Suppressive Nexus. <i>Molecular Cancer Research</i> , 2015, 13, 828-838.	3.4	119
178	Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. <i>International Urology and Nephrology</i> , 2015, 47, 87-94.	1.4	75
179	Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , 2015, 161, 1681-1696.	28.9	2,562
180	Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer. <i>Journal of Urology</i> , 2015, 194, 1120-1131.	0.4	64
181	Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway. <i>Clinical Cancer Research</i> , 2015, 21, 5360-5370.	7.0	68
182	Correlating Bladder Cancer Risk Genes with Their Targeting MicroRNAs Using MmiRNA-Tar. <i>Genomics, Proteomics and Bioinformatics</i> , 2015, 13, 177-182.	6.9	8
183	Salvage Systemic Therapy for Advanced Urothelial Carcinoma: On the Cusp of a Sea Change?. <i>Oncologist</i> , 2015, 20, 461-463.	3.7	4
184	Radiotherapy in the Era of Precision Medicine. <i>Seminars in Radiation Oncology</i> , 2015, 25, 227-236.	2.2	29

#	ARTICLE	IF	CITATIONS
185	Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2015, 68, 959-967.	1.9	395
186	New advances in genitourinary cancer: evidence gathered in 2014. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 443-464.	5.9	4
187	On Molecular Classification of Bladder Cancer: Out of One, Many. <i>European Urology</i> , 2015, 68, 921-923.	1.9	47
188	Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 479-496.	5.9	101
189	Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 204.e1-204.e7.	1.6	34
190	Pretreatment lymphocyte-monocyte ratio as a potential prognostic factor in a cohort of patients with upper tract urothelial carcinoma. <i>Journal of Clinical Pathology</i> , 2015, 68, 351-355.	2.0	38
191	Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma. <i>Cancer Treatment Reviews</i> , 2015, 41, 699-706.	7.7	14
192	Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation. <i>Scientific Reports</i> , 2015, 5, 8293.	3.3	106
193	Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder. <i>British Journal of Cancer</i> , 2015, 112, 1626-1635.	6.4	27
194	Cytotoxic and DNA-targeted therapy in urothelial cancer: Have we squeezed the lemon enough?. <i>Cancer</i> , 2015, 121, 179-187.	4.1	12
195	Emerging antibody-based therapeutic strategies for bladder cancer: A systematic review. <i>Journal of Controlled Release</i> , 2015, 214, 40-61.	9.9	28
196	An overview of new biomolecular pathways in pathogen-related cancers. <i>Future Oncology</i> , 2015, 11, 1625-1639.	2.4	12
197	The ssDNA Mutator APOBEC3A Is Regulated by Cooperative Dimerization. <i>Structure</i> , 2015, 23, 903-911.	3.3	79
198	The cancer COMPASS: navigating the functions of MLL complexes in cancer. <i>Cancer Genetics</i> , 2015, 208, 178-191.	0.4	122
199	Human ortholog of <i>Drosophila</i> Melted impedes SMAD2 release from TGF- $\beta$ 2 receptor I to inhibit TGF- $\beta$ 2 signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E3000-9.	7.1	20
200	Recurrent CDKN1B (p27) mutations in hairy cell leukemia. <i>Blood</i> , 2015, 126, 1005-1008.	1.4	88
201	Targeting FGFR Signaling in Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2684-2694.	7.0	399
202	Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors. <i>Molecular Cancer Research</i> , 2015, 13, 1306-1315.	3.4	24

#	ARTICLE	IF	CITATIONS
203	APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. <i>Cancer Discovery</i> , 2015, 5, 704-712.	9.4	392
204	Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. <i>Free Radical Biology and Medicine</i> , 2015, 88, 108-146.	2.9	661
205	Prospective Comprehensive Genomic Profiling of Advanced Gastric Carcinoma Cases Reveals Frequent Clinically Relevant Genomic Alterations and New Routes for Targeted Therapies. <i>Oncologist</i> , 2015, 20, 499-507.	3.7	64
206	Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer. <i>American Journal of Pathology</i> , 2015, 185, 1385-1395.	3.8	60
207	Zinc transporter genes and urological cancers: integrated analysis suggests a role for ZIP11 in bladder cancer. <i>Tumor Biology</i> , 2015, 36, 7431-7437.	1.8	22
208	Somatic structural variation and cancer. <i>Briefings in Functional Genomics</i> , 2015, 14, 339-351.	2.7	26
209	Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer. <i>Urologic Clinics of North America</i> , 2015, 42, 217-224.	1.8	9
210	Epidemiology of Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 177-189.	2.2	138
211	Second-Line Therapies in Metastatic Urothelial Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 341-359.	2.2	11
212	Targeted Therapy in Advanced Bladder Cancer. <i>Urologic Clinics of North America</i> , 2015, 42, 253-262.	1.8	14
213	First-Line Treatment and Prognostic Factors of Metastatic Bladder Cancer for Platinum-Eligible Patients. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 319-328.	2.2	21
214	Neoadjuvant Chemotherapy in the Management of Muscle-Invasive Bladder Cancer. <i>Urologic Clinics of North America</i> , 2015, 42, 181-187.	1.8	7
215	Pan-cancer transcriptome analysis reveals long noncoding RNAs with conserved function. <i>RNA Biology</i> , 2015, 12, 628-642.	3.1	85
216	Effects of omics data combinations on in silico tumor-normal tissue classification. <i>Genes and Genomics</i> , 2015, 37, 525-535.	1.4	1
218	DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. <i>BMC Cancer</i> , 2015, 15, 242.	2.6	25
219	Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 8.	5.0	82
220	Integrative epigenomic analysis of differential DNA methylation in urothelial carcinoma. <i>Genome Medicine</i> , 2015, 7, 23.	8.2	42
221	The next steps in next-gen sequencing of cancer genomes. <i>Journal of Clinical Investigation</i> , 2015, 125, 462-468.	8.2	34

#	ARTICLE	IF	CITATIONS
222	Molecular Pathology Informatics. Surgical Pathology Clinics, 2015, 8, 187-194.	1.7	6
224	Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas. Cancer Research, 2015, 75, 2017-2028.	0.9	27
225	The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer. Cancer Genetics, 2015, 208, 206-214.	0.4	48
226	The development of immunotherapy in urothelial bladder cancer. Nature Reviews Clinical Oncology, 2015, 12, 193-194.	27.6	8
227	Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2015, 13, 410-420.	1.9	17
228	A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma. European Urology, 2015, 68, 824-832.	1.9	111
229	Applications of NGS to Screen FFPE Tumours for Detecting Fusion Transcripts. , 2015, , 155-177.		0
230	Molecular pathogenesis of ovarian clear cell carcinoma. Future Oncology, 2015, 11, 1389-1405.	2.4	26
231	Phosphotyrosine Signaling Analysis in Human Tumors Is Confounded by Systemic Ischemia-Driven Artifacts and Intra-Specimen Heterogeneity. Cancer Research, 2015, 75, 1495-1503.	0.9	42
233	Prognostic Factors in Urothelial Carcinoma of the Bladder. Advances in Anatomic Pathology, 2015, 22, 102-112.	4.3	21
234	Molecular biology and targeted therapies for urothelial carcinoma. Cancer Treatment Reviews, 2015, 41, 341-353.	7.7	43
235	Transformation Assay in Bhas 42 Cells: A Model Using Initiated Cells to Study Mechanisms of Carcinogenesis and Predict Carcinogenic Potential of Chemicals. Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews, 2015, 33, 1-35.	2.9	20
236	1 $\alpha$ ,25(OH)2D3 differentially regulates miRNA expression in human bladder cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2015, 148, 166-171.	2.5	23
237	Novel molecular targets for urothelial carcinoma. Expert Opinion on Therapeutic Targets, 2015, 19, 515-525.	3.4	7
238	Canine urothelial carcinoma: genomically aberrant and comparatively relevant. Chromosome Research, 2015, 23, 311-331.	2.2	52
239	Synergy of Histone-Deacetylase Inhibitor AR-42 with Cisplatin in Bladder Cancer. Journal of Urology, 2015, 194, 547-555.	0.4	25
240	First-line Treatment of Metastatic Disease. Hematology/Oncology Clinics of North America, 2015, 29, 329-340.	2.2	10
241	Therapeutic Opportunities in the Intrinsic Subtypes of Muscle-Invasive Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 377-394.	2.2	57

#	ARTICLE	IF	CITATIONS
243	Opportunities to improve clinical trial design in urothelial bladder cancer. <i>Clinical Research and Regulatory Affairs</i> , 2015, 32, 61-69.	2.1	0
244	Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors. <i>Seminars in Oncology</i> , 2015, 42, 801-819.	2.2	75
245	Targeted therapies in bladder cancer: an overview of in vivo research. <i>Nature Reviews Urology</i> , 2015, 12, 681-694.	3.8	63
246	Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems. <i>BMC Medical Genomics</i> , 2015, 8, 25.	1.5	58
247	3-BrPA eliminates human bladder cancer cells with highly oncogenic signatures via engagement of specific death programs and perturbation of multiple signaling and metabolic determinants. <i>Molecular Cancer</i> , 2015, 14, 135.	19.2	32
248	Targeting epigenetic regulations in cancer. <i>Acta Biochimica Et Biophysica Sinica</i> , 2016, 48, 97-109.	2.0	60
249	A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis. <i>Cancer Research</i> , 2015, 75, 4042-4052.	0.9	96
250	An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. <i>Nature Genetics</i> , 2015, 47, 1067-1072.	21.4	354
251	Pan-cancer stratification of solid human epithelial tumors and cancer cell lines reveals commonalities and tissue-specific features of the CpG island methylator phenotype. <i>Epigenetics and Chromatin</i> , 2015, 8, 14.	3.9	42
252	Mutation signatures implicate aristolochic acid in bladder cancer development. <i>Genome Medicine</i> , 2015, 7, 38.	8.2	87
253	Urothelial Cancer With Occult Bone Marrow Metastases and Isolated Thrombocytopenia. <i>Urology Case Reports</i> , 2015, 3, 98-100.	0.3	2
254	Targeting Signaling Transduction Pathways in Bladder Cancer. <i>Current Oncology Reports</i> , 2015, 17, 58.	4.0	37
255	ATDC/TRIM29 Drives Invasive Bladder Cancer Formation through miRNA-Mediated and Epigenetic Mechanisms. <i>Cancer Research</i> , 2015, 75, 5155-5166.	0.9	59
256	Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise. <i>Clinical Cancer Research</i> , 2015, 21, 4514-4524.	7.0	110
257	Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. <i>Annals of Oncology</i> , 2015, 26, 2367-2374.	1.2	40
258	Assess the expression of ubiquitin specific protease USP2a for bladder cancer diagnosis. <i>BMC Urology</i> , 2015, 15, 80.	1.4	12
259	Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 487-495.	2.8	53
260	Limited evidence that cancer susceptibility regions are preferential targets for somatic mutation. <i>Genome Biology</i> , 2015, 16, 193.	8.8	19



#	ARTICLE	IF	CITATIONS
261	Urothelial cancer gene regulatory networks inferred from large-scale RNAseq, Bead and Oligo gene expression data. BMC Systems Biology, 2015, 9, 21.	3.0	11
262	Muscle-invasive urothelial bladder cancer: an update on systemic therapy. Therapeutic Advances in Urology, 2015, 7, 312-330.	2.0	34
263	Patterns of Chromosomal Aberrations in Solid Tumors. Recent Results in Cancer Research, 2015, 200, 115-142.	1.8	44
265	Reprint of "Abstraction for data integration: Fusing mammalian molecular, cellular and phenotype big datasets for better knowledge extraction" Computational Biology and Chemistry, 2015, 59, 123-138.	2.3	14
266	Urothelial carcinoma with squamous differentiation" The pathologists' perspective. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 437-443.	1.6	20
267	Bridging the Gap in Upper Tract Urothelial Carcinoma. European Urology, 2015, 68, 978-979.	1.9	4
268	The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches. Seminars in Cancer Biology, 2015, 35, 125-132.	9.6	20
269	Genomic Characterization of Upper Tract Urothelial Carcinoma. European Urology, 2015, 68, 970-977.	1.9	202
270	Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 426.e21-426.e29.	1.6	5
271	Immunoprofile-based subgrouping of urothelial bladder carcinomas for survival prediction. Human Pathology, 2015, 46, 1464-1470.	2.0	9
272	Do Circulating Tumor Cells Have a Role in Deciding on Adjuvant Chemotherapy After Radical Cystectomy?. Current Urology Reports, 2015, 16, 46.	2.2	14
273	An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancer. Genome Biology, 2015, 16, 140.	8.8	60
274	The emerging role of the androgen receptor in bladder cancer. Endocrine-Related Cancer, 2015, 22, R265-R277.	3.1	55
275	Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nature Genetics, 2015, 47, 1168-1178.	21.4	1,491
276	Molecular mechanisms of squamous differentiation in urothelial cell carcinoma: A paradigm for molecular subtyping of urothelial cell carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 444-450.	1.6	15
277	Development of Fibroblast Growth Factor Receptor Inhibitors: Kissing Frogs to Find a Prince?. Journal of Clinical Oncology, 2015, 33, 3372-3374.	1.6	12
278	Genetically altered cancer epigenome. , 2015, , 265-289.		1
279	Morphologic and Molecular Characteristics of Bladder Cancer. Surgical Pathology Clinics, 2015, 8, 663-676.	1.7	8



#	ARTICLE	IF	CITATIONS
280	Three Genes to Predict Response to Chemotherapy for Bladder Cancer: Individualised Cancer Care at the Doorstep. <i>European Urology</i> , 2015, 68, 968-969.	1.9	3
281	Invasive urothelial carcinoma exhibiting basal cell immunohistochemical markers: A variant of urothelial carcinoma associated with aggressive features. <i>Pathology Research and Practice</i> , 2015, 211, 610-618.	2.3	11
282	The Cancer Genome Atlas Clinical Explorer: a web and mobile interface for identifying clinicalâ€“genomic driver associations. <i>Genome Medicine</i> , 2015, 7, 112.	8.2	80
283	The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. <i>BMC Genomics</i> , 2015, 16, 403.	2.8	86
284	Future Directions and Targeted Therapies in Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 361-376.	2.2	22
285	Modelling bladder cancer in mice: opportunities and challenges. <i>Nature Reviews Cancer</i> , 2015, 15, 42-54.	28.4	114
286	Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. <i>Nature Reviews Cancer</i> , 2015, 15, 25-41.	28.4	928
287	Targeted Therapies for Metastatic Bladder Cancer. <i>Journal of Urology</i> , 2015, 193, 8-9.	0.4	4
288	Antitumor mechanisms when pRb and p53 are genetically inactivated. <i>Oncogene</i> , 2015, 34, 4547-4557.	5.9	30
289	The Role of EGFR Family Inhibitors in Muscle Invasive Bladder Cancer: A Review of Clinical Data and Molecular Evidence. <i>Journal of Urology</i> , 2015, 193, 19-29.	0.4	64
290	Combined CDKN1A/TP53 Mutation in Bladder Cancer Is a Therapeutic Target. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 174-182.	4.1	28
291	Cancer Stem Cell Division: When the Rules of Asymmetry Are Broken. <i>Stem Cells and Development</i> , 2015, 24, 405-416.	2.1	58
292	Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer. <i>Gut</i> , 2015, 64, 636-645.	12.1	163
293	Comparison of gene expression patterns across 12 tumor types identifies a cancer supercluster characterized by TP53 mutations and cell cycle defects. <i>Oncogene</i> , 2015, 34, 2732-2740.	5.9	46
294	Toward an integrated pipeline for protein biomarker development. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 677-686.	2.3	56
295	Genomic characterization of high-risk non-muscle invasive bladder cancer. <i>Oncotarget</i> , 2016, 7, 75176-75184.	1.8	64
296	<i>FGFR3-TACC3</i> fusion in solid tumors: mini review. <i>Oncotarget</i> , 2016, 7, 55924-55938.	1.8	103
297	Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma. <i>Bladder Cancer</i> , 2016, 2, 111-117.	0.4	8

#	ARTICLE	IF	CITATIONS
298	Liquid biopsies in bladder cancer—did we find the Holy Grail for biomarker analyses?. <i>Translational Andrology and Urology</i> , 2016, 5, 980-983.	1.4	8
299	Mutations and expression of the NFE2L2/KEAP1/CUL3 pathway in Chinese patients with lung squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2016, 8, 1639-1644.	1.4	13
300	Beyond Cisplatin — I. <i>Bladder Cancer</i> , 2016, 2, 365-367.	0.4	0
301	Genetic and Epigenetic Alterations in Bladder Cancer. <i>International Neurourology Journal</i> , 2016, 20, S84-94.	1.2	49
302	Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression. <i>Bladder Cancer</i> , 2016, 2, 127-137.	0.4	44
303	Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy. <i>Bladder Cancer</i> , 2016, 2, 101-109.	0.4	31
304	Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence. <i>Oncotarget</i> , 2016, 7, 14153-14160.	1.8	43
305	Mutations of Chromatin Structure Regulating Genes in Human Malignancies. <i>Current Protein and Peptide Science</i> , 2016, 17, 411-437.	1.4	25
306	Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank. <i>Bladder Cancer</i> , 2016, 2, 203-213.	0.4	3
307	High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model. <i>Oncotarget</i> , 2016, 7, 9102-9117.	1.8	24
308	A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma. <i>Bladder Cancer</i> , 2016, 2, 241-250.	0.4	34
309	The Cellular Response to Oxidatively Induced DNA Damage and Polymorphism of Some DNA Repair Genes Associated with Clinicopathological Features of Bladder Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-13.	4.0	14
310	Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3305-3322.	4.3	26
311	The role of microRNAs in bladder cancer. <i>Investigative and Clinical Urology</i> , 2016, 57, S60.	2.0	75
312	Effectiveness of capecitabine with or without docetaxel therapy for the treatment of patients with advanced urothelial carcinoma: a single-institution experience. <i>Oncotarget</i> , 2016, 7, 63722-63729.	1.8	2
313	Stem Cells, Biomarkers and Genetic Profiling: Approaching Future Challenges in Urology. <i>Urologia</i> , 2016, 83, 4-13.	0.7	18
314	Using Copy Number Alterations to Identify New Therapeutic Targets for Bladder Carcinoma. <i>International Journal of Molecular Sciences</i> , 2016, 17, 271.	4.1	9
315	Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 15-25.	0.4	29

#	ARTICLE	IF	CITATIONS
316	Î <sup>125</sup> I-NP63 induces the expression of FAT2 and Slug to promote tumor invasion. <i>Oncotarget</i> , 2016, 7, 28592-28611.	1.8	49
317	The State of Immune Checkpoint Inhibition in Urothelial Carcinoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 96-100.	2.0	5
318	Spectrum of genomic alterations in <i>FGFR3</i> : current appraisal of the potential role of <i>FGFR3</i> in advanced urothelial carcinoma. <i>BJU International</i> , 2016, 118, 681-691.	2.5	15
319	Pharmacogenetic characterization of naturally occurring germline NT5C1A variants to chemotherapeutic nucleoside analogs. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 271-279.	1.5	1
320	Molecular Subtypes of Non-muscle Invasive Bladder Cancer. <i>Cancer Cell</i> , 2016, 30, 1-3.	16.8	20
321	Comprehensive mutation profiling of mucinous gastric carcinoma. <i>Journal of Pathology</i> , 2016, 240, 137-148.	4.5	32
322	Noninvasive Papillary Basal-like Urothelial Carcinoma: A Subgroup of Urothelial Carcinomas With Immunohistochemical Features of Basal Urothelial Cells Associated With a High Rate of Recurrence and Progression. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016, 24, 575-582.	1.2	5
323	Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. <i>Clinical Cancer Research</i> , 2016, 22, 4309-4321.	7.0	182
324	Genetic and epigenetic alterations of microRNAs and implications for human cancers and other diseases. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 193-214.	2.8	52
325	MicroRNA expression profiling in bladder cancer: the challenge of next-generation sequencing in tissues and biofluids. <i>International Journal of Cancer</i> , 2016, 138, 2334-2345.	5.1	55
326	Key signaling pathways in the muscle-invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment. <i>International Journal of Cancer</i> , 2016, 138, 2562-2569.	5.1	34
327	Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. <i>Cancer</i> , 2016, 122, 702-711.	4.1	81
328	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1213-1224.	4.9	93
330	SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016). <i>Clinical and Translational Oncology</i> , 2016, 18, 1197-1205.	2.4	10
331	Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia. <i>Genome Biology</i> , 2016, 17, 140.	8.8	67
332	Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types. <i>BMC Genomics</i> , 2016, 17, 394.	2.8	28
334	PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma. <i>BMC Cancer</i> , 2016, 16, 553.	2.6	25
335	Divergent viral presentation among human tumors and adjacent normal tissues. <i>Scientific Reports</i> , 2016, 6, 28294.	3.3	60

#	ARTICLE	IF	CITATIONS
336	FOXA1, GATA3 and PPAR $\gamma$ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines. Scientific Reports, 2016, 6, 38531.	3.3	112
337	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	4.5	82
338	Insights into the role of NRF2 in cancer provided by cancer genomics. Current Opinion in Toxicology, 2016, 1, 111-117.	5.0	18
339	Integrative modelling of tumour DNA methylation quantifies the contribution of metabolism. Nature Communications, 2016, 7, 13666.	12.8	37
340	MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated. Nature Communications, 2016, 7, 13701.	12.8	36
341	Genitourinary tumours in the targeted therapies era. Anti-Cancer Drugs, 2016, 27, 917-943.	1.4	8
345	Elevated preoperative plasma fibrinogen level is an independent predictor of malignancy and advanced stage disease in patients with bladder urothelial tumors. International Journal of Surgery, 2016, 36, 249-254.	2.7	11
346	The <i>cis</i> -regulatory switchboard of pancreatic ductal cancer. EMBO Journal, 2016, 35, 558-560.	7.8	2
347	Development of target specific agents for bladder cancer. Expert Review of Precision Medicine and Drug Development, 2016, 1, 361-368.	0.7	1
348	The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. OncoImmunology, 2016, 5, e1134412.	4.6	135
349	A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 681-691.	4.4	46
350	Transforming Growth Factor- $\beta$ 2 Is an Upstream Regulator of Mammalian Target of Rapamycin Complex 2-Dependent Bladder Cancer Cell Migration and Invasion. American Journal of Pathology, 2016, 186, 1351-1360.	3.8	33
351	Dysregulated FGF signalling in neoplastic disorders. Seminars in Cell and Developmental Biology, 2016, 53, 126-135.	5.0	69
352	mTOR inhibitors in urinary bladder cancer. Tumor Biology, 2016, 37, 11541-11551.	1.8	23
353	Integrated analysis of multidimensional omics data on cutaneous melanoma prognosis. Genomics, 2016, 107, 223-230.	2.9	57
354	Biased Expression of the FOXP3 <sup>hi</sup> 3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance. Clinical Cancer Research, 2016, 22, 5349-5361.	7.0	21
355	Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy. BioDrugs, 2016, 30, 263-273.	4.6	22
356	Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunology Research, 2016, 4, 563-568.	3.4	293

#	ARTICLE	IF	CITATIONS
357	Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report. Journal of Medical Case Reports, 2016, 10, 98.	0.8	3
358	Urothelial carcinoma management in elderly or unfit patients. European Journal of Cancer, Supplement, 2016, 14, 1-20.	2.2	45
359	Cohesin mutations in human cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 1-11.	7.4	101
360	Parsing Multi-omic Data to Understand Urothelial Cell Carcinoma Progression. Journal of Urology, 2016, 195, 1645-1645.	0.4	0
361	Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With <i>ERBB</i> Alterations. Journal of Clinical Oncology, 2016, 34, 2165-2171.	1.6	134
362	Systemic therapy for metastatic bladder cancer in 2016 and beyond. Future Oncology, 2016, 12, 1179-1192.	2.4	5
363	Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. European Urology, 2016, 70, 611-620.	1.9	120
364	Targeted p53 activation by saRNA suppresses human bladder cancer cells growth and metastasis. Journal of Experimental and Clinical Cancer Research, 2016, 35, 53.	8.6	29
365	The Conundrum of Genetic "Drivers" in Benign Conditions. Journal of the National Cancer Institute, 2016, 108, djw036.	6.3	113
366	Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. Annals of Oncology, 2016, 27, 1311-1316.	1.2	49
367	Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nature Genetics, 2016, 48, 607-616.	21.4	933
368	Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. Immunotherapy, 2016, 8, 583-600.	2.0	71
369	Analyzing Somatic Genome Rearrangements in Human Cancers by Using Whole-Exome Sequencing. American Journal of Human Genetics, 2016, 98, 843-856.	6.2	33
370	Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nature Genetics, 2016, 48, 600-606.	21.4	352
371	Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles. Nature Medicine, 2016, 22, 685-691.	30.7	64
372	Deregulation of Rho GTPases in cancer. Small GTPases, 2016, 7, 123-138.	1.6	150
373	Oncogenic viruses: Lessons learned using next-generation sequencing technologies. European Journal of Cancer, 2016, 61, 61-68.	2.8	7
374	Phosphatidylinositol-3 kinase-dependent translational regulation of Id1 involves the PPM1G phosphatase. Oncogene, 2016, 35, 5807-5816.	5.9	13

#	ARTICLE	IF	CITATIONS
375	Targeted Therapy for Metastatic Urothelial Cancer: A Work in Progress. Journal of Clinical Oncology, 2016, 34, 2088-2092.	1.6	8
376	Emerging power of proteomics for delineation of intrinsic tumor subtypes and resistance mechanisms to anti-cancer therapies. Expert Review of Proteomics, 2016, 13, 929-939.	3.0	1
378	Simple and Efficient Stratification of Invasive Bladder Cancer Patients. EBioMedicine, 2016, 12, 6-7.	6.1	2
379	Epigenomic Consequences of Coding and Noncoding Driver Mutations. Trends in Cancer, 2016, 2, 585-605.	7.4	8
380	Intrinsic subtypes and bladder cancer metastasis. Asian Journal of Urology, 2016, 3, 260-267.	1.2	31
381	The complex role of NRF2 in cancer: A genomic view. Current Opinion in Toxicology, 2016, 1, 37-45.	5.0	10
382	Ulceration in bladder cancer associates with extravesical disease, independent of cell cycle, or hypoxia pathways status. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 484.e9-484.e17.	1.6	1
383	The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 533.e1-533.e10.	1.6	17
384	Biomarkers of Response and Resistance to DNA Repair Targeted Therapies. Clinical Cancer Research, 2016, 22, 5651-5660.	7.0	116
386	Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope. Cancer Treatment Reviews, 2016, 50, 208-216.	7.7	19
387	Krüppel-like factor 4 is a novel prognostic predictor for urothelial carcinoma of bladder and it regulates TWIST1-mediated epithelial-mesenchymal transition. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 485.e15-485.e24.	1.6	19
388	Understanding the biology of urothelial cancer metastasis. Asian Journal of Urology, 2016, 3, 211-222.	1.2	21
389	Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. EBioMedicine, 2016, 12, 105-117.	6.1	257
390	Simul-seq: combined DNA and RNA sequencing for whole-genome and transcriptome profiling. Nature Methods, 2016, 13, 953-958.	19.0	34
391	DNA methylation in urothelial carcinoma. Epigenomics, 2016, 8, 1415-1428.	2.1	21
392	Genomic characterization of response to chemoradiation in urothelial bladder cancer. Cancer, 2016, 122, 3715-3723.	4.1	50
393	Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma. Cancer Research, 2016, 76, 5894-5906.	0.9	87
394	Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. Cell, 2016, 166, 1041-1054.	28.9	206

#	ARTICLE	IF	CITATIONS
395	Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 408-436.	329.8	33
396	Isoquercitrin inhibits bladder cancer progression in vivo and in vitro by regulating the PI3K/Akt and PKC signaling pathways. <i>Oncology Reports</i> , 2016, 36, 165-172.	2.6	42
397	Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. <i>Nature Medicine</i> , 2016, 22, 1056-1061.	30.7	62
398	miR-92b targets DAB2IP to promote EMT in bladder cancer migration and invasion. <i>Oncology Reports</i> , 2016, 36, 1693-1701.	2.6	45
399	The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a026930.	6.2	309
400	A phase I, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 316-323.	2.0	4
401	Enhancer deregulation in cancer and other diseases. <i>BioEssays</i> , 2016, 38, 1003-1015.	2.5	79
402	The multi-omic landscape of transcription factor inactivation in cancer. <i>Genome Medicine</i> , 2016, 8, 89.	8.2	26
403	Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma. <i>Molecular Oncology</i> , 2016, 10, 1450-1460.	4.6	44
404	Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer. <i>European Urology</i> , 2016, 70, 714-717.	1.9	15
405	Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma. <i>EBioMedicine</i> , 2016, 10, 85-100.	6.1	56
406	ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 547-552.	2.8	25
407	The Emerging Molecular Landscape of Urothelial Carcinoma. <i>Surgical Pathology Clinics</i> , 2016, 9, 391-404.	1.7	30
408	Structure/Function Analysis of Recurrent Mutations in SETD2 Protein Reveals a Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and Histone H3 Lys-36 Trimethylation. <i>Journal of Biological Chemistry</i> , 2016, 291, 21283-21295.	3.4	64
409	E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2630-2639.	4.1	26
410	Emerging role of immunotherapy in urothelial carcinoma—Advanced disease. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 538-547.	1.6	41
411	National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3346-3348.	1.6	6
412	Targeting Bladder Cancer Stem Cells. , 2016, , 211-229.		0



#	ARTICLE	IF	CITATIONS
413	Re: Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. <i>European Urology</i> , 2016, 70, 1076.	1.9	0
414	Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. <i>Nature Genetics</i> , 2016, 48, 1330-1338.	21.4	161
415	Drug repositioning needs a rethink. <i>Nature</i> , 2016, 535, 355-355.	27.8	9
416	A place for precision medicine in bladder cancer: targeting the FGFRs. <i>Future Oncology</i> , 2016, 12, 2243-2263.	2.4	39
417	Immunochemical and molecular assessment of urothelial neoplasms and aspects of the 2016 World Health Organization classification. <i>Histopathology</i> , 2016, 69, 717-726.	2.9	14
418	Increased global transcription activity as a mechanism of replication stress in cancer. <i>Nature Communications</i> , 2016, 7, 13087.	12.8	232
419	Clonal evolution of chemotherapy-resistant urothelial carcinoma. <i>Nature Genetics</i> , 2016, 48, 1490-1499.	21.4	250
420	Cohesin Mutations in Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a026476.	6.2	68
421	Systematic analysis of mutation distribution in three dimensional protein structures identifies cancer driver genes. <i>Scientific Reports</i> , 2016, 6, 26483.	3.3	20
422	Pitfalls of improperly procured adjacent non-neoplastic tissue for somatic mutation analysis using next-generation sequencing. <i>BMC Medical Genomics</i> , 2016, 9, 64.	1.5	14
423	Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. <i>Scientific Reports</i> , 2016, 6, 27702.	3.3	46
424	Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7769-E7777.	7.1	145
425	Emerging role of immunotherapy in urothelial carcinomaâ€”Immunobiology/biomarkers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 556-565.	1.6	23
426	Making urothelial carcinomas less immune to immunotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 534-537.	1.6	2
427	Therapeutics Targeting FGF Signaling Network in Human Diseases. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 1081-1096.	8.7	172
428	Emerging role of checkpoint inhibition in localized bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 548-555.	1.6	19
429	Heterogeneous network-based propagation algorithm for discovering bladder cancer-related genes. , 2016, , .		0
430	Characterization of cytokinome landscape for clinical responses in human cancers. <i>OncImmunology</i> , 2016, 5, e1214789.	4.6	21



#	ARTICLE	IF	CITATIONS
431	Comprehensive evaluation and validation of targeted next-generation sequencing performance in two clinical laboratories. <i>International Journal of Oncology</i> , 2016, 49, 235-242.	3.3	9
432	Aldo-keto reductase 1C1 induced by interleukin-1 $\beta$ mediates the invasive potential and drug resistance of metastatic bladder cancer cells. <i>Scientific Reports</i> , 2016, 6, 34625.	3.3	58
433	Circulating biomarkers to guide systemic therapy for urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 502-509.	1.6	8
434	The miR-130 family promotes cell migration and invasion in bladder cancer through FAK and Akt phosphorylation by regulating PTEN. <i>Scientific Reports</i> , 2016, 6, 20574.	3.3	102
435	An empirical likelihood ratio test robust to individual heterogeneity for differential expression analysis of RNA-seq. <i>Briefings in Bioinformatics</i> , 2018, 19, bbw103.	6.5	3
436	The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. <i>Nature Communications</i> , 2016, 7, 11479.	12.8	1,221
437	The translational potential of microRNAs as biofluid markers of urological tumours. <i>Nature Reviews Urology</i> , 2016, 13, 734-752.	3.8	104
438	Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU). <i>Current Oncology Reports</i> , 2016, 18, 72.	4.0	6
439	Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting. <i>Bladder Cancer</i> , 2016, 2, 37-47.	0.4	184
440	BcCluster: A Bladder Cancer Database at the Molecular Level. <i>Bladder Cancer</i> , 2016, 2, 65-76.	0.4	4
441	Circulating Biomarkers in Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 369-379.	0.4	25
442	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 165-202.	0.4	30
443	Genetic Alteration in Phosphofructokinase Family Promotes Growth of Muscle-Invasive Bladder Cancer. <i>International Journal of Biological Markers</i> , 2016, 31, 286-293.	1.8	33
444	Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. <i>Scientific Reports</i> , 2016, 6, 19649.	3.3	15
445	Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1457-1472.	3.7	112
446	Cancer immunotherapy. <i>Current Opinion in Urology</i> , 2016, 26, 556-563.	1.8	5
447	ONE-CLASS DETECTION OF CELL STATES IN TUMOR SUBTYPES. , 2016, , .		36
448	Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. <i>Urology</i> , 2016, 94, 314.e1-314.e7.	1.0	16

#	ARTICLE	IF	CITATIONS
449	GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis. <i>Cancer Research</i> , 2016, 76, 5175-5185.	0.9	36
450	Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises. <i>Future Oncology</i> , 2016, 12, 2049-2058.	2.4	8
451	Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. <i>Journal of Urology</i> , 2016, 196, 1021-1029.	0.4	971
452	Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 469-476.	1.6	8
453	Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature. <i>Pharmacological Research</i> , 2016, 111, 290-302.	7.1	156
454	Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. <i>Cancer Cell</i> , 2016, 30, 27-42.	16.8	486
456	Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a026211.	6.2	105
457	Bladder cancer. <i>Lancet</i> , The, 2016, 388, 2796-2810.	13.7	1,031
458	Molecular substratification of bladder cancer: moving towards individualized patient management. <i>Therapeutic Advances in Urology</i> , 2016, 8, 215-233.	2.0	38
459	Infiltrating T Cells Promote Bladder Cancer Progression via Increasing IL1-Androgen Receptor-HIF1-VEGFA Signals. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1943-1951.	4.1	21
460	Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e81-e90.	1.9	4
461	ELF5 isoform expression is tissue-specific and significantly altered in cancer. <i>Breast Cancer Research</i> , 2016, 18, 4.	5.0	37
462	A holistic view of cancer bioenergetics: mitochondrial function and respiration play fundamental roles in the development and progression of diverse tumors. <i>Clinical and Translational Medicine</i> , 2016, 5, 3.	4.0	65
463	Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. <i>Journal of Clinical Oncology</i> , 2016, 34, 3529-3536.	1.6	70
464	Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. <i>Journal of Clinical Oncology</i> , 2016, 34, 2627-2635.	1.6	69
465	HDAC inhibitors cause site-specific chromatin remodeling at PU.1-bound enhancers in K562 cells. <i>Epigenetics and Chromatin</i> , 2016, 9, 15.	3.9	20
466	Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress. <i>Future Oncology</i> , 2016, 12, 355-372.	2.4	16
467	Genomic profiling of advanced bladder cancer to guide the use of targeted therapeutics. <i>Cancer</i> , 2016, 122, 676-677.	4.1	0

#	ARTICLE	IF	CITATIONS
468	Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. <i>British Journal of Cancer</i> , 2016, 115, 12-19.	6.4	9
469	Phase II study of dual phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma. <i>BJU International</i> , 2016, 118, 408-415.	2.5	53
470	Prostate tumor overexpressed 1 expression in invasive urothelial carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 937-947.	2.5	7
471	miR-1182 inhibits growth and mediates the chemosensitivity of bladder cancer by targeting hTERT. <i>Biochemical and Biophysical Research Communications</i> , 2016, 470, 445-452.	2.1	40
472	Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 2981-2992.	7.0	78
473	The kinome 'at large' in cancer. <i>Nature Reviews Cancer</i> , 2016, 16, 83-98.	28.4	226
474	Programmed Death-Ligand 1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node Metastasis: A Reliable Treatment Selection Biomarker?. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 183-187.	1.9	42
475	Curcumin reverses benzidine-induced cell proliferation by suppressing ERK1/2 pathway in human bladder cancer T24 cells. <i>Experimental and Toxicologic Pathology</i> , 2016, 68, 215-222.	2.1	12
476	Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA. <i>European Journal of Human Genetics</i> , 2016, 24, 1167-1174.	2.8	115
477	Enabling systematic interrogation of protein-protein interactions in live cells with a versatile ultra-high-throughput biosensor platform. <i>Journal of Molecular Cell Biology</i> , 2016, 8, 271-281.	3.3	27
478	New era of integrated cancer biomarker discovery using reverse-phase protein arrays. <i>Drug Metabolism and Pharmacokinetics</i> , 2016, 31, 35-45.	2.2	32
479	Proteomics identification of PGAM1 as a potential therapeutic target for urothelial bladder cancer. <i>Journal of Proteomics</i> , 2016, 132, 85-92.	2.4	45
480	Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival. <i>Journal of Urology</i> , 2016, 195, 1911-1919.	0.4	35
481	Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 299-312.	4.1	48
482	BRCAness revisited. <i>Nature Reviews Cancer</i> , 2016, 16, 110-120.	28.4	976
483	Pharmacogenomics. <i>Urologic Clinics of North America</i> , 2016, 43, 77-86.	1.8	9
484	Large-scale profiling of microRNAs for The Cancer Genome Atlas. <i>Nucleic Acids Research</i> , 2016, 44, e3-e3.	14.5	125
485	Systematic discovery of complex insertions and deletions in human cancers. <i>Nature Medicine</i> , 2016, 22, 97-104.	30.7	93

#	ARTICLE	IF	CITATIONS
486	17-DMAG induces heat shock protein 90 functional impairment in human bladder cancer cells: knocking down the hallmark traits of malignancy. Tumor Biology, 2016, 37, 6861-6873.	1.8	5
487	Novel therapeutic targets in advanced urothelial carcinoma. Critical Reviews in Oncology/Hematology, 2016, 98, 106-115.	4.4	45
488	The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organsâ€”Part B: Prostate and Bladder Tumours. European Urology, 2016, 70, 106-119.	1.9	1,323
489	Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Clinical Oncology, 2016, 34, 1945-1952.	1.6	202
490	Improving Systemic Chemotherapy for Bladder Cancer. Current Oncology Reports, 2016, 18, 27.	4.0	42
491	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. Advances in Immunology, 2016, 130, 95-190.	2.2	160
492	FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence. Biomarkers in Medicine, 2016, 10, 243-253.	1.4	23
493	Molecular Pathology Informatics. Clinics in Laboratory Medicine, 2016, 36, 57-66.	1.4	4
494	Origins of Bladder Cancer. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 149-174.	22.4	140
495	Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells. Oncogene, 2016, 35, 4518-4528.	5.9	49
496	Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 4.e11-4.e17.	1.6	14
497	A Review of Neoadjuvant and Adjuvant Chemotherapy for Nonmetastatic Muscle Invasive Bladder Cancer. Urology Practice, 2016, 3, 41-49.	0.5	0
498	Chemotherapy for Muscle-Invasive Bladder Cancer. Current Treatment Options in Oncology, 2016, 17, 6.	3.0	19
499	Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. Journal of Urology, 2016, 195, 1684-1689.	0.4	36
500	Evolving concepts in muscle-invasive bladder cancer. World Journal of Urology, 2016, 34, 1-2.	2.2	6
501	Molecular Pathology of Solid Tumors. , 2016, , 557-594.		0
502	Novel fusion transcripts in bladder cancer identified by RNA-seq. Cancer Letters, 2016, 374, 224-228.	7.2	28
503	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Human Molecular Genetics, 2016, 25, 1203-1214.	2.9	38

#	ARTICLE	IF	CITATIONS
504	High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with $\sim 1/4240$ -Fold Higher Drug Concentration in Urine than Serum. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 430-438.	4.1	16
505	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet</i> , The, 2016, 387, 1909-1920.	13.7	3,077
506	Role for anti-PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma. <i>Lancet</i> , The, 2016, 387, 1881-1882.	13.7	8
509	New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 793-801.	7.0	60
510	SOX4 Is Essential for Prostate Tumorigenesis Initiated by PTEN Ablation. <i>Cancer Research</i> , 2016, 76, 1112-1121.	0.9	67
511	Emerging Bladder Cancer Biomarkers and Targets of Therapy. <i>Urologic Clinics of North America</i> , 2016, 43, 63-76.	1.8	21
512	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. <i>Nature Biotechnology</i> , 2016, 34, 155-163.	17.5	634
513	A step closer to individualized treatment for bladder cancer. <i>Nature Reviews Urology</i> , 2016, 13, 127-128.	3.8	2
514	Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?. <i>Annals of Oncology</i> , 2016, 27, 344-352.	1.2	9
515	A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. <i>European Urology</i> , 2016, 69, 855-862.	1.9	228
516	Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond—A Comprehensive Review of the Current Literature. <i>Journal of Urology</i> , 2016, 195, 254-263.	0.4	99
517	The Neoadjuvant Paradigm for Development of Systemic Therapy and Precision Medicine for Bladder Cancer. <i>European Urology</i> , 2016, 69, 863-865.	1.9	0
518	CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1. <i>Journal of Urology</i> , 2016, 195, 771-779.	0.4	38
519	ccmGDB: a database for cancer cell metabolism genes. <i>Nucleic Acids Research</i> , 2016, 44, D959-D968.	14.5	41
521	Thematic Review Series: Phospholipases: Central Role in Lipid Signaling and Disease Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression. <i>Journal of Lipid Research</i> , 2016, 57, 25-35.	4.2	41
522	Use of Artificial Intelligence and Machine Learning Algorithms with Gene Expression Profiling to Predict Recurrent Nonmuscle Invasive Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2016, 195, 493-498.	0.4	42
523	Evaluation of somatic copy number estimation tools for whole-exome sequencing data. <i>Briefings in Bioinformatics</i> , 2016, 17, 185-192.	6.5	44
524	Significance of HER2 expression in patients with upper tract urothelial carcinoma: A meta-analysis. <i>Urological Science</i> , 2016, 27, 238-243.	0.6	3

#	ARTICLE	IF	CITATIONS
525	Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2017, 15, 145-151.e2.	1.9	40
526	Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response. Oncogene, 2017, 36, 35-46.	5.9	85
527	Base changes in tumour DNA have the power to reveal the causes and evolution of cancer. Oncogene, 2017, 36, 158-167.	5.9	58
528	Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer. World Journal of Urology, 2017, 35, 367-378.	2.2	8
529	Immunohistochemistry Biomarkers in Nonmuscle Invasive Bladder Cancer. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, 178-183.	1.2	7
530	Expression of <sc>CUL</sc>1 correlates with tumour grade and recurrence in urothelial carcinoma. ANZ Journal of Surgery, 2017, 87, 624-629.	0.7	3
531	Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer. Journal of Cellular Physiology, 2017, 232, 436-446.	4.1	41
532	Flat Intraurothelial Neoplasia Exhibiting Diffuse Immunoreactivity for CD44 and Cytokeratin 5 (Urothelial Stem Cell/Basal Cell Markers): A Variant of Intraurothelial Neoplasia Commonly Associated With Muscle-invasive Urothelial Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, 505-512.	1.2	8
533	Single-cell Sequencing Reveals Variants in ARID1A, GPRC5A and MLL2 Driving Self-renewal of Human Bladder Cancer Stem Cells. European Urology, 2017, 71, 8-12.	1.9	108
534	In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 267-274.	2.8	58
535	A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma. European Urology, 2017, 71, 858-862.	1.9	59
536	Bioinformatic identification of prognostic signature defined by copy number alteration and expression of CCNE1 in non-muscle invasive bladder cancer. Experimental and Molecular Medicine, 2017, 49, e282-e282.	7.7	20
537	Integrated genomic and molecular characterization of cervical cancer. Nature, 2017, 543, 378-384.	27.8	1,158
538	Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2 : CALGB 151111 (Alliance). Journal of Thoracic Oncology, 2017, 12, 704-713.	1.1	71
539	The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges. Cancer Treatment Reviews, 2017, 53, 138-145.	7.7	20
540	The NF1 gene in tumor syndromes and melanoma. Laboratory Investigation, 2017, 97, 146-157.	3.7	144
541	Notch as a tumour suppressor. Nature Reviews Cancer, 2017, 17, 145-159.	28.4	301
542	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clinical Cancer Research, 2017, 23, 3610-3618.	7.0	225

#	ARTICLE	IF	CITATIONS
543	Insertions and Deletions Target Lineage-Defining Genes in Human Cancers. <i>Cell</i> , 2017, 168, 460-472.e14.	28.9	106
544	ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer. <i>Cancer Research</i> , 2017, 77, 1035-1046.	0.9	15
545	Tp53 and its potential therapeutic role as a target in bladder cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 401-414.	3.4	28
546	Tumor-infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer. <i>Oncolmmunology</i> , 2017, 6, e1293211.	4.6	57
547	Now Is the Time for Perioperative Chemotherapy in Upper Tract Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 816-817.	1.6	1
548	Radiomics assessment of bladder cancer grade using texture features from diffusion-weighted imaging. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 1281-1288.	3.4	123
550	Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. <i>Scientific Reports</i> , 2017, 7, 42713.	3.3	85
551	PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2017, 376, 1073-1074.	27.0	46
552	PlcKING on Fibroblast Growth Factor Receptors as Bladder Cancer Therapeutic Targets. <i>European Urology</i> , 2017, 71, 863-865.	1.9	1
553	Emerging themes of regulation at the Golgi. <i>Current Opinion in Cell Biology</i> , 2017, 45, 17-23.	5.4	41
554	MicroRNA-124-3p affects proliferation, migration and apoptosis of bladder cancer cells through targeting AURKA. <i>Cancer Biomarkers</i> , 2017, 19, 93-101.	1.7	35
555	Heterarchy of transcription factors driving basal and luminal cell phenotypes in human urothelium. <i>Cell Death and Differentiation</i> , 2017, 24, 809-818.	11.2	41
556	Is The Cancer Genome Atlas (TCGA) bladder cancer cohort representative of invasive bladder cancer?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 458.e1-458.e7.	1.6	7
557	Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	165
558	Scanning for KRAS, NRAS, BRAF, and PIK3CA mutations by DNA melting analysis with TaqMan probes. <i>Molecular Biology</i> , 2017, 51, 41-48.	1.3	2
559	SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a026468.	6.2	60
560	The importance of regulatory ubiquitination in cancer and metastasis. <i>Cell Cycle</i> , 2017, 16, 634-648.	2.6	134
561	Integrated genomic analysis of recurrence-associated small non-coding RNAs in oesophageal cancer. <i>Gut</i> , 2017, 66, 215-225.	12.1	34



#	ARTICLE	IF	CITATIONS
562	The evolving genomic landscape of urothelial carcinoma. <i>Nature Reviews Urology</i> , 2017, 14, 215-229.	3.8	89
563	RASAL2, a RAS GTPase-activating protein, inhibits stemness and epithelialâ€mesenchymal transition via MAPK/SOX2 pathway in bladder cancer. <i>Cell Death and Disease</i> , 2017, 8, e2600-e2600.	6.3	38
564	<scp>ASP</scp>5878, a selective <scp>FGFR</scp> inhibitor, to treat <scp>FGFR</scp>3â€dependent urothelial cancer with or without chemoresistance. <i>Cancer Science</i> , 2017, 108, 236-242.	3.9	19
565	Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy. <i>BJU International</i> , 2017, 119, 854-861.	2.5	27
566	Multi-OMICS: a critical technical perspective on integrative lipidomics approaches. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2017, 1862, 808-811.	2.4	29
567	Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy?. <i>ESMO Open</i> , 2017, 2, e000123.	4.5	5
568	Sleeping beauty: awakening urothelium from its slumber. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, F732-F743.	2.7	44
569	Bladder cancer cell growth and motility implicate cannabinoid 2 receptor-mediated modifications of sphingolipids metabolism. <i>Scientific Reports</i> , 2017, 7, 42157.	3.3	28
570	Exploration of bladder cancer molecular mechanisms based on miRNA-mRNA regulatory network. <i>Oncology Reports</i> , 2017, 37, 1461-1468.	2.6	10
571	Role of Inflammation in the Perioperative Management of Urothelial Bladder Cancer With Squamous-Cell Features: Impact of Neutrophil-to-Lymphocyte Ratio on Outcomes and Response to Neoadjuvant Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e697-e706.	1.9	17
572	Molecular classification of urothelial carcinoma: global <scp>mRNA</scp> classification versus tumourâ€cell phenotype classification. <i>Journal of Pathology</i> , 2017, 242, 113-125.	4.5	258
573	Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. <i>European Urology</i> , 2017, 72, 544-554.	1.9	638
576	Bladder cancer. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17022.	30.5	590
577	Integrative epigenetic and genetic pan-cancer somatic alteration portraits. <i>Epigenetics</i> , 2017, 12, 561-574.	2.7	18
578	Toward personalized management in bladder cancer: the promise of novel molecular taxonomy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 271-280.	2.8	15
579	Intrinsic Molecular Processes: Impact on Mutagenesis. <i>Trends in Cancer</i> , 2017, 3, 357-371.	7.4	4
580	Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 593-599.	1.6	20
581	Knowledge about the presence or absence of miRNA isoforms (isomiRs) can successfully discriminate amongst 32 TCGA cancer types. <i>Nucleic Acids Research</i> , 2017, 45, 2973-2985.	14.5	158



#	ARTICLE	IF	CITATIONS
582	Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives. <i>Drugs</i> , 2017, 77, 1077-1089.	10.9	67
583	Fibulin-3 promotes muscle-invasive bladder cancer. <i>Oncogene</i> , 2017, 36, 5243-5251.	5.9	34
584	High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer. <i>Translational Oncology</i> , 2017, 10, 340-345.	3.7	22
585	Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 683-694.	3.0	6
586	Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	107
587	ProcessDriver: A computational pipeline to identify copy number drivers and associated disrupted biological processes in cancer. <i>Genomics</i> , 2017, 109, 233-240.	2.9	3
588	Biomarkers for precision medicine in bladder cancer. <i>International Journal of Clinical Oncology</i> , 2017, 22, 207-213.	2.2	30
589	On a FOX hunt: functions of FOX transcriptional regulators in bladder cancer. <i>Nature Reviews Urology</i> , 2017, 14, 98-106.	3.8	30
590	Dose dense MVAC prior to radical cystectomy: a real-world experience. <i>World Journal of Urology</i> , 2017, 35, 1729-1736.	2.2	8
591	Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2201-2214.	4.1	59
592	Seeking the Molecular Truth in Bladder Cancer: Biology = Genome – (Transcriptome) 2. <i>European Urology</i> , 2017, 72, 366-367.	1.9	7
593	Recent progress in immunotherapy for urological cancer. <i>International Journal of Urology</i> , 2017, 24, 735-742.	1.0	12
594	Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing. <i>Acta Neuropathologica</i> , 2017, 134, 691-703.	7.7	131
595	Updates for the radiologist in non-muscle-invasive, muscle-invasive, and metastatic bladder cancer. <i>Abdominal Radiology</i> , 2017, 42, 2710-2724.	2.1	6
596	Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2017, 72, 641-649.	1.9	170
597	Optimizing management of upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 492-498.	1.6	18
598	Identification of epigenetic interactions between miRNA and DNA methylation associated with gene expression as potential prognostic markers in bladder cancer. <i>BMC Medical Genomics</i> , 2017, 10, 30.	1.5	59
599	The potential of organoids in urological cancer research. <i>Nature Reviews Urology</i> , 2017, 14, 401-414.	3.8	72

#	ARTICLE	IF	CITATIONS
600	Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. <i>British Journal of Cancer</i> , 2017, 117, 113-123.	6.4	84
601	Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma. <i>Modern Pathology</i> , 2017, 30, 1133-1143.	5.5	44
602	Emerging drugs for urothelial (bladder) cancer. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 149-164.	2.4	9
603	Perspectives of the Nrf-2 signaling pathway in cancer progression and therapy. <i>Toxicology Reports</i> , 2017, 4, 306-318.	3.3	108
604	Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. <i>European Urology</i> , 2017, 72, 354-365.	1.9	195
605	Targeted therapies in the treatment of urothelial cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 465-472.	1.6	13
606	Plasmacytoid Urothelial Carcinoma of the Urinary Bladder. <i>American Journal of Clinical Pathology</i> , 2017, 147, 500-506.	0.7	52
607	The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. <i>Cancer</i> , 2017, 123, 1912-1924.	4.1	52
608	Understanding the Genetic Landscape of Small Cell Carcinoma of the Urinary Bladder and Implications for Diagnosis, Prognosis, and Treatment. <i>JAMA Oncology</i> , 2017, 3, 1570.	7.1	38
609	Age at diagnosis, obesity, smoking, and molecular subtypes in muscle-invasive bladder cancer. <i>Cancer Causes and Control</i> , 2017, 28, 539-544.	1.8	14
610	p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant. <i>Histopathology</i> , 2017, 71, 296-304.	2.9	37
611	Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin. <i>Cancer Cytopathology</i> , 2017, 125, 416-426.	2.4	26
612	Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior. <i>Scientific Reports</i> , 2017, 7, 40714.	3.3	41
613	Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin. <i>Scientific Reports</i> , 2017, 7, 45983.	3.3	69
614	Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network. <i>Scientific Reports</i> , 2017, 7, 738.	3.3	12
615	The impact of advanced proteomics in the search for markers and therapeutic targets of bladder cancer. <i>Tumor Biology</i> , 2017, 39, 101042831769118.	1.8	8
616	Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics. <i>Scientific Reports</i> , 2017, 7, 201.	3.3	46
617	Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1. <i>Signal Transduction and Targeted Therapy</i> , 2017, 2, .	17.1	35

#	ARTICLE	IF	CITATIONS
618	Comprehensive somatic genome alterations of urachal carcinoma. <i>Journal of Medical Genetics</i> , 2017, 54, 572-578.	3.2	30
619	Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment. <i>Immunotherapy</i> , 2017, 9, 451-460.	2.0	12
620	Gene expression profiling in bladder cancer identifies potential therapeutic targets. <i>International Journal of Oncology</i> , 2017, 50, 1147-1159.	3.3	17
622	The Mechanistic Role of the Calcium-Activated Chloride Channel ANO1 in Tumor Growth and Signaling. <i>Advances in Experimental Medicine and Biology</i> , 2017, 966, 1-14.	1.6	28
623	Contemporary update on neoadjuvant therapy for bladder cancer. <i>Nature Reviews Urology</i> , 2017, 14, 348-358.	3.8	24
624	High expression of insulin receptor on tumour-associated blood vessels in invasive bladder cancer predicts poor overall and progression-free survival. <i>Journal of Pathology</i> , 2017, 242, 193-205.	4.5	24
625	The enigmatic oncogene and tumor suppressor-like properties of RAD54B: Insights into genome instability and cancer. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 513-523.	2.8	16
626	ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ. <i>Urologia Internationalis</i> , 2017, 98, 282-289.	1.3	30
627	Multiple Roles for the MLL/COMPASS Family in the Epigenetic Regulation of Gene Expression and in Cancer. <i>Annual Review of Cancer Biology</i> , 2017, 1, 425-446.	4.5	36
628	Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 171-190.	4.4	22
629	Genetics of Pheochromocytomas and Paragangliomas. <i>Endocrinology and Metabolism Clinics of North America</i> , 2017, 46, 459-489.	3.2	9
630	Bioinformatic approaches to interrogating vitamin D receptor signaling. <i>Molecular and Cellular Endocrinology</i> , 2017, 453, 3-13.	3.2	11
631	Inherited DNA repair gene mutations detected by tumor next generation sequencing in urinary tract cancers. <i>Familial Cancer</i> , 2017, 16, 545-550.	1.9	3
632	Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer. <i>British Journal of Cancer</i> , 2017, 116, 1077-1087.	6.4	48
633	MiR-193b Mediates CEBPD-Induced Cisplatin Sensitization Through Targeting ETS1 and Cyclin D1 in Human Urothelial Carcinoma Cells. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 1563-1573.	2.6	44
634	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2017, 389, 67-76.	13.7	1,728
635	Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 244-254.	2.8	96
636	A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157. <i>Clinical Cancer Research</i> , 2017, 23, 3003-3011.	7.0	59

#	ARTICLE	IF	CITATIONS
637	Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase-Mediated Eukaryotic Initiation Factor 2 $\pm$ Activity and Is Targetable by PEGylated Arginine Deiminase. American Journal of Pathology, 2017, 187, 200-213.	3.8	23
638	Lycorine induces apoptosis of bladder cancer T24 cells by inhibiting phospho-Akt and activating the intrinsic apoptotic cascade. Biochemical and Biophysical Research Communications, 2017, 483, 197-202.	2.1	35
639	Stage- and subunit-specific functions of polycomb repressive complex 2 in bladder urothelial formation and regeneration. Development (Cambridge), 2017, 144, 400-408.	2.5	12
640	Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 225-232.	3.3	20
641	Cross-species analysis of the canine and human bladder cancer transcriptome and exome. Genes Chromosomes and Cancer, 2017, 56, 328-343.	2.8	34
642	Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis. Nature Communications, 2017, 8, 1081.	12.8	16
643	Update of systemic immunotherapy for advanced urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 678-686.	1.6	12
644	Vitamin D Receptor Signaling and Cancer. Endocrinology and Metabolism Clinics of North America, 2017, 46, 1009-1038.	3.2	52
645	Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1240-1267.	4.9	220
646	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell, 2017, 171, 540-556.e25.	28.9	1,742
647	A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma. Pharmacotherapy, 2017, 37, 1391-1405.	2.6	14
648	Onco-proteogenomics: Multi-omics level data integration for accurate phenotype prediction. Critical Reviews in Clinical Laboratory Sciences, 2017, 54, 414-432.	6.1	16
649	Comprehensive Analysis of Hypermutation in Human Cancer. Cell, 2017, 171, 1042-1056.e10.	28.9	596
650	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nature Communications, 2017, 8, 1050.	12.8	115
651	Comprehensive analysis of normal adjacent to tumor transcriptomes. Nature Communications, 2017, 8, 1077.	12.8	394
652	Identification and replication of the interplay of four genetic high-risk variants for urinary bladder cancer. Carcinogenesis, 2017, 38, 1167-1179.	2.8	18
653	Prospects and progress of immunotherapy for bladder cancer. Expert Opinion on Biological Therapy, 2017, 17, 1-15.	3.1	29
654	Nucleotide Excision Repair: From Neurodegeneration to Cancer. Advances in Experimental Medicine and Biology, 2017, 1007, 17-39.	1.6	20

#	ARTICLE	IF	CITATIONS
655	Independent prognostic miRNAs for bladder urothelial carcinoma. <i>Oncology Letters</i> , 2017, 14, 3001-3005.	1.8	7
656	The anti-tumor effect of intravesical administration of normal urothelial cells on bladder cancer. <i>Cytotherapy</i> , 2017, 19, 1233-1245.	0.7	5
657	Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. <i>Annals of Oncology</i> , 2017, 28, 2458-2463.	1.2	68
658	Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer. <i>Scientific Reports</i> , 2017, 7, 11702.	3.3	110
659	Genomic Activation of <i>PPARG</i> Reveals a Candidate Therapeutic Axis in Bladder Cancer. <i>Cancer Research</i> , 2017, 77, 6987-6998.	0.9	65
660	The roles of ubiquitin modifying enzymes in neoplastic disease. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 456-483.	7.4	35
661	Network-based machine learning and graph theory algorithms for precision oncology. <i>Npj Precision Oncology</i> , 2017, 1, 25.	5.4	74
662	Tumour virology in the era of high-throughput genomics. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160265.	4.0	26
663	Merkel cell polyomavirus and Merkel cell carcinoma. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160276.	4.0	78
664	TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. <i>Clinical Cancer Research</i> , 2017, 23, 7072-7083.	7.0	87
665	Molecular Signatures for Tumor Classification. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 881-891.	2.8	22
666	geneSurv: An interactive web-based tool for survival analysis in genomics research. <i>Computers in Biology and Medicine</i> , 2017, 89, 487-496.	7.0	4
667	FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 337-345.	2.8	39
669	UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. <i>Neoplasia</i> , 2017, 19, 649-658.	5.3	4,166
670	Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 758-766.	2.8	21
671	Tumor vesical: presente y futuro. <i>Medicina Clínica</i> , 2017, 149, 449-455.	0.6	101
672	Mutational signatures efficiently identify different mutational processes underlying cancers with similar somatic mutation spectra. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2017, 806, 27-30.	1.0	2
673	Detect differentially methylated regions using non-homogeneous hidden Markov model for methylation array data. <i>Bioinformatics</i> , 2017, 33, 3701-3708.	4.1	10

#	ARTICLE	IF	CITATIONS
674	Comparison of algorithms for the detection of cancer drivers at subgene resolution. <i>Nature Methods</i> , 2017, 14, 782-788.	19.0	72
675	Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma. <i>Human Pathology</i> , 2017, 67, 69-77.	2.0	34
676	Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies. <i>Cancer Cell</i> , 2017, 32, 155-168.e6.	16.8	93
677	Phthalazino[1,2- <i>b</i> ]quinazolinones as p53 Activators: Cell Cycle Arrest, Apoptotic Response and Bcl-xl Complex Reorganization in Bladder Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6853-6866.	6.4	42
678	Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. <i>Clinical Cancer Research</i> , 2017, 23, 4441-4449.	7.0	342
679	Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer. <i>Pharmacogenomics</i> , 2017, 18, 1167-1178.	1.3	7
680	Evasion of immunosurveillance by genomic alterations of PPAR $\gamma$ /RXR $\alpha$ in bladder cancer. <i>Nature Communications</i> , 2017, 8, 103.	12.8	107
681	Pan-urolologic cancer genomic subtypes that transcend tissue of origin. <i>Nature Communications</i> , 2017, 8, 199.	12.8	49
682	Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer. <i>Scientific Reports</i> , 2017, 7, 5554.	3.3	73
683	Checkpoint inhibitors in the treatment of urological malignancies. <i>ESMO Open</i> , 2017, 2, e000165.	4.5	21
684	The KMT1A-GATA3-STAT3 Circuit Is a Novel Self-Renewal Signaling of Human Bladder Cancer Stem Cells. <i>Clinical Cancer Research</i> , 2017, 23, 6673-6685.	7.0	49
685	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6487-6497.	7.0	121
686	Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. <i>European Urology Focus</i> , 2017, 3, 577-583.	3.1	10
688	The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6580-6591.	7.0	43
689	In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E7301-E7310.	7.1	88
690	Precursor Lesions of Urologic Malignancies. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1615-1632.	2.5	6
691	Targeting mTOR in urothelial cancerâ€”Beating a dead horse or ready for prime time?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 600-601.	1.6	0
692	Breast cancer metastasis suppressor OTUD1 deubiquitinates SMAD7. <i>Nature Communications</i> , 2017, 8, 2116.	12.8	90

#	ARTICLE	IF	CITATIONS
693	Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline. Expert Opinion on Emerging Drugs, 2017, 22, 347-355.	2.4	0
694	Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer. Cell Death and Disease, 2017, 8, 3217.	6.3	30
695	Modulation of immunosurveillance by tumor-intrinsic genomic alterations. Immunotherapy, 2017, 9, 1305-1307.	2.0	0
696	Identification of potentially oncogenic alterations from tumor-only samples reveals Fanconi anemia pathway mutations in bladder carcinomas. Npj Genomic Medicine, 2017, 2, 29.	3.8	14
697	Discovery of Bladder Cancer-related Genes Using Integrative Heterogeneous Network Modeling of Multi-omics Data. Scientific Reports, 2017, 7, 15639.	3.3	13
698	Comprehensive genomic analysis of Oesophageal Squamous Cell Carcinoma reveals clinical relevance. Scientific Reports, 2017, 7, 15324.	3.3	49
699	Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency. Cancer Cell, 2017, 32, 701-715.e7.	16.8	224
700	Molecular Landscape of Non-Muscle Invasive Bladder Cancer. Cancer Cell, 2017, 32, 550-551.	16.8	18
701	Bladder cancer: Present and future. Medicina Clínica (English Edition), 2017, 149, 449-455.	0.2	51
702	Pembrolizumab in the treatment of advanced urothelial cancer. Future Oncology, 2017, 13, 2745-2758.	2.4	4
703	The prognostic role of epigenetic dysregulation in bladder cancer: A systematic review. Cancer Treatment Reviews, 2017, 61, 82-93.	7.7	21
704	Translational utility of a hierarchical classification strategy in biomolecular data analytics. Scientific Reports, 2017, 7, 14981.	3.3	7
705	Genetics: A clearer view. Nature, 2017, 551, S44-S45.	27.8	2
706	Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer. Mayo Clinic Proceedings, 2017, 92, 1564-1582.	3.0	35
707	Urothelial Bladder Cancer: An Update on Molecular Pathology with Clinical Implications. European Urology Supplements, 2017, 16, 272-294.	0.1	6
708	Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma: A Step Closer to Clinical Translation?. European Urology, 2017, 72, 960-961.	1.9	32
709	Lessons Learned from Two Decades of Anticancer Drugs. Trends in Pharmacological Sciences, 2017, 38, 852-872.	8.7	74
710	Landmarks in the treatment of muscle-invasive bladder cancer. Nature Reviews Urology, 2017, 14, 565-574.	3.8	122



#	ARTICLE	IF	CITATIONS
711	A novel network regularized matrix decomposition method to detect mutated cancer genes in tumour samples with inter-patient heterogeneity. Scientific Reports, 2017, 7, 2855.	3.3	10
712	Editorial comment. Urology, 2017, 106, 124.	1.0	0
713	Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine. Journal of Experimental and Clinical Cancer Research, 2017, 36, 1.	8.6	76
714	The NF1 somatic mutational landscape in sporadic human cancers. Human Genomics, 2017, 11, 13.	2.9	203
715	Network approaches to systems biology analysis of complex disease: integrative methods for multi-omics data. Briefings in Bioinformatics, 2018, 19, 1370-1381.	6.5	185
716	Mutagenic Factors and Complex Clonal Relationship of Multifocal Urothelial Cell Carcinoma. European Urology, 2017, 71, 841-843.	1.9	20
717	Reply from Authors re: Xue-Ru Wu. Attention to Detail by Single-cell sequencing. Eur Urol 2017;71:13â€“4. European Urology, 2017, 71, 15-16.	1.9	1
718	Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patientsâ€™ prognosis. Journal of Cancer Research and Clinical Oncology, 2017, 143, 521-532.	2.5	16
719	Validation of the Preoperative Platelet-to-Lymphocyte Ratio as a Prognostic Factor in a European Cohort of Patients with Upper Tract Urothelial Carcinoma. Urologia Internationalis, 2017, 98, 320-327.	1.3	22
720	Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy. Journal of Urology, 2017, 197, 590-595.	0.4	102
721	Challenges in the Diagnosis of Urothelial Carcinoma Variants: Can Emerging Molecular Data Complement Pathology Review?. Urology, 2017, 102, 7-16.	1.0	15
723	mTORC2 activation is regulated by the urokinase receptor (uPAR) in bladder cancer. Cellular Signalling, 2017, 29, 96-106.	3.6	11
724	Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy. Acta Pharmaceutica Sinica B, 2017, 7, 27-37.	12.0	120
725	The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. European Urology, 2017, 71, 237-246.	1.9	62
726	Recent progress with nextâ€“generation biomarkers in muscleâ€“invasive bladder cancer. International Journal of Urology, 2017, 24, 7-15.	1.0	12
727	Role of <i>KEAP1</i> and <i>NRF2</i> and <i>TP53</i> Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. Cancer Discovery, 2017, 7, 86-101.	9.4	239
729	Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors. European Journal of Medicinal Chemistry, 2017, 126, 122-132.	5.5	11
730	Heterogeneous nuclear ribonucleoprotein K is associated with poor prognosis and regulates proliferation and apoptosis in bladder cancer. Journal of Cellular and Molecular Medicine, 2017, 21, 1266-1279.	3.6	69



#	ARTICLE	IF	CITATIONS
731	The epigenetic landscape of renal cancer. Nature Reviews Nephrology, 2017, 13, 47-60.	9.6	99
732	Upstaging of nonurothelial histology in bladder cancer at the time of surgical treatment in the National Cancer Data Base. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 34.e1-34.e8.	1.6	12
733	Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. Nature Reviews Clinical Oncology, 2017, 14, 221-234.	27.6	89
734	Improved detection of synthetic lethal interactions in <i>Drosophila</i> cells using variable dose analysis (VDA). Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E10755-E10762.	7.1	8
735	Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nature Communications, 2017, 8, 2193.	12.8	99
737	Epigenetic and genetic deregulation in cancer target distinct signaling pathway domains. Nucleic Acids Research, 2017, 45, 583-596.	14.5	18
738	CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatment Strategy for Bladder Cancer. Bladder Cancer, 2017, 3, 79-88.	0.4	21
739	Cancer vaccines at the age of immune checkpoint inhibitors: reasonable approach as combination therapy in advanced urothelial carcinoma?. Annals of Oncology, 2017, 28, 680-682.	1.2	4
740	Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance. Oncotarget, 2017, 8, 70982-71001.	1.8	42
741	Transcriptional response profiles of paired tumor-normal samples offer novel perspectives in pan-cancer analysis. Oncotarget, 2017, 8, 41334-41347.	1.8	22
742	Bladder Cancer Markers and Recent Innovations. , 2017, , .		1
743	FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801 synergistically inhibit cell growth and induce apoptosis in bladder cancer cells. Oncology Reports, 2018, 39, 627-632.	2.6	9
744	Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines. International Journal of Molecular Sciences, 2017, 18, 1680.	4.1	13
746	Taking it to the HILT: High-intensity local treatment with radical cystectomy for metastatic bladder cancer. Canadian Urological Association Journal, 2017, 11, 249-50.	0.6	0
747	EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?. International Journal of Molecular Sciences, 2017, 18, 1172.	4.1	73
748	AR-Signaling in Human Malignancies: Prostate Cancer and Beyond. Cancers, 2017, 9, 7.	3.7	49
749	Ubiquitin Specific Peptidase 22 Regulates Histone H2B Mono-Ubiquitination and Exhibits Both Oncogenic and Tumor Suppressor Roles in Cancer. Cancers, 2017, 9, 167.	3.7	43
750	MicroRNA Expression Profile Identifies High Grade, Non-Muscle-Invasive Bladder Tumors at Elevated Risk to Progress to an Invasive Phenotype. Genes, 2017, 8, 77.	2.4	19

#	ARTICLE	IF	CITATIONS
751	Genome-Wide Screen of miRNAs and Targeting mRNAs Reveals the Negatively Regulatory Effect of miR-130b-3p on PTEN by PI3K and Integrin $\beta$ 1 Signaling Pathways in Bladder Carcinoma. International Journal of Molecular Sciences, 2017, 18, 78.	4.1	28
752	Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. International Journal of Molecular Sciences, 2017, 18, 308.	4.1	353
753	Concurrent Autophagy Inhibition Overcomes the Resistance of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Human Bladder Cancer Cells. International Journal of Molecular Sciences, 2017, 18, 321.	4.1	25
754	Overexpression of Transforming Acidic Coiled Coil-Containing Protein 3 Reflects Malignant Characteristics and Poor Prognosis of Glioma. International Journal of Molecular Sciences, 2017, 18, 235.	4.1	9
755	Differential Effects of Histone Acetyltransferase GCN5 or PCAF Knockdown on Urothelial Carcinoma Cells. International Journal of Molecular Sciences, 2017, 18, 1449.	4.1	22
756	Understanding the Role of Non-Coding RNAs in Bladder Cancer: From Dark Matter to Valuable Therapeutic Targets. International Journal of Molecular Sciences, 2017, 18, 1514.	4.1	55
757	Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation. ELife, 2017, 6, .	6.0	55
758	Single-Cell mRNA Sequencing in Cancer Research: Integrating the Genomic Fingerprint. Frontiers in Genetics, 2017, 8, 73.	2.3	27
759	Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression. Frontiers in Medicine, 2017, 4, 30.	2.6	13
760	Signal Transduction Networks Analysis: The Reverse Phase Protein Array. , 2017, , .		0
761	Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs. International Journal of Genomics, 2017, 2017, 1-9.	1.6	40
762	Tsc2 disruption in mesenchymal progenitors results in tumors with vascular anomalies overexpressing Lgals3. ELife, 2017, 6, .	6.0	13
763	Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?. Translational Andrology and Urology, 2017, 6, 1067-1080.	1.4	19
765	Identification of key pathways and genes influencing prognosis in bladder urothelial carcinoma. OncoTargets and Therapy, 2017, Volume 10, 1673-1686.	2.0	21
766	Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. OncoTargets and Therapy, 2017, Volume 10, 1487-1502.	2.0	12
767	Helminth infection-“induced malignancy. PLoS Pathogens, 2017, 13, e1006393.	4.7	47
768	Systemic Chemotherapy in Muscle Invasive and Metastatic Bladder Cancer: Present and Future. Urologia, 2017, 84, 130-141.	0.7	8
769	Whole-genome analysis of papillary kidney cancer finds significant noncoding alterations. PLoS Genetics, 2017, 13, e1006685.	3.5	38

#	ARTICLE	IF	CITATIONS
770	IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer. BMC Cancer, 2017, 17, 636.	2.6	18
771	Association of a novel point mutation in MSH2 gene with familial multiple primary cancers. Journal of Hematology and Oncology, 2017, 10, 158.	17.0	4
772	Predicting cancer type from tumour DNA signatures. Genome Medicine, 2017, 9, 104.	8.2	40
773	Biomarkers for immunotherapy in bladder cancer: a moving target. , 2017, 5, 94.		144
774	Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmetteâ€“GuÃ©rin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer. Medical Oncology, 2017, 34, 172.	2.5	19
775	SegCorr a statistical procedure for the detection of genomic regions of correlated expression. BMC Bioinformatics, 2017, 18, 333.	2.6	5
776	Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. European Urology, 2017, 72, 952-959.	1.9	263
777	Identification of lung adenocarcinoma specific dysregulated genes with diagnostic and prognostic value across 27 TCGA cancer types. Oncotarget, 2017, 8, 87292-87306.	1.8	16
778	Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study. Oncotarget, 2017, 8, 56398-56407.	1.8	25
779	The landscape of genetics and biomarkers in bladder cancer. Translational Andrology and Urology, 2017, 6, 1027-1030.	1.4	4
780	Advances in Organoid Culturing of Patient-Derived Tumors. , 2017, , 365-375.		0
781	DNA Repair Pathway Alterations in Bladder Cancer. Cancers, 2017, 9, 28.	3.7	39
782	Opportunities of next-generation sequencing in non-muscle invasive bladder cancer outcome prediction. Translational Andrology and Urology, 2017, 6, 1043-1048.	1.4	17
783	B7-H3 Promotes the Migration and Invasion of Human Bladder Cancer Cells via the PI3K/Akt/STAT3 Signaling Pathway. Journal of Cancer, 2017, 8, 816-824.	2.5	71
784	Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precision Oncology, 2017, 2017, 1-15.	3.0	796
785	Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities With Colorectal Cancer, Including a Hypermutable Phenotype. JCO Precision Oncology, 2017, 1, 1-12.	3.0	17
786	Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention. Oncotarget, 2017, 8, 69435-69455.	1.8	27
787	Improving outcome and prognosis prediction in non-muscle invasive bladder cancer using a gene expression score. Translational Andrology and Urology, 2017, 6, 991-993.	1.4	1

#	ARTICLE	IF	CITATIONS
788	Current markers and their value in the era of immuno-oncology. Translational Andrology and Urology, 2017, 6, 1111-1116.	1.4	6
789	Next-generation sequencing in non-muscle-invasive bladder cancerâ€”a step towards personalized medicine for a superficial bladder tumor. Translational Andrology and Urology, 2017, 6, 1198-1202.	1.4	2
790	Trimodality therapy in variant urothelial carcinoma: choose wisely. Translational Andrology and Urology, 2017, 6, 322-325.	1.4	3
791	Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility. Modern Pathology, 2018, 31, 1270-1281.	5.5	24
792	Novel biomarkers in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 115-119.	1.6	5
793	PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53. Oncogene, 2018, 37, 2793-2805.	5.9	42
794	An <sc>FGFR</sc> 3/ <sc>MYC</sc> positive feedback loop provides new opportunities for targeted therapies in bladder cancers. EMBO Molecular Medicine, 2018, 10, .	6.9	54
795	Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies. Current Treatment Options in Oncology, 2018, 19, 16.	3.0	5
796	Super-Enhancer-Driven Long Non-Coding RNA LINC01503, Regulated by TP63, Is Over-Expressed and Oncogenic in Squamous Cell Carcinoma. Gastroenterology, 2018, 154, 2137-2151.e1.	1.3	165
797	Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 749-758.	2.8	43
798	<sc>P</sc>athogenic and targetable genetic alterations in 70 urachal adenocarcinomas. International Journal of Cancer, 2018, 143, 1764-1773.	5.1	44
799	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, 2018, 173, 400-416.e11.	28.9	2,277
800	Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Cell, 2018, 173, 515-528.e17.	28.9	540
801	Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell, 2018, 173, 321-337.e10.	28.9	2,111
802	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell Reports, 2018, 23, 227-238.e3.	6.4	407
803	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports, 2018, 23, 194-212.e6.	6.4	245
804	Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy. BJU International, 2018, 122, 627-632.	2.5	24
805	Unravelling disparate roles of NOTCH in bladder cancer. Nature Reviews Urology, 2018, 15, 345-357.	3.8	42

#	ARTICLE	IF	CITATIONS
806	Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer. Bladder Cancer, 2018, 4, 77-90.	0.4	19
807	Knockdown of tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ) enhances tumorigenesis both in vivo and in vitro in bladder cancer. Oncology Reports, 2018, 39, 2127-2135.	2.6	11
808	Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma. Journal of Urology, 2018, 199, 1129-1142.	0.4	34
810	Arsenic promotes the <scp>COX2/PGE2</scp>“SOX2</scp> axis to increase the malignant stemness properties of urothelial cells. International Journal of Cancer, 2018, 143, 113-126.	5.1	21
811	The New Age of -omics in Urothelial Cancer “ Re-wording Its Diagnosis and Treatment. EBioMedicine, 2018, 28, 43-50.	6.1	12
812	TGFÎ <sup>2</sup> attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature, 2018, 554, 544-548.	27.8	3,359
813	Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases. Clinical Cancer Research, 2018, 24, 2182-2193.	7.0	68
814	TACC3 transcriptionally upregulates E2F1 to promote cell growth and confer sensitivity to cisplatin in bladder cancer. Cell Death and Disease, 2018, 9, 72.	6.3	20
815	Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy. Oncogenesis, 2018, 7, 2.	4.9	68
816	A practical guide to bladder cancer pathology. Nature Reviews Urology, 2018, 15, 143-154.	3.8	36
817	Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401774604.	3.2	11
818	Risk Factors and Molecular Features Associated with Bladder Cancer Development. Molecular Pathology Library, 2018, , 3-28.	0.1	1
819	Stromal Contributions to Tumor Progression in Urothelial Carcinoma of the Bladder. Molecular Pathology Library, 2018, , 209-220.	0.1	0
820	Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas. Journal of the National Cancer Institute, 2018, 110, 448-459.	6.3	112
821	Subtyping Bladder Cancers: Biology vs Bioinformatics. Journal of the National Cancer Institute, 2018, 110, 439-440.	6.3	4
822	Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case“Control Study. Journal of the National Cancer Institute, 2018, 110, 527-533.	6.3	22
823	<scp>GP</scp>73 promotes invasion and metastasis of bladder cancer by regulating the epithelial“mesenchymal transition through the <scp>TGF</scp>“Î <sup>2</sup> /Smad2 signalling pathway. Journal of Cellular and Molecular Medicine, 2018, 22, 1650-1665.	3.6	23
824	A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer. Oncogene, 2018, 37, 1911-1925.	5.9	102

#	ARTICLE	IF	CITATIONS
825	Current approaches for identifying high-risk non-muscle invasive bladder cancer. Expert Review of Anticancer Therapy, 2018, 18, 223-235.	2.4	6
826	Blocking PD-1/PD-L1 in Genitourinary Malignancies. Cancer Journal (Sudbury, Mass ), 2018, 24, 20-30.	2.0	17
827	Network science in clinical trials: A patient-centered approach. Seminars in Cancer Biology, 2018, 52, 135-150.	9.6	9
828	Clinical and RNA expression integrated signature for urothelial bladder cancer prognosis. Cancer Biomarkers, 2018, 21, 535-546.	1.7	6
830	Proteomics and Metabolomics for AKI Diagnosis. Seminars in Nephrology, 2018, 38, 63-87.	1.6	59
831	ERBB2 mutation: A promising target in non-squamous cervical cancer. Gynecologic Oncology, 2018, 148, 311-316.	1.4	27
832	Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. Journal of Pharmacology and Experimental Therapeutics, 2018, 364, 494-503.	2.5	85
833	PanCancer insights from The Cancer Genome Atlas: the pathologist's perspective. Journal of Pathology, 2018, 244, 512-524.	4.5	144
834	Ex vivo culture of tumor cells from N-methyl-N-nitrosourea-induced bladder cancer in rats: Development of organoids and an immortalized cell line. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 160.e23-160.e32.	1.6	13
835	XIAP overexpression promotes bladder cancer invasion <i>in vitro</i> and lung metastasis <i>in vivo</i> via enhancing nucleolin-mediated Rho GDI $\alpha$ mRNA stability. International Journal of Cancer, 2018, 142, 2040-2055.	5.1	46
836	BCG and Anti-PDL-1 Ab in Bladder Cancers. , 2018, , 357-369.		0
837	Multi-omic profiling refines the molecular view. Nature Reviews Clinical Oncology, 2018, 15, 203-204.	27.6	22
838	An update on the molecular pathology of urinary bladder tumors. Pathology Research and Practice, 2018, 214, 1-6.	2.3	33
839	Modeling Bladder Cancer with Genetic Engineering: Fidelity of Human-to-Laboratory Models. Molecular Pathology Library, 2018, , 221-237.	0.1	0
840	Diagnostic, Prognostic, and Predictive Biomarkers on Bladder Tissue and Blood. Molecular Pathology Library, 2018, , 117-136.	0.1	0
841	Precision Molecular Pathology of Bladder Cancer. Molecular Pathology Library, 2018, , .	0.1	0
842	Response to Immunotherapy: Application of Molecular Pathology to Predict Successful Response. Molecular Pathology Library, 2018, , 181-194.	0.1	0
843	Molecular Alterations in the Pathogenesis of Bladder Cancer Subtypes and Urothelial Carcinoma Variants. Molecular Pathology Library, 2018, , 65-83.	0.1	0

#	ARTICLE	IF	CITATIONS
844	Treatment Paradigms in Bladder Cancer: Clinical Implications of Histological and Molecular Analysis. Molecular Pathology Library, 2018, , 85-101.	0.1	0
845	Precision oncology in the age of integrative genomics. Nature Biotechnology, 2018, 36, 46-60.	17.5	104
846	Emerging Molecular Approaches in the Analysis of Urine in Bladder Cancer Diagnosis. Molecular Pathology Library, 2018, , 195-207.	0.1	0
847	Genomic Assessment of Muscle-Invasive Bladder Cancer: Insights from the Cancer Genome Atlas (TCGA) Project. Molecular Pathology Library, 2018, , 43-64.	0.1	0
848	LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Research, 2018, 46, D956-D963.	14.5	1,497
849	SQUID: transcriptomic structural variation detection from RNA-seq. Genome Biology, 2018, 19, 52.	8.8	27
850	Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment. Human Genomics, 2018, 12, 20.	2.9	11
851	Treatment resistance in urothelial carcinoma: an evolutionary perspective. Nature Reviews Clinical Oncology, 2018, 15, 495-509.	27.6	37
852	Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 342.e7-342.e14.	1.6	11
853	INO80 Chromatin Remodeling Coordinates Metabolic Homeostasis with Cell Division. Cell Reports, 2018, 22, 611-623.	6.4	28
854	Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. Human Pathology, 2018, 77, 63-69.	2.0	27
855	Importin-11 overexpression promotes the migration, invasion, and progression of bladder cancer associated with the deregulation of CDKN1A and THBS1. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 311.e1-311.e13.	1.6	16
856	The long tail of oncogenic drivers in prostate cancer. Nature Genetics, 2018, 50, 645-651.	21.4	601
857	Integrative Analysis of Omics Big Data. Methods in Molecular Biology, 2018, 1754, 109-135.	0.9	54
858	The evolving genomic landscape in urothelial cancer. Current Opinion in Oncology, 2018, 30, 197-202.	2.4	7
859	Systematic characterization of pan-cancer mutation clusters. Molecular Systems Biology, 2018, 14, e7974.	7.2	39
860	Identification of differentially expressed genes and biological pathways in bladder cancer. Molecular Medicine Reports, 2018, 17, 6425-6434.	2.4	16
861	The evolution of bladder cancer genomics: What have we learned and how can we use it?. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 313-320.	1.6	73



#	ARTICLE	IF	CITATIONS
863	Wnt7a activates canonical Wnt signaling, promotes bladder cancer cell invasion, and is suppressed by miR-370-3p. <i>Journal of Biological Chemistry</i> , 2018, 293, 6693-6706.	3.4	86
864	The emerging role of immunotherapy in advanced urothelial cancers. <i>Current Opinion in Oncology</i> , 2018, 30, 172-180.	2.4	23
865	RE: Elevated Bladder Cancer in Northern New England: The Role of Drinking Water and Arsenic. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1273-1274.	6.3	1
866	Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer. <i>Translational Oncology</i> , 2018, 11, 467-476.	3.7	19
867	Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics. <i>Oncogene</i> , 2018, 37, 3039-3044.	5.9	40
868	A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. <i>Scientific Reports</i> , 2018, 8, 3737.	3.3	128
869	Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers. <i>European Urology Focus</i> , 2018, 4, 94-97.	3.1	3
870	Study on genetic stability in human urothelial cells in vitro. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2018, 12, e720-e726.	2.7	2
871	Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma. <i>European Urology Focus</i> , 2018, 4, 880-888.	3.1	25
872	Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder. <i>European Urology Focus</i> , 2018, 4, 907-915.	3.1	40
873	The anti-PD-1 era “an opportunity to enhance radiotherapy for patients with bladder cancer. <i>Nature Reviews Urology</i> , 2018, 15, 251-259.	3.8	27
874	Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. <i>European Urology Focus</i> , 2018, 4, 442-454.	3.1	10
875	Protein kinase D inhibitor CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 939-963.	5.4	36
876	Regulation and Dysregulation of Chromosome Structure in Cancer. <i>Annual Review of Cancer Biology</i> , 2018, 2, 21-40.	4.5	26
877	Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer. <i>Molecular Cancer Research</i> , 2018, 16, 69-77.	3.4	33
878	Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1) “Deficient Carcinomas of the Urinary System. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e373-e382.	1.9	3
879	Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e403-e410.	1.9	11
880	Immunotherapy for metastatic urothelial carcinoma. <i>Current Opinion in Urology</i> , 2018, 28, 1-7.	1.8	6

#	ARTICLE	IF	CITATIONS
881	Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. <i>Seminars in Cancer Biology</i> , 2018, 52, 216-227.	9.6	14
882	Treatment for presumed BK polyomavirus nephropathy and risk of urinary tract cancers among kidney transplant recipients in the United States. <i>American Journal of Transplantation</i> , 2018, 18, 245-252.	4.7	39
883	Clinical Proteomics for Precision Medicine: The Bladder Cancer Case. <i>Proteomics - Clinical Applications</i> , 2018, 12, 1700074.	1.6	21
885	A Practical Approach to Tumor Heterogeneity in Clinical Research and Diagnostics. <i>Pathobiology</i> , 2018, 85, 7-17.	3.8	13
886	Prevalence and clonality of synchronous primary carcinomas in the bladder and prostate. <i>Journal of Pathology</i> , 2018, 244, 5-10.	4.5	3
887	The Emerging Role of PD-1/PD-L1 in Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma. <i>Annals of Pharmacotherapy</i> , 2018, 52, 60-68.	1.9	5
888	The Neddylation Inhibitor Pevonedistat (MLN4924) Suppresses and Radiosensitizes Head and Neck Squamous Carcinoma Cells and Tumors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 368-380.	4.1	45
889	Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 8.e1-8.e8.	1.6	8
890	Molecular Subtype Profiling of Urothelial Carcinoma Using a Subtype-Specific Immunohistochemistry Panel. <i>Methods in Molecular Biology</i> , 2018, 1655, 53-64.	0.9	32
891	Urinary Protein Markers for the Detection and Prognostication of Urothelial Carcinoma. <i>Methods in Molecular Biology</i> , 2018, 1655, 251-273.	0.9	6
892	Detection of APOBEC3 Proteins and Catalytic Activity in Urothelial Carcinoma. <i>Methods in Molecular Biology</i> , 2018, 1655, 97-107.	0.9	8
893	Epigenetic Treatment Options in Urothelial Carcinoma. <i>Methods in Molecular Biology</i> , 2018, 1655, 289-317.	0.9	1
894	Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer. <i>Methods in Molecular Biology</i> , 2018, 1655, 335-350.	0.9	117
895	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. <i>Clinical Cancer Research</i> , 2018, 24, 1965-1973.	7.0	85
896	Re: Comprehensive Molecular Characterization of Muscle Invasive Bladder Cancer. <i>European Urology</i> , 2018, 73, 479-480.	1.9	2
897	The Rho GTPase signalling pathway in urothelial carcinoma. <i>Nature Reviews Urology</i> , 2018, 15, 83-91.	3.8	15
898	Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 117-129.	1.9	28
899	Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. <i>Nature Reviews Urology</i> , 2018, 15, 92-111.	3.8	139

#	ARTICLE	IF	CITATIONS
900	Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. Nature Reviews Urology, 2018, 15, 112-124.	3.8	73
901	Advancing care through genomics and immune checkpoint blockade. Nature Reviews Urology, 2018, 15, 71-72.	3.8	8
902	A suite of DNA methylation markers that can detect most common human cancers. Epigenetics, 2018, 13, 61-72.	2.7	48
903	Circulating Tumor DNA in Bladder Cancer: Novel Applications and Future Directions. European Urology, 2018, 73, 541-542.	1.9	9
904	Viral sequences in human cancer. Virology, 2018, 513, 208-216.	2.4	100
906	Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract. Translational Oncology, 2018, 11, 37-42.	3.7	35
907	Recent developments in the management of bladder cancer: Introduction. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 95-96.	1.6	9
908	Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 413-422.	1.6	32
909	Biomarkers for immunotherapy in urological cancers. Current Opinion in Urology, 2018, 28, 25-28.	1.8	1
910	Re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 2017;72:354-365. European Urology, 2018, 73, e102-e103.	1.9	0
911	Clustering of RNA-Seq samples: Comparison study on cancer data. Methods, 2018, 132, 42-49.	3.8	22
912	ERBB3-Activating Mutations in Small Bowel Adenocarcinomas. JCO Precision Oncology, 2018, 2, 1-9.	3.0	1
913	Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 342-353.	3.8	20
914	Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of Clinical Oncology, 2018, 36, 1685-1694.	1.6	399
915	Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology, 2018, 36, 1949-1956.	1.6	110
916	Unmet Clinical Needs and Future Perspectives in Non-muscle-invasive Bladder Cancer. European Urology Focus, 2018, 4, 472-480.	3.1	8
917	Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells. Oncotarget, 2018, 9, 28514-28531.	1.8	8
918	The complex relationship between upper urinary tract and bladder cancer: clinical and predictive issues. Translational Andrology and Urology, 2018, 7, S248-S251.	1.4	5

#	ARTICLE	IF	CITATIONS
919	Subject level clustering using a negative binomial model for small transcriptomic studies. BMC Bioinformatics, 2018, 19, 474.	2.6	8
920	The value of molecular markers in classification and prediction of progression in non-muscle-invasive bladder cancer. Translational Andrology and Urology, 2018, 7, 736-739.	1.4	5
921	Urinary biomarker for the detection of recurrence following non-muscle invasive bladder cancer: are we there yet?. Translational Andrology and Urology, 2018, 7, S109-S110.	1.4	0
922	Epigenetic silencing of miR-200b is associated with cisplatin resistance in bladder cancer. Oncotarget, 2018, 9, 24457-24469.	1.8	31
923	Subclassification, survival prediction and drug target analyses of chemotherapy-naïve muscle-invasive bladder cancer with a molecular screening. Oncotarget, 2018, 9, 25935-25945.	1.8	22
924	Increased expression of TNFRSF14 indicates good prognosis and inhibits bladder cancer proliferation by promoting apoptosis. Molecular Medicine Reports, 2018, 18, 3403-3410.	2.4	16
925	The papilla as a biomarker in the molecular era of bladder oncology. Surgical and Experimental Pathology, 2018, 1, .	0.6	1
928	Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. Current Urology Reports, 2018, 19, 109.	2.2	47
929	Updates on the Genetics and Molecular Subtypes of Urothelial Carcinoma and Select Variants. Surgical Pathology Clinics, 2018, 11, 713-723.	1.7	26
930	PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis. International Journal of Biological Sciences, 2018, 14, 1883-1891.	6.4	110
931	Mutational landscape of non-muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 295-303.	1.6	31
932	Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. Lancet Oncology, The, 2018, 19, e683-e695.	10.7	74
934	Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma. Future Science OA, 2018, 4, FSO341.	1.9	8
935	Molecular Characterization of Bladder Cancer. Current Urology Reports, 2018, 19, 107.	2.2	10
937	Is APC hypermethylation a diagnostic biomarker for bladder cancer? A meta-analysis. OncoTargets and Therapy, 2018, Volume 11, 8359-8369.	2.0	7
938	RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective. Cancers, 2018, 10, 518.	3.7	10
939	IL-23 concentration dependently regulates T24 cell proliferation, migration and invasion and is associated with prognosis in patients with bladder cancer. Oncology Reports, 2018, 40, 3685-3693.	2.6	3
940	Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 287-294.	1.6	28

#	ARTICLE	IF	CITATIONS
941	Immunotherapy Advances in Urothelial Carcinoma. Current Treatment Options in Oncology, 2018, 19, 79.	3.0	5
942	The urothelial cell line UROtsa transformed by arsenite and cadmium display basal characteristics associated with muscle invasive urothelial cancers. PLoS ONE, 2018, 13, e0207877.	2.5	15
943	The continuing role of chemotherapy in the management of advanced urothelial cancer. Therapeutic Advances in Urology, 2018, 10, 455-480.	2.0	16
944	Expression of GFR $\alpha$ 3 correlates with tumor progression and promotes cell metastasis in urothelial carcinoma. Minerva Urology and Nephrology, 2018, 70, 79-86.	2.5	2
945	Prime time for immunotherapy in advanced urothelial cancer. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 24-32.	1.1	2
946	Inhibition of TPL2 by interferon- $\gamma$ suppresses bladder cancer through activation of PDE4D. Journal of Experimental and Clinical Cancer Research, 2018, 37, 288.	8.6	14
947	Clinical, prognostic, and therapeutic significance of heat shock protein 27 in bladder cancer. Oncotarget, 2018, 9, 7961-7974.	1.8	9
948	Identification and Characterization of MicroRNAs Associated with Somatic Copy Number Alterations in Cancer. Cancers, 2018, 10, 475.	3.7	6
949	Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy. British Journal of Cancer, 2018, 119, 801-807.	6.4	29
950	Urinary Exosomal and cell-free DNA Detects Somatic Mutation and Copy Number Alteration in Urothelial Carcinoma of Bladder. Scientific Reports, 2018, 8, 14707.	3.3	41
951	Glandular Tumors of the Urachus and Urinary Bladder: A Practical Overview of a Broad Differential Diagnosis. Archives of Pathology and Laboratory Medicine, 2018, 142, 1164-1176.	2.5	9
952	Bladder cancer detection by urinary extracellular vesicle mRNA analysis. Oncotarget, 2018, 9, 32810-32821.	1.8	23
953	Identification of miR-200c and miR141-Mediated lncRNA-mRNA Crosstalks in Muscle-Invasive Bladder Cancer Subtypes. Frontiers in Genetics, 2018, 9, 422.	2.3	26
954	Extracellular Vesicles in Bladder Cancer: Biomarkers and Beyond. International Journal of Molecular Sciences, 2018, 19, 2822.	4.1	35
955	CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making. Scientific Reports, 2018, 8, 14383.	3.3	32
956	Immune infiltrates and PD-L1 expression in treatment-naïve acinar prostatic adenocarcinoma: an exploratory analysis. Journal of Clinical Pathology, 2018, 71, 1023-1027.	2.0	11
957	Onco-Multi-OMICS Approach: A New Frontier in Cancer Research. BioMed Research International, 2018, 2018, 1-14.	1.9	218
958	Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro. Drug Design, Development and Therapy, 2018, Volume 12, 1727-1742.	4.3	22

#	ARTICLE	IF	CITATIONS
959	Genomics of drug sensitivity in bladder cancer: an integrated resource for pharmacogenomic analysis in bladder cancer. BMC Medical Genomics, 2018, 11, 88.	1.5	3
960	Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy. PLoS ONE, 2018, 13, e0205746.	2.5	38
961	mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants. International Journal of Molecular Sciences, 2018, 19, 3396.	4.1	35
962	A Festschrift in Honor of Edward M. Messing, MD, FACS. Bladder Cancer, 2018, 4, S1-S43.	0.4	0
963	Exploration of genetics commonness between bladder cancer and breast cancer based on a silcio analysis on disease subtypes. Technology and Health Care, 2018, 26, 361-377.	1.2	3
964	miRâ€™124 regulates STAT3â€™mediated cell proliferation, migration and apoptosis in bladder cancer. Oncology Letters, 2018, 16, 5875-5881.	1.8	19
965	miRNAâ€™26aâ€™5p and miRâ€™26bâ€™5p inhibit the proliferation of bladder cancer cells by regulating PDCD10. Oncology Reports, 2018, 40, 3523-3532.	2.6	30
966	CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer. British Journal of Cancer, 2018, 119, 961-970.	6.4	27
967	Multiregion segmentation of bladder cancer structures in MRI with progressive dilated convolutional networks. Medical Physics, 2018, 45, 5482-5493.	3.0	60
968	Precision medicine and bladder cancer heterogeneity. Bulletin Du Cancer, 2018, 105, 925-931.	1.6	19
969	Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo. Molecules, 2018, 23, 2643.	3.8	19
970	Expression pattern of p53-binding protein 1 as a new molecular indicator of genomic instability in bladder urothelial carcinoma. Scientific Reports, 2018, 8, 15477.	3.3	9
972	Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. British Journal of Cancer, 2018, 119, 707-712.	6.4	28
973	Update on multiparametric MRI of urinary bladder cancer. Journal of Magnetic Resonance Imaging, 2018, 48, 882-896.	3.4	48
974	Impact of Immunohistochemistry-Based Subtypes in Muscle-Invasive Bladder Cancer on Response to Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1408-1416.	0.8	17
975	Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma. Clinical Genitourinary Cancer, 2018, 16, 437-444.e6.	1.9	7
976	A machine learning approach for somatic mutation discovery. Science Translational Medicine, 2018, 10, .	12.4	80
977	Immune checkpoint inhibitors for urothelial carcinoma. Investigative and Clinical Urology, 2018, 59, 285.	2.0	94

#	ARTICLE	IF	CITATIONS
978	Identification of a functional antioxidant response element at the HIF1A locus. Redox Biology, 2018, 19, 401-411.	9.0	77
979	Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer. International Journal of Molecular Sciences, 2018, 19, 2777.	4.1	15
980	Diagnostic and prognostic biomarkers of common urological cancers based on aberrant DNA methylation. Epigenomics, 2018, 10, 1189-1199.	2.1	17
981	Genetic Alterations of TRAF Proteins in Human Cancers. Frontiers in Immunology, 2018, 9, 2111.	4.8	67
983	Genomic case report of a low grade bladder tumor metastasis to lung. BMC Urology, 2018, 18, 74.	1.4	3
985	Diagnostic and Prognostic Implications of FGFR3high/Ki67high Papillary Bladder Cancers. International Journal of Molecular Sciences, 2018, 19, 2548.	4.1	14
986	Molecular Prognostication in Bladder Cancer. Cancer Treatment and Research, 2018, 175, 165-191.	0.5	5
987	The Role and Importance of Timely Radical Cystectomy for High-Risk Non-muscle-Invasive Bladder Cancer. Cancer Treatment and Research, 2018, 175, 193-214.	0.5	3
988	A distinct class of antioxidant response elements is consistently activated in tumors with NRF2 mutations. Redox Biology, 2018, 19, 235-249.	9.0	37
989	Advances in risk stratification of bladder cancer to guide personalized medicine. F1000Research, 2018, 7, 1137.	1.6	34
990	Tissue-based molecular markers in upper tract urothelial carcinoma and their prognostic implications. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 22-37.	1.5	17
991	Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discovery, 2018, 8, 1422-1437.	9.4	126
992	A feed forward loop enforces YAP/TAZ signaling during tumorigenesis. Nature Communications, 2018, 9, 3510.	12.8	75
993	EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nature Communications, 2018, 9, 3503.	12.8	224
994	The Cancer Genome Atlas Project in Bladder Cancer. Cancer Treatment and Research, 2018, 175, 259-271.	0.5	16
995	CUA Annual Meeting Abstracts 2018. Canadian Urological Association Journal, 2018, 12, S51-144.	0.6	0
996	Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma. Current Treatment Options in Oncology, 2018, 19, 36.	3.0	22
997	Personalized Medicine. , 2018, , 659-673.		0



#	ARTICLE	IF	CITATIONS
998	Section VI. Chemotherapy for Metastatic Bladder Cancer. , 2018, , 523-537.		0
999	Modified citrus pectin inhibited bladder tumor growth through downregulation of galectin-3. Acta Pharmacologica Sinica, 2018, 39, 1885-1893.	6.1	44
1000	Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors. Anti-Cancer Drugs, 2018, 29, 549-559.	1.4	12
1001	Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy. Cancer Research, 2018, 78, 3954-3968.	0.9	82
1002	Molecular subtype classification of urothelial carcinoma in Lynch syndrome. Molecular Oncology, 2018, 12, 1286-1295.	4.6	25
1003	Detection of Urothelial Bladder Carcinoma via Microfluidic Immunoassay and Single-Cell DNA Copy-Number Alteration Analysis of Captured Urinary-Exfoliated Tumor Cells. Cancer Research, 2018, 78, 4073-4085.	0.9	34
1004	LINC00857 expression predicts and mediates the response to platinum-based chemotherapy in muscle-invasive bladder cancer. Cancer Medicine, 2018, 7, 3342-3350.	2.8	31
1005	Targeting Rac and Cdc42 GTPases in Cancer. Cancer Research, 2018, 78, 3101-3111.	0.9	197
1006	Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers. Cancer Research, 2018, 78, 4642-4657.	0.9	60
1007	Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer. Bladder Cancer, 2018, 4, 19-29.	0.4	41
1008	Current and future biomarkers in gastric cancer. Biomedicine and Pharmacotherapy, 2018, 103, 1688-1700.	5.6	44
1009	Identification of an enhancer region within the TP63/LEPREL1 locus containing genetic variants associated with bladder cancer risk. Cellular Oncology (Dordrecht), 2018, 41, 555-568.	4.4	11
1010	Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy. EBioMedicine, 2018, 35, 198-203.	6.1	33
1011	Molecularly-driven precision medicine for advanced bladder cancer. World Journal of Urology, 2018, 36, 1749-1757.	2.2	4
1012	p190 RhoGAP promotes contact inhibition in epithelial cells by repressing YAP activity. Journal of Cell Biology, 2018, 217, 3183-3201.	5.2	21
1013	Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer. Bladder Cancer, 2018, 4, 9-18.	0.4	18
1014	Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. ELife, 2018, 7, .	6.0	118
1015	Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR. Oncogene, 2018, 37, 5858-5872.	5.9	20

#	ARTICLE	IF	CITATIONS
1016	Basalâ€subtype bladder tumours show a â€hotâ€™ immunophenotype. Histopathology, 2018, 73, 748-757.	2.9	43
1017	X chromosome protects against bladder cancer in females via a <i>KDM6A</i>-dependent epigenetic mechanism. Science Advances, 2018, 4, eaar5598.	10.3	99
1018	Nivolumab and its use in the second-line treatment of metastatic urothelial cancer. Future Oncology, 2018, 14, 2683-2690.	2.4	1
1019	Defining the frequency of human papillomavirus and polyomavirus infection in urothelial bladder tumours. Scientific Reports, 2018, 8, 11290.	3.3	28
1020	Single-cell RNA-seq analysis identifies markers of resistance to targeted BRAF inhibitors in melanoma cell populations. Genome Research, 2018, 28, 1353-1363.	5.5	71
1021	RECK isoforms have opposing effects on cell migration. Molecular Biology of the Cell, 2018, 29, 1825-1838.	2.1	20
1022	Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer. Bladder Cancer, 2018, 4, 429-440.	0.4	5
1023	Prolyl oligopeptidase inhibitor suppresses the upregulation of ACSDKP in patients with acute myeloid leukemia. Experimental and Therapeutic Medicine, 2018, 15, 5431-5435.	1.8	1
1024	Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology. Drug Discovery Today, 2018, 23, 1848-1872.	6.4	12
1025	Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma. BMC Urology, 2018, 18, 68.	1.4	18
1026	A novel regulatory circuit of miRâ€™152 and DNMT1 in human bladder cancer. Oncology Reports, 2018, 40, 1803-1812.	2.6	9
1027	Characterization of the Olfactory Receptor OR10H1 in Human Urinary Bladder Cancer. Frontiers in Physiology, 2018, 9, 456.	2.8	34
1028	Molecular Landscape of Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2018, 4, 131-132.	0.4	3
1029	Identifying Cancer Specific Driver Modules Using a Network-Based Method. Molecules, 2018, 23, 1114.	3.8	5
1030	Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1019-1040.	2.0	55
1031	Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications. European Urology, 2018, 74, 741-753.	1.9	54
1032	MMP23B expression and protein levels in blood and urine are associated with bladder cancer. Carcinogenesis, 2018, 39, 1254-1263.	2.8	9
1033	<i>FGFR3</i> mutation increases bladder tumourigenesis by suppressing acute inflammation. Journal of Pathology, 2018, 246, 331-343.	4.5	33

#	ARTICLE	IF	CITATIONS
1034	Effects of multi and selective targeted tyrosine kinase inhibitors on function and signaling of different bladder cancer cells. Biomedicine and Pharmacotherapy, 2018, 106, 316-325.	5.6	7
1035	Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. Molecular Cancer Therapeutics, 2018, 17, 1902-1916.	4.1	48
1036	Bladder Cancer: New Insights into Its Molecular Pathology. Cancers, 2018, 10, 100.	3.7	77
1037	Molecular Basics on Genitourinary Malignancies. , 2018, , 1-15.		0
1038	Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines. International Journal of Molecular Sciences, 2018, 19, 590.	4.1	29
1039	Novel therapies in urothelial carcinoma: a biomarker-driven approach. Annals of Oncology, 2018, 29, 2302-2312.	1.2	9
1040	Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nature Reviews Urology, 2018, 15, 615-625.	3.8	284
1041	Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes. Clinical Cancer Research, 2018, 24, 6115-6124.	7.0	14
1042	A Pan-Cancer Compendium of Genes Deregulated by Somatic Genomic Rearrangement across More Than 1,400 Cases. Cell Reports, 2018, 24, 515-527.	6.4	70
1043	Notch Pathway: Bioinformatic Analysis of Related Transcription Factors within Bladder Cancer Types and Subtypes. Irbm, 2018, 39, 261-267.	5.6	0
1044	Comprehensive gene expression analysis of canine invasive urothelial bladder carcinoma by RNA-Seq. BMC Cancer, 2018, 18, 472.	2.6	53
1045	Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma. Clinical Epigenetics, 2018, 10, 19.	4.1	22
1046	Chromatin 3D “ will it make understanding of cancer transformation finally possible?. Bio-Algorithms and Med-Systems, 2018, 14, .	2.4	0
1047	HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors. Breast Cancer Research, 2018, 20, 8.	5.0	44
1048	Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines. Clinical Epigenetics, 2018, 10, 1.	4.1	93
1049	Promoter methylation of DNA damage repair (DDR) genes in human tumor entities: RBBP8/CtIP is almost exclusively methylated in bladder cancer. Clinical Epigenetics, 2018, 10, 15.	4.1	32
1050	New insights from the widening homogeneity perspective to target intratumor heterogeneity. Cancer Communications, 2018, 38, 1-7.	9.2	9
1051	Enhancer Logic and Mechanics in Development and Disease. Trends in Cell Biology, 2018, 28, 608-630.	7.9	146

#	ARTICLE	IF	CITATIONS
1052	Alternative splicing of ALCAM enables tunable regulation of cell-cell adhesion through differential proteolysis. Scientific Reports, 2018, 8, 3208.	3.3	13
1054	A Gene Expression Signature Predicts Bladder Cancer Cell Line Sensitivity to EGFR Inhibition. Bladder Cancer, 2018, 4, 269-282.	0.4	6
1055	Low Frequency of Intratumor Heterogeneity in Bladder Cancer Tissue Microarrays. Bladder Cancer, 2018, 4, 327-337.	0.4	18
1056	Antibody-Drug Conjugates in Bladder Cancer. Bladder Cancer, 2018, 4, 247-259.	0.4	29
1057	A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression. Neoplasia, 2018, 20, 894-904.	5.3	50
1058	The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. Nature Communications, 2018, 9, 3292.	12.8	153
1059	Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies. Bladder Cancer, 2018, 4, 149-159.	0.4	27
1060	HER2 Activation Factors in Arsenite-Exposed Bladder Epithelial Cells. Toxicological Sciences, 2018, 166, 354-369.	3.1	3
1061	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nature Genetics, 2018, 50, 1271-1281.	21.4	438
1062	Structural Alterations in Human Fibroblast Growth Factor Receptors in Carcinogenesis. Biochemistry (Moscow), 2018, 83, 930-943.	1.5	4
1063	ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?. PLoS ONE, 2018, 13, e0202965.	2.5	25
1064	Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma. Canadian Urological Association Journal, 2018, 13, 24-28.	0.6	23
1065	The clinical applications of The Cancer Genome Atlas project for bladder cancer. Expert Review of Anticancer Therapy, 2018, 18, 973-980.	2.4	12
1066	Approved checkpoint inhibitors in bladder cancer: which drug should be used when?. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591878831.	3.2	49
1067	Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer. PLoS Genetics, 2018, 14, e1007571.	3.5	33
1068	Molecular Subtypes of Bladder Cancer. Current Oncology Reports, 2018, 20, 77.	4.0	111
1069	Differential transcription factor expression by human epithelial cells of buccal and urothelial derivation. Experimental Cell Research, 2018, 369, 284-294.	2.6	12
1070	Advances in medical treatments for genitourinary cancers. Revista Médica Clínica Las Condes, 2018, 29, 155-162.	0.2	0

#	ARTICLE	IF	CITATIONS
1071	Epigenetic silencing of miR-1271 enhances MEK1 and TEAD4 expression in gastric cancer. <i>Cancer Medicine</i> , 2018, 7, 3411-3424.	2.8	21
1072	Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype. <i>Human Pathology</i> , 2018, 80, 55-64.	2.0	36
1073	RHO GTPases in cancer: known facts, open questions, and therapeutic challenges. <i>Biochemical Society Transactions</i> , 2018, 46, 741-760.	3.4	58
1074	Tissue-specific DNA methylation loss during ageing and carcinogenesis is linked to chromosome structure, replication timing and cell division rates. <i>Nucleic Acids Research</i> , 2018, 46, 7022-7039.	14.5	33
1075	Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy. <i>PLoS ONE</i> , 2018, 13, e0190854.	2.5	42
1076	Smoking intensity and bladder cancer aggressiveness at diagnosis. <i>PLoS ONE</i> , 2018, 13, e0194039.	2.5	29
1077	Aldehydes are the predominant forces inducing DNA damage and inhibiting DNA repair in tobacco smoke carcinogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E6152-E6161.	7.1	88
1078	Fibroblast Growth Factor Receptor Inhibitors: Enhancing Therapeutic Strategies for Solid Tumors. , 2019, , 101-121.		0
1079	Implementing precision cancer medicine in the genomic era. <i>Seminars in Cancer Biology</i> , 2019, 55, 16-27.	9.6	24
1080	A comparison of mechanistic signaling pathway activity analysis methods. <i>Briefings in Bioinformatics</i> , 2019, 20, 1655-1668.	6.5	33
1081	<i>ERCC2</i> Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 977-988.	7.0	104
1082	DMCM: a Data-adaptive Mutation Clustering Method to identify cancer-related mutation clusters. <i>Bioinformatics</i> , 2019, 35, 389-397.	4.1	28
1083	Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 16987-16996.	7.1	14
1084	TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer. <i>PLoS ONE</i> , 2019, 14, e0220173.	2.5	6
1085	Genomic profile of urine has high diagnostic sensitivity compared to cytology in non-invasive urothelial bladder cancer. <i>Cancer Science</i> , 2019, 110, 3235-3243.	3.9	24
1087	Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in TSC2-deficient cells by downregulating tumor suppressor retinoic acid receptor $\beta^2$ (RAR $\beta^2$ ). <i>Oncogene</i> , 2019, 38, 7367-7383.	5.9	11
1088	Establishing and characterization of human and murine bladder cancer organoids. <i>Translational Andrology and Urology</i> , 2019, 8, S310-S313.	1.4	2
1089	p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas. <i>Cell Reports</i> , 2019, 28, 1860-1878.e9.	6.4	68

#	ARTICLE	IF	CITATIONS
1090	Predictive biomarkers for drug response in bladder cancer. International Journal of Urology, 2019, 26, 1044-1053.	1.0	50
1091	Molecular profiling of clear cell adenocarcinoma of the urinary tract. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 727-734.	2.8	13
1092	5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs. Nature Cell Biology, 2019, 21, 978-990.	10.3	410
1093	Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?. Future Oncology, 2019, 15, 1505-1524.	2.4	12
1094	Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20. Annals of Diagnostic Pathology, 2019, 43, 151397.	1.3	26
1095	Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go. Future Oncology, 2019, 15, 2199-2202.	2.4	14
1096	Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer. Cancer Cytopathology, 2019, 127, 578-585.	2.4	16
1097	Molecular Basics on Genitourinary Malignancies. , 2019, , 3-17.		0
1098	LSD1 Inhibition Promotes Epithelial Differentiation through Derepression of Fate-Determining Transcription Factors. Cell Reports, 2019, 28, 1981-1992.e7.	6.4	55
1099	Emergence of <i>ERBB2</i> Mutation as a Biomarker and an Actionable Target in Solid Cancers. Oncologist, 2019, 24, e1303-e1314.	3.7	64
1100	Integrin $\alpha 7$ high expression correlates with deteriorative tumor features and worse overall survival, and its knockdown inhibits cell proliferation and invasion but increases apoptosis in breast cancer. Journal of Clinical Laboratory Analysis, 2019, 33, e22979.	2.1	12
1101	DNA topoisomerase III $\alpha$ and RAD21 cohesin complex component are predicted as potential therapeutic targets in bladder cancer. Oncology Letters, 2019, 18, 518-528.	1.8	7
1102	Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 349-356.	2.8	33
1103	Fidelity of a PDX-CR model for bladder cancer. Biochemical and Biophysical Research Communications, 2019, 517, 49-56.	2.1	17
1104	Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs. International Journal of Molecular Sciences, 2019, 20, 3162.	4.1	10
1105	Molecular and histopathology directed therapy for advanced bladder cancer. Nature Reviews Urology, 2019, 16, 465-483.	3.8	119
1106	Mechanism of methylation and acetylation of high GDNF transcription in glioma cells: A review. Heliyon, 2019, 5, e01951.	3.2	12
1107	Predictive value of phenotypic signatures of bladder cancer response to cisplatin-based neoadjuvant chemotherapy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 572.e1-572.e11.	1.6	9

#	ARTICLE	IF	CITATIONS
1108	The case for BK polyomavirus as a cause of bladder cancer. <i>Current Opinion in Virology</i> , 2019, 39, 8-15.	5.4	27
1109	Establishment of a novel experimental model for muscle-invasive bladder cancer using a dog bladder cancer organoid culture. <i>Cancer Science</i> , 2019, 110, 2806-2821.	3.9	75
1110	Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 322.	8.6	23
1111	Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2019, 381, 338-348.	27.0	885
1112	Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy. <i>JCI Insight</i> , 2019, 4, .	5.0	30
1113	Differential responses of epithelial cells from urinary and biliary tract to eggs of <i>Schistosoma haematobium</i> and <i>S. mansoni</i> . <i>Scientific Reports</i> , 2019, 9, 10731.	3.3	11
1114	Systematic analysis of the intersection of disease mutations with protein modifications. <i>BMC Medical Genomics</i> , 2019, 12, 109.	1.5	16
1115	CD8+ Cytotoxic Immune Infiltrate in Non-Muscle Invasive Bladder Cancer: A Standardized Methodology to Study Association with Clinico-Pathological Features and Prognosis. <i>Bladder Cancer</i> , 2019, 5, 159-169.	0.4	5
1116	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 573.e19-573.e29.	1.6	13
1117	Establishment of permutation for cancer risk estimation in the urothelium based on genome-wide DNA methylation analysis. <i>Carcinogenesis</i> , 2019, 40, 1308-1319.	2.8	21
1118	ASC-J9 <sup>®</sup> increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF- $\kappa$ B survival signals. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 275.	8.6	18
1119	RHO Family GTPases in the Biology of Lymphoma. <i>Cells</i> , 2019, 8, 646.	4.1	26
1120	Role of Targeted Therapies in Management of Metastatic Urothelial Cancer in the Era of Immunotherapy. <i>Current Treatment Options in Oncology</i> , 2019, 20, 67.	3.0	12
1121	What makes cells move: Requirements and obstacles for leader cells in collective invasion. <i>Experimental Cell Research</i> , 2019, 382, 111481.	2.6	10
1122	Tumor M2-PK: A novel urine marker of bladder cancer. <i>PLoS ONE</i> , 2019, 14, e0218737.	2.5	12
1123	Prognostic Impact of Canonical TGF- $\beta$ 2 Signaling in Urothelial Bladder Cancer. <i>Medicina (Lithuania)</i> , 2019, 55, 302.	2.0	16
1124	Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. <i>Nature Medicine</i> , 2019, 25, 1073-1081.	30.7	125
1125	High-Throughput Sequencing-Based Investigation of Viruses in Human Cancers by Multienrichment Approach. <i>Journal of Infectious Diseases</i> , 2019, 220, 1312-1324.	4.0	13



#	ARTICLE	IF	CITATIONS
1126	Genomic data analysis workflows for tumors from patient-derived xenografts (PDXs): challenges and guidelines. BMC Medical Genomics, 2019, 12, 92.	1.5	29
1127	Amentoflavone Induces Apoptosis and Reduces Expression of Anti-apoptotic and Metastasis-associated Proteins in Bladder Cancer. Anticancer Research, 2019, 39, 3641-3649.	1.1	32
1128	Label propagation defines signaling networks associated with recurrently mutated cancer genes. Scientific Reports, 2019, 9, 9401.	3.3	1
1129	SOX4 regulates invasion of bladder cancer cells via repression of WNT5a. International Journal of Oncology, 2019, 55, 359-370.	3.3	20
1130	Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nature Communications, 2019, 10, 2977.	12.8	140
1131	Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. Genome Medicine, 2019, 11, 60.	8.2	36
1132	Epigenetic synthetic lethality approaches in cancer therapy. Clinical Epigenetics, 2019, 11, 136.	4.1	26
1133	Pparg promotes differentiation and regulates mitochondrial gene expression in bladder epithelial cells. Nature Communications, 2019, 10, 4589.	12.8	50
1134	Somatic substitution signature as an innovative tool in lung cancer diagnosis. Scientific Reports, 2019, 9, 14561.	3.3	2
1135	Identification of a novel oncogenic mutation of FGFR4 in gastric cancer. Scientific Reports, 2019, 9, 14627.	3.3	10
1138	Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration. Cell Reports, 2019, 29, 2338-2354.e7.	6.4	74
1139	Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. Critical Reviews in Oncology/Hematology, 2019, 144, 102812.	4.4	7
1140	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. International Journal of Molecular Sciences, 2019, 20, 5452.	4.1	53
1141	PRODIGY: personalized prioritization of driver genes. Bioinformatics, 2020, 36, 1831-1839.	4.1	32
1142	Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. PLoS ONE, 2019, 14, e0221288.	2.5	16
1143	Weighted gene coexpression network analysis identifies a new biomarker of CENPF for prediction disease prognosis and progression in nonmuscle invasive bladder cancer. Molecular Genetics & Genomic Medicine, 2019, 7, e982.	1.2	30
1144	Inferring subgroup-specific driver genes from heterogeneous cancer samples via subspace learning with subgroup indication. Bioinformatics, 2020, 36, 1855-1863.	4.1	53
1145	Prevalence of HIV infection among Chinese voluntary blood donors during 2010â€2017: an updated systematic review and metaâ€analysis. Transfusion, 2019, 59, 3431-3441.	1.6	1

#	ARTICLE	IF	CITATIONS
1146	Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet. <i>Frontiers in Genetics</i> , 2019, 10, 1125.	2.3	28
1147	The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab. <i>Biomolecules</i> , 2019, 9, 629.	4.0	10
1148	Plasmacytoid urothelial carcinoma: a rapid autopsy case report with unique clinicopathologic and genomic profile. <i>Diagnostic Pathology</i> , 2019, 14, 113.	2.0	8
1149	Hyper-Activation of STAT3 Sustains Progression of Non-Papillary Basal-Type Bladder Cancer via FOSL1 Regulome. <i>Cancers</i> , 2019, 11, 1219.	3.7	32
1150	Tollâ€like receptors: The role in bladder cancer development, progression and immunotherapy. <i>Scandinavian Journal of Immunology</i> , 2019, 90, e12818.	2.7	46
1151	A Pan-cancer Transcriptome Analysis Reveals Pervasive Regulation through Alternative Promoters. <i>Cell</i> , 2019, 178, 1465-1477.e17.	28.9	144
1152	Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer. <i>PLoS ONE</i> , 2019, 14, e0221785.	2.5	31
1153	Spectrum: fast density-aware spectral clustering for single and multi-omic data. <i>Bioinformatics</i> , 2020, 36, 1159-1166.	4.1	57
1154	Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. <i>Annals of Oncology</i> , 2019, 30, 1821-1830.	1.2	99
1155	Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification. <i>BMC Cancer</i> , 2019, 19, 897.	2.6	14
1156	Identification of key DNA methylation-driven genes in prostate adenocarcinoma: an integrative analysis of TCGA methylation data. <i>Journal of Translational Medicine</i> , 2019, 17, 311.	4.4	48
1157	Multi-view based integrative analysis of gene expression data for identifying biomarkers. <i>Scientific Reports</i> , 2019, 9, 13504.	3.3	13
1158	Systematic screening of protein-coding gene expression identified HMMR as a potential independent indicator of unfavorable survival in patients with papillary muscle-invasive bladder cancer. <i>Biomedicine and Pharmacotherapy</i> , 2019, 120, 109433.	5.6	19
1159	PLEKHS1: A new molecular marker predicting risk of progression of nonâ€muscleâ€invasive bladder cancer. <i>Oncology Letters</i> , 2019, 18, 3471-3480.	1.8	10
1160	Development and External Validation of a Novel 12-Gene Signature for Prediction of Overall Survival in Muscle-Invasive Bladder Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 856.	2.8	16
1161	SOX4 is activated by C-MYC in prostate cancer. <i>Medical Oncology</i> , 2019, 36, 92.	2.5	22
1162	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 826-836.	1.6	33
1163	Detecting viral sequences in NGS data. <i>Current Opinion in Virology</i> , 2019, 39, 41-48.	5.4	52

#	ARTICLE	IF	CITATIONS
1164	Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer. <i>Cell Death and Differentiation</i> , 2019, 26, 2100-2114.	11.2	63
1165	Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis. <i>Seminars in Oncology</i> , 2019, 46, 65-72.	2.2	14
1166	Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis. <i>Epigenetics</i> , 2019, 14, 67-80.	2.7	91
1167	The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer. <i>EMBO Reports</i> , 2019, 20, .	4.5	93
1168	Mutations in gliclazide-associated genes may predict poor bladder cancer prognosis. <i>FEBS Open Bio</i> , 2019, 9, 457-467.	2.3	6
1169	Bladder Cancer in the Genomic Era. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 695-704.	2.5	50
1170	Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721881537.	2.0	7
1171	Clinical Development of FGFR3 Inhibitors for the Treatment of Urothelial Cancer. <i>Bladder Cancer</i> , 2019, 5, 87-102.	0.4	10
1172	Targeted Gene Sequencing Panels: Applicability for Neoantigen Profiling of Colon and Rectal Adenocarcinoma. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2019, 13, 146-153.	0.4	1
1173	&lt;p&gt;Loss of ARID1A promotes proliferation, migration and invasion via the Akt signaling pathway in NPC&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 4931-4946.	1.9	27
1174	The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-17.	7.7	118
1175	Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms. <i>BMC Cancer</i> , 2019, 19, 604.	2.6	41
1176	Circular RNA circSLC8A1 acts as a sponge of miR-130b/miR-494 in suppressing bladder cancer progression via regulating PTEN. <i>Molecular Cancer</i> , 2019, 18, 111.	19.2	216
1177	Molecular pathology of the luminal class of urothelial tumors. <i>Journal of Pathology</i> , 2019, 249, 308-318.	4.5	30
1178	Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 445-455.	2.8	38
1179	Exosomes containing ErbB2/CRK induce vascular growth in premetastatic niches and promote metastasis of bladder cancer. <i>Cancer Science</i> , 2019, 110, 2119-2132.	3.9	34
1180	Tumor-infiltrating M2 1/2 macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer. <i>Oncology Reports</i> , 2019, 42, 581-594.	2.6	86
1181	Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. <i>Nature</i> , 2019, 571, 413-418.	27.8	192

#	ARTICLE	IF	CITATIONS
1182	Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3KÎ± Inhibitor TAK-117 in Preclinical Bladder Cancer Models. <i>Molecular Cancer Research</i> , 2019, 17, 1931-1944.	3.4	23
1183	Mechanisms behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro. <i>Cancers</i> , 2019, 11, 777.	3.7	7
1184	Ras-association domain family 1 (RASSF1A) gene regulates progression, migration and invasion of bladder cancer. <i>Surgical Oncology</i> , 2019, 30, 63-71.	1.6	6
1185	DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes. , 2019, 7, 148.		67
1186	Prognostic value and association with epithelial-mesenchymal transition and molecular subtypes of the proteoglycan biglycan in advanced bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 530.e9-530.e18.	1.6	29
1187	Characterization of mRNA Expression and Endogenous RNA Profiles in Bladder Cancer Based on The Cancer Genome Atlas (TCGA) Database. <i>Medical Science Monitor</i> , 2019, 25, 3041-3060.	1.1	27
1188	Identifying Epistasis in Cancer Genomes: A Delicate Affair. <i>Cell</i> , 2019, 177, 1375-1383.	28.9	81
1189	Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2599.	4.1	18
1190	Need for a personalized approach for muscle invasive bladder cancer: role of tumor biology in response to neoadjuvant chemotherapy. <i>Translational Andrology and Urology</i> , 2019, 8, S99-S103.	1.4	3
1191	Understanding chemotherapy-induced changes in bladder cancer biology: a necessary step towards tailored treatment in cisplatin-refractory disease. <i>Translational Andrology and Urology</i> , 2019, 8, S116-S118.	1.4	1
1192	Can post-neoadjuvant therapy molecular classification guide future treatment selection for muscle-invasive bladder cancer?. <i>Translational Andrology and Urology</i> , 2019, 8, S91-S92.	1.4	0
1193	Value of quantitative and qualitative analyses of serum and urine cell-free DNA as diagnostic tools for bladder cancer: a meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 645-653.	2.4	3
1194	Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 5584-5594.	7.0	80
1195	Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. <i>Cell Reports</i> , 2019, 27, 1781-1793.e4.	6.4	102
1196	Enrichment of genes associated with squamous differentiation in cancer initiating cells isolated from urothelial cells transformed by the environmental toxicant arsenite. <i>Toxicology and Applied Pharmacology</i> , 2019, 374, 41-52.	2.8	14
1197	Conceptual Framework for Therapeutic Development Beyond Antiâ€PD-1/PD-L1 in Urothelial Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 284-300.	3.8	14
1198	Integrative Metabolomic and Transcriptomic Analysis for the Study of Bladder Cancer. <i>Cancers</i> , 2019, 11, 686.	3.7	31
1199	Long non-coding RNAs in genitourinary malignancies: a whole new world. <i>Nature Reviews Urology</i> , 2019, 16, 484-504.	3.8	80

#	ARTICLE	IF	CITATIONS
1200	E74 like ETS transcription factor 3 (ELF3) is a negative regulator of epithelial- mesenchymal transition in bladder carcinoma. <i>Cancer Biomarkers</i> , 2019, 25, 223-232.	1.7	19
1201	Molecular subtypes applied to a population-based modern cystectomy series do not predict cancer-specific survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 791-799.	1.6	30
1202	Gelsolin-like actin-capping protein has prognostic value and promotes tumorigenesis and epithelial-mesenchymal transition <i>via</i> the Hippo signaling pathway in human bladder cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984123.	3.2	20
1203	Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. <i>European Urology</i> , 2019, 76, 200-206.	1.9	41
1204	Antiproliferative and toxicogenomic effects of resveratrol in bladder cancer cells with different TP53 status. <i>Environmental and Molecular Mutagenesis</i> , 2019, 60, 740-751.	2.2	25
1205	Inhibition of GLI2 with antisense oligonucleotides: A potential therapy for the treatment of bladder cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 20634-20647.	4.1	10
1206	CSTP1 inhibits IL-6 expression through targeting Akt/FoxO3a signaling pathway in bladder cancer cells. <i>Experimental Cell Research</i> , 2019, 380, 80-89.	2.6	11
1207	Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer. <i>Molecular Pharmacology</i> , 2019, 96, 36-46.	2.3	22
1208	Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e751-e758.	1.9	12
1209	Chemovirotherapeutic Treatment Using Camptothecin Enhances Oncolytic Measles Virus-Mediated Killing of Breast Cancer Cells. <i>Scientific Reports</i> , 2019, 9, 6767.	3.3	23
1210	High-Dimensional Data Approaches to Understanding Nuclear Hormone Receptor Signaling. <i>Methods in Molecular Biology</i> , 2019, 1966, 291-311.	0.9	1
1211	Analysis of the role of mutations in the KMT2D histone lysine methyltransferase in bladder cancer. <i>FEBS Open Bio</i> , 2019, 9, 693-706.	2.3	19
1212	Genomics, Other omics Technologies, Precision Medicine, and Additional Biotechnology-Related Techniques. , 2019, , 191-237.		1
1213	Noninvasive Detection of Bladder Cancer by Shallow-Depth Genome-Wide Bisulfite Sequencing of Urinary Cell-Free DNA for Methylation and Copy Number Profiling. <i>Clinical Chemistry</i> , 2019, 65, 927-936.	3.2	34
1214	Mutations in CDKN2A and the FGFR3 genes on bladder cancer diagnosis: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2019, 37, 2001-2007.	2.2	6
1215	Hope and challenge: Precision medicine in bladder cancer. <i>Cancer Medicine</i> , 2019, 8, 1806-1816.	2.8	34
1216	A novel 4-gene prognostic signature for hypermutated colorectal cancer. <i>Cancer Management and Research</i> , 2019, Volume 11, 1985-1996.	1.9	12
1217	Identification of a nine-gene panel as a prognostic indicator for recurrence with muscle-invasive bladder cancer. <i>Journal of Surgical Oncology</i> , 2019, 119, 1145-1154.	1.7	29

#	ARTICLE	IF	CITATIONS
1218	CD47-Targeted Near-Infrared Photoimmunotherapy for Human Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3561-3571.	7.0	70
1219	Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3689-3701.	7.0	81
1220	Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures. <i>Cancer Immunology Research</i> , 2019, 7, 737-750.	3.4	691
1221	Dual Role of the Alternative Reading Frame ARF Protein in Cancer. <i>Biomolecules</i> , 2019, 9, 87.	4.0	36
1222	Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts. <i>Translational Oncology</i> , 2019, 12, 661-668.	3.7	16
1223	Urachal cancer—current concepts of a rare cancer. <i>Der Pathologe</i> , 2019, 40, 31-39.	1.6	15
1224	Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. <i>European Urology</i> , 2019, 76, 73-81.	1.9	117
1225	Low doses of decitabine improve the chemotherapy efficacy against basal-like bladder cancer by targeting cancer stem cells. <i>Oncogene</i> , 2019, 38, 5425-5439.	5.9	19
1226	Precision therapy in advanced urothelial cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 81-93.	0.7	4
1227	PPAR $\beta$ inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 3724-3736.	3.6	33
1228	PPAR $\beta$ activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway. <i>BMC Cancer</i> , 2019, 19, 204.	2.6	64
1229	Transcriptional Analysis of Immunohistochemically Defined Subgroups of Non-Muscle-Invasive Papillary High-Grade Upper Tract Urothelial Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 570.	4.1	16
1230	Systematic Review: Targeting HER2 in Bladder Cancer. <i>Bladder Cancer</i> , 2019, 5, 1-12.	0.4	34
1231	Role of adjuvant cisplatin-based chemotherapy following radical cystectomy in locally advanced muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized trials. <i>Investigative and Clinical Urology</i> , 2019, 60, 64.	2.0	12
1232	Clinical implication of the mammalian target of rapamycin pathway in upper tract urothelial carcinoma with negative GATA binding protein-3 expression. <i>International Journal of Urology</i> , 2019, 26, 678-679.	1.0	2
1233	Extracellular matrix protein 1 (ECM1) is associated with carcinogenesis potential of human bladder cancer. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1423-1432.	2.0	28
1234	Whole-exome sequencing revealed mutational profiles of giant cell glioblastomas. <i>Brain Pathology</i> , 2019, 29, 782-792.	4.1	11
1235	Prothymosin- $\alpha$ enhances phosphatase and tensin homolog expression and binds with tripartite motif-containing protein 21 to regulate Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2 signaling in human bladder cancer. <i>Cancer Science</i> , 2019, 110, 1208-1219.	3.9	14



#	ARTICLE	IF	CITATIONS
1236	A virome-wide clonal integration analysis platform for discovering cancer viral etiology. <i>Genome Research</i> , 2019, 29, 819-830.	5.5	47
1237	Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1291.	4.1	47
1238	Diagnostic and prognostic roles of CK20 in the pathology of urothelial lesions. A systematic review. <i>Pathology Research and Practice</i> , 2019, 215, 152413.	2.3	8
1239	Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	3.0	23
1240	Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms. <i>Journal of Hematology and Oncology</i> , 2019, 12, 38.	17.0	66
1241	Management of metastatic bladder cancer. <i>Cancer Treatment Reviews</i> , 2019, 76, 10-21.	7.7	190
1242	The Untranslated Regions of mRNAs in Cancer. <i>Trends in Cancer</i> , 2019, 5, 245-262.	7.4	70
1243	YWHAZ amplification/overexpression defines aggressive bladder cancer and contributes to chemo- and radio-resistance by suppressing caspase-mediated apoptosis. <i>Journal of Pathology</i> , 2019, 248, 476-487.	4.5	17
1244	Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer. <i>Seminars in Cancer Biology</i> , 2019, 59, 3-22.	9.6	29
1245	Prevalence and role of HER2 mutations in cancer. , 2019, 199, 188-196.		44
1246	Molecular Characterization of Neuroendocrine-like Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3908-3920.	7.0	71
1247	The Case for Proteomics and Phosphoproteomics in Personalized Cancer Medicine. <i>Proteomics - Clinical Applications</i> , 2019, 13, e1800113.	1.6	88
1248	CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 90.	8.6	29
1249	New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 91.	8.6	45
1250	Regorefenib induces extrinsic/intrinsic apoptosis and inhibits MAPK/NF- $\kappa$ B-mediated tumor progression in bladder cancer in vitro and in vivo. <i>Environmental Toxicology</i> , 2019, 34, 679-688.	4.0	37
1251	Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy. <i>Journal of Pathology</i> , 2019, 248, 230-242.	4.5	32
1252	Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer. <i>Journal of Cancer</i> , 2019, 10, 697-707.	2.5	16
1253	mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 755.	4.1	406



#	ARTICLE	IF	CITATIONS
1254	Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT). Scientific Reports, 2019, 9, 2084.	3.3	57
1255	Biomarkers in Non-Schistosomiasis-related squamous cell carcinoma of the urinary bladder: A review. Critical Reviews in Oncology/Hematology, 2019, 135, 76-84.	4.4	9
1256	PIK3CA in cancer: The past 30 years. Seminars in Cancer Biology, 2019, 59, 36-49.	9.6	122
1257	Whole-genome sequencing identifies ADGRG6 enhancer mutations and FRS2 duplications as angiogenesis-related drivers in bladder cancer. Nature Communications, 2019, 10, 720.	12.8	57
1258	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nature Reviews Cancer, 2019, 19, 133-150.	28.4	1,657
1259	Are there differences between de novo and secondary upper tract urothelial carcinoma tumours?. Canadian Urological Association Journal, 2019, 13, E292-E299.	0.6	0
1260	Recent advances in the metabolomic study of bladder cancer. Expert Review of Proteomics, 2019, 16, 315-324.	3.0	28
1261	Molecular Predictors of Complete Response Following Neoadjuvant Chemotherapy in Urothelial Carcinoma of the Bladder and Upper Tracts. International Journal of Molecular Sciences, 2019, 20, 793.	4.1	25
1262	The road less travelled: The efficacy of canine pluripotent stem cells. Experimental Cell Research, 2019, 377, 94-102.	2.6	5
1263	Mouse and human urothelial cancer organoids: A tool for bladder cancer research. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 4567-4574.	7.1	171
1264	Improving survival prediction using a novel feature selection and feature reduction framework based on the integration of clinical and molecular data. , 2019, , .		6
1266	Neoadjuvant chemotherapy in bladder cancer: not a matter on how much but on who it is effective. Translational Andrology and Urology, 2019, 8, S480-S481.	1.4	0
1268	Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness. BMJ Open, 2019, 9, e022268.	1.9	16
1269	The Quest for an Ideal Neoadjuvant Systemic Therapy in Cisplatinâ€ineligible Patients with Muscleâ€invasive Localized Urothelial Carcinoma. Oncologist, 2019, 24, 580-583.	3.7	0
1270	The long-term efficacy of one-shot neoadjuvant intra-arterial chemotherapy combined with radical cystectomy versus radical cystectomy alone for bladder cancer: a propensity-score matching study. BMC Urology, 2019, 19, 117.	1.4	3
1271	Mouse Models of Muscle-invasive Bladder Cancer: Key Considerations for Clinical Translation Based on Molecular Subtypes. European Urology Oncology, 2019, 2, 239-247.	5.4	6
1272	TGF-Î² and microRNA Interplay in Genitourinary Cancers. Cells, 2019, 8, 1619.	4.1	19
1273	p53/PCDH17/Beclin-1 Proteins as Prognostic Predictors for Urinary Bladder Cancer. Journal of Cancer, 2019, 10, 6207-6216.	2.5	15

#	ARTICLE	IF	CITATIONS
1274	Variant Histology in Bladder Cancer—Current Understanding of Pathologic Subtypes. <i>Current Urology Reports</i> , 2019, 20, 80.	2.2	12
1275	Epithelial tumor suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma. <i>Nature Communications</i> , 2019, 10, 5438.	12.8	41
1276	The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice. <i>Journal of Translational Medicine</i> , 2019, 17, 394.	4.4	21
1277	Tumor diversity and the trade-off between universal cancer tasks. <i>Nature Communications</i> , 2019, 10, 5423.	12.8	53
1278	Identification of an immunotherapy-responsive molecular subtype of bladder cancer. <i>EBioMedicine</i> , 2019, 50, 238-245.	6.1	88
1279	Survival-Associated Alternative Splicing Events in Pan-Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 1317.	2.8	8
1280	Tumors of the Urinary System. , 2019, , 645-656.		2
1281	Immunogenomic Analysis of Exceptional Responder to ALT-803 (IL-15 Analogue) in BCG Unresponsive Nonmuscle Invasive Bladder Cancer: A Case Series and Review of the Literature. <i>Journal of Immunotherapy</i> , 2019, 42, 354-358.	2.4	6
1282	Is the extirpative surgery for primary tumor helpful for the patients with metastatic urothelial cancer at the time of diagnosis?. <i>Medicine (United States)</i> , 2019, 98, e15930.	1.0	3
1283	Molecular subtyping of bladder cancer. <i>Current Opinion in Urology</i> , 2019, 29, 198-202.	1.8	4
1284	Clinical implications of molecular subtyping in bladder cancer. <i>Current Opinion in Urology</i> , 2019, 29, 350-356.	1.8	20
1285	Targeting advanced urothelial carcinoma-developing strategies. <i>Current Opinion in Oncology</i> , 2019, 31, 207-215.	2.4	14
1286	Immunotherapy in nonmuscle invasive bladder cancer: current and emerging treatments. <i>Current Opinion in Oncology</i> , 2019, 31, 183-187.	2.4	7
1287	Sex discrepancy characterization revealed by somatic DNA alterations in muscle-invasive bladder carcinoma. <i>Chinese Medical Journal</i> , 2019, 132, 2492-2494.	2.3	0
1288	Intrinsic Molecular Subclassification of Urothelial Carcinoma of the Bladder: Are We Finally there?. <i>Advances in Anatomic Pathology</i> , 2019, 26, 251-256.	4.3	9
1289	Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989028.	3.2	74
1290	The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. <i>Oncologist</i> , 2019, 24, 1348-1355.	3.7	10
1291	Modeling Tumor Heterogeneity in Bladder Cancer: The Current State of the Field and Future Needs. <i>Bladder Cancer</i> , 2019, 5, 251-261.	0.4	3

#	ARTICLE	IF	CITATIONS
1292	The molecular limitations of biomarker research in bladder cancer. World Journal of Urology, 2019, 37, 837-848.	2.2	31
1293	Spectral clustering via sparse graph structure learning with application to proteomic signaling networks in cancer. Computational Statistics and Data Analysis, 2019, 132, 46-69.	1.2	6
1294	Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer. Clinical Cancer Research, 2019, 25, 5082-5093.	7.0	82
1295	The long noncoding RNA HIF1A-AS2 facilitates cisplatin resistance in bladder cancer. Journal of Cellular Biochemistry, 2019, 120, 243-252.	2.6	47
1296	Lung-Enriched Mutations in the p53 Tumor Suppressor: A Paradigm for Tissue-Specific Gain of Oncogenic Function. Molecular Cancer Research, 2019, 17, 3-9.	3.4	17
1297	Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder. Clinical and Translational Oncology, 2019, 21, 280-288.	2.4	6
1298	Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. European Urology, 2019, 75, 423-432.	1.9	205
1299	SIU-ICUD consultation on bladder cancer: basic science. World Journal of Urology, 2019, 37, 15-29.	2.2	3
1300	Large-scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survival. Cancer, 2019, 125, 921-932.	4.1	42
1301	Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts. Journal of Pathology, 2019, 247, 563-573.	4.5	63
1302	Radiogenomics for Precision Medicine With a Big Data Analytics Perspective. IEEE Journal of Biomedical and Health Informatics, 2019, 23, 2063-2079.	6.3	34
1303	Comprehensive genomic variation profiling of cervical intraepithelial neoplasia and cervical cancer identifies potential targets for cervical cancer early warning. Journal of Medical Genetics, 2019, 56, 186-194.	3.2	43
1304	Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA. Cancer Discovery, 2019, 9, 500-509.	9.4	143
1305	Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer. Carcinogenesis, 2019, 40, 84-92.	2.8	27
1306	High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of <i>GPR126</i> in Bladder Cancer. Molecular Cancer Research, 2019, 17, 469-475.	3.4	18
1307	Beyond BCG: the approaching era of personalised bladder-sparing therapies for non-muscle-invasive urothelial cancers. Future Oncology, 2019, 15, 409-420.	2.4	5
1308	Long non-coding RNA ARAP1-AS1 promotes the progression of bladder cancer by regulating miR-4735-3p/NOTCH2 axis. Cancer Biology and Therapy, 2019, 20, 552-561.	3.4	29
1309	Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia. Modern Pathology, 2019, 32, 717-724.	5.5	35

#	ARTICLE	IF	CITATIONS
1310	Canine Cancer Genomics: Lessons for Canine and Human Health. Annual Review of Animal Biosciences, 2019, 7, 449-472.	7.4	47
1311	Genomic classification and risk stratification of bladder cancer. World Journal of Urology, 2019, 37, 1751-1757.	2.2	10
1312	NOTCH1 regulates the proliferation and migration of bladder cancer cells by cooperating with long non-coding RNA HCG18 and microRNA-34c5p. Journal of Cellular Biochemistry, 2019, 120, 6596-6604.	2.6	43
1313	Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment—Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review. Urologia Internationalis, 2019, 102, 249-261.	1.3	15
1314	Treatment of Metastatic Bladder Cancer. , 2019, , 123-137.		0
1315	Elevated pre-existing lymphocytic infiltrates in tumour stroma predict poor prognosis in resectable urothelial carcinoma of the bladder. Histopathology, 2019, 75, 354-364.	2.9	4
1316	Assessment of HER2 Expression in Canine Urothelial Carcinoma of the Urinary Bladder. Veterinary Pathology, 2019, 56, 369-376.	1.7	25
1317	Histo-genomics: digital pathology at the forefront of precision medicine. Diagnosis, 2019, 6, 203-212.	1.9	23
1318	Recurrent activating mutations of PPAR $\gamma$ 3 associated with luminal bladder tumors. Nature Communications, 2019, 10, 253.	12.8	44
1319	Identification of several cell cycle relevant genes highly correlated with the progression and prognosis of human bladder urothelial tumor. Journal of Cellular Physiology, 2019, 234, 13439-13451.	4.1	5
1320	Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer, 2019, 125, 533-540.	4.1	38
1321	ATDC mediates a TP63-regulated basal cancer invasive program. Oncogene, 2019, 38, 3340-3354.	5.9	17
1322	Serum Metabolic Profiling Identified a Distinct Metabolic Signature in Bladder Cancer Smokers: A Key Metabolic Enzyme Associated with Patient Survival. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 770-781.	2.5	37
1323	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. Clinical Cancer Research, 2019, 25, 967-976.	7.0	164
1324	Serine/threonine kinase 32C is overexpressed in bladder cancer and contributes to tumor progression. Cancer Biology and Therapy, 2019, 20, 307-320.	3.4	9
1325	Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer. World Journal of Urology, 2019, 37, 1773-1784.	2.2	22
1326	Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma. Molecular Cancer Therapeutics, 2019, 18, 185-195.	4.1	18
1327	Unraveling the Exposome. , 2019, , .		9

#	ARTICLE	IF	CITATIONS
1328	Chromatinâ€‘regulatory genes served as potential therapeutic targets for patients with urothelial bladder carcinoma. Journal of Cellular Physiology, 2019, 234, 6976-6982.	4.1	7
1329	Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. Clinical Cancer Research, 2019, 25, 210-221.	7.0	48
1330	Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of nonâ€‘muscleâ€‘invasive disease. BJU International, 2019, 123, 947-958.	2.5	9
1331	MiR-203a functions as a tumor suppressor in bladder cancer by targeting SIX4. Neoplasma, 2019, 66, 211-221.	1.6	27
1332	Clinical and molecular characteristics of bladder urothelial carcinoma subtypes. Journal of Cellular Biochemistry, 2019, 120, 9956-9963.	2.6	10
1333	Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 209-217.	2.8	10
1334	CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of <i>RB1</i> Status. Clinical Cancer Research, 2019, 25, 390-402.	7.0	44
1335	Molecular markers in bladder cancer. World Journal of Urology, 2019, 37, 31-40.	2.2	86
1336	The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer. European Urology, 2019, 75, 435-444.	1.9	97
1337	Immunohistochemistry of cytokeratin (<sc>CK</sc>) 5/6, <sc>CD</sc>44 and <sc>CK</sc>20 as prognostic biomarkers of nonâ€‘muscleâ€‘invasive papillary upper tract urothelial carcinoma. Histopathology, 2019, 74, 483-493.	2.9	27
1338	Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. European Urology Focus, 2019, 5, 201-204.	3.1	30
1339	Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test. European Urology Focus, 2019, 5, 664-675.	3.1	5
1340	Molecular subtyping of cancer: current status and moving toward clinical applications. Briefings in Bioinformatics, 2019, 20, 572-584.	6.5	91
1341	Computational medicine: quantitative modeling of complex diseases. Briefings in Bioinformatics, 2020, 21, 429-440.	6.5	9
1342	Morphological classification of pancreatic ductal adenocarcinoma that predicts molecular subtypes and correlates with clinical outcome. Gut, 2020, 69, 317-328.	12.1	91
1343	Intracellular Signaling. , 2020, , 24-46.e12.		0
1346	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. European Urology, 2020, 77, 420-433.	1.9	741
1347	The impact of smoking on the effectiveness of immune checkpoint inhibitors â€‘ a systematic review and meta-analysis. Acta OncolÃ³gica, 2020, 59, 96-100.	1.8	13

#	ARTICLE	IF	CITATIONS
1348	Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. <i>Oncogene</i> , 2020, 39, 6265-6285.	5.9	52
1349	Carcinoma of the Bladder. , 2020, , 1382-1400.e4.		2
1350	Proteomeâ€based classification of Nonmuscle Invasive Bladder Cancer. <i>International Journal of Cancer</i> , 2020, 146, 281-294.	5.1	35
1351	SOX4: The unappreciated oncogene. <i>Seminars in Cancer Biology</i> , 2020, 67, 57-64.	9.6	114
1352	An EMTâ€related gene signature for the prognosis of human bladder cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 605-617.	3.6	132
1353	Functional genetic variant of WW domain containing oxidoreductase gene associated with urothelial cell carcinoma clinicopathologic characteristics and long-term survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 41.e1-41.e9.	1.6	5
1354	Targeting FGFR in bladder cancer: ready for clinical practice?. <i>Acta Clinica Belgica</i> , 2020, 75, 49-56.	1.2	7
1355	Cytological features of micropapillary and plasmacytoid variants of urothelial carcinoma. <i>Diagnostic Cytopathology</i> , 2020, 48, 111-117.	1.0	9
1356	HER2 Status in Molecular Subtypes of Urothelial Carcinoma of the Renal Pelvis and Ureter. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e443-e449.	1.9	11
1357	Phosphorylation of TFPC2L1 by CDK1 is required for stem cell pluripotency and bladder carcinogenesis. <i>EMBO Molecular Medicine</i> , 2020, 12, e10880.	6.9	47
1358	Using multi-layer perceptron with Laplacian edge detector for bladder cancer diagnosis. <i>Artificial Intelligence in Medicine</i> , 2020, 102, 101746.	6.5	80
1359	Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder. <i>American Journal of Pathology</i> , 2020, 190, 323-332.	3.8	20
1360	Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer. <i>European Urology Focus</i> , 2020, 6, 642-649.	3.1	38
1361	Intravesical Gene Therapy. <i>Urologic Clinics of North America</i> , 2020, 47, 93-101.	1.8	10
1362	Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 262-268.	1.6	15
1363	Updates on the Genomics of Bladder Cancer and Novel Molecular Taxonomy. <i>Advances in Anatomic Pathology</i> , 2020, 27, 36-43.	4.3	20
1364	Mechanisms of immune evasion in bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 3-14.	4.2	127
1365	Amplification of 7p12 Is Associated with Pathologic Nonresponse to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. <i>American Journal of Pathology</i> , 2020, 190, 442-452.	3.8	5

#	ARTICLE	IF	CITATIONS
1366	CABPA is a master regulator of luminal identity and restrains aggressive diseases in bladder cancer. <i>Cell Death and Differentiation</i> , 2020, 27, 1862-1877.	11.2	35
1367	Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA. <i>Cancer Letters</i> , 2020, 472, 108-118.	7.2	8
1368	Unraveling cancer lineage drivers in squamous cell carcinomas. , 2020, 206, 107448.		20
1369	CRYAB inhibits migration and invasion of bladder cancer cells through the PI3K/AKT and ERK pathways. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 254-260.	1.3	24
1370	Long-term treatment with arsenite activates HER1 and HER2 through upregulating EGF, TGF $\beta$ , and HSP90 in a human uroepithelial cell line. <i>Cell Biology and Toxicology</i> , 2020, 36, 279-284.	5.3	3
1371	Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma. <i>Drugs</i> , 2020, 80, 1-7.	10.9	40
1372	Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers. <i>Cancer Prevention Research</i> , 2020, 13, 273-282.	1.5	6
1373	Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. <i>Journal of Clinical Oncology</i> , 2020, 38, 406-414.	1.6	60
1374	Urothelial Carcinoma Detection Based on Copy Number Profiles of Urinary Cell-Free DNA by Shallow Whole-Genome Sequencing. <i>Clinical Chemistry</i> , 2020, 66, 188-198.	3.2	28
1375	Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis. <i>World Journal of Urology</i> , 2020, 38, 2227-2236.	2.2	12
1376	Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer. <i>Urologic Clinics of North America</i> , 2020, 47, 35-46.	1.8	12
1377	Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 449-458.	1.6	14
1378	Value of Biomarker Expression for Randomized Clinical Trial Design: One (More) Missed Opportunity. <i>Journal of Clinical Oncology</i> , 2020, 38, 649-651.	1.6	2
1379	Macroscopic somatic clonal expansion in morphologically normal human urothelium. <i>Science</i> , 2020, 370, 82-89.	12.6	115
1380	Future strategies to enhance kidney preservation in upper urinary tract urothelial carcinoma. <i>Translational Andrology and Urology</i> , 2020, 9, 1831-1840.	1.4	4
1381	8p11.23 Amplification in Breast Cancer: Molecular Characteristics, Prognosis and Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3079.	2.4	16
1382	SETD2 as a regulator of N6-methyladenosine RNA methylation and modifiers in cancer. <i>European Journal of Cancer Prevention</i> , 2020, 29, 556-564.	1.3	7
1383	Genomic Instability Signature of Palindromic Non-Coding Somatic Mutations in Bladder Cancer. <i>Cancers</i> , 2020, 12, 2882.	3.7	13



#	ARTICLE	IF	CITATIONS
1384	EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer. <i>Oncogene</i> , 2020, 39, 6856-6870.	5.9	31
1386	Genomic Profiling Identified ERCC2 E606Q Mutation in Helicase Domain Respond to Platinum-Based Neoadjuvant Therapy in Urothelial Bladder Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1643.	2.8	4
1387	Targeted Molecular Therapeutics for Bladder Cancer—A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7268.	4.1	33
1388	Framework for quality assessment of whole genome cancer sequences. <i>Nature Communications</i> , 2020, 11, 5040.	12.8	5
1389	Comparative bioinformatics analysis of prognostic and differentially expressed genes in non-muscle and muscle invasive bladder cancer. <i>Journal of Proteomics</i> , 2020, 229, 103951.	2.4	4
1390	Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies. <i>Human Pathology</i> , 2020, 106, 54-61.	2.0	5
1391	Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer. <i>Scientific Reports</i> , 2020, 10, 16641.	3.3	10
1392	Comprehensive Molecular Characterization of Squamous Cell Carcinomas. , 2020, , .		1
1393	Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers. <i>Bladder Cancer</i> , 2020, 6, 211-213.	0.4	4
1394	Current status of genetic urinary biomarkers for surveillance of non-muscle invasive bladder cancer: a systematic review. <i>BMC Urology</i> , 2020, 20, 99.	1.4	6
1395	Small nucleolar RNAs signature (SNORS) identified clinical outcome and prognosis of bladder cancer (BLCA). <i>Cancer Cell International</i> , 2020, 20, 299.	4.1	5
1397	CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner. <i>Cancer Immunology Research</i> , 2020, 8, 1180-1192.	3.4	19
1398	Remarkable Response to Erdafitinib in Metastatic Lung Adenocarcinoma With FGFR Fusion. <i>JCO Precision Oncology</i> , 2020, 4, 823-824.	3.0	4
1399	The Expression Profiles of ADME Genes in Human Cancers and Their Associations with Clinical Outcomes. <i>Cancers</i> , 2020, 12, 3369.	3.7	15
1400	Angiogenesis related gene expression significantly associated with the prognostic role of an urothelial bladder carcinoma. <i>Translational Andrology and Urology</i> , 2020, 9, 2200-2210.	1.4	12
1401	Human Papillomavirus Prevalence and Integration Status in Tissue Samples of Bladder Cancer in the Chinese Population. <i>Journal of Infectious Diseases</i> , 2021, 224, 114-122.	4.0	12
1402	Development and validation of a nomogram for predicting survival in patients with non-metastatic primary adenocarcinoma of the bladder. <i>Translational Cancer Research</i> , 2020, 9, 5155-5165.	1.0	1
1403	Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies. <i>Seminars in Oncology</i> , 2020, 47, 367-379.	2.2	6

#	ARTICLE	IF	CITATIONS
1404	NRF2 and the Ambiguous Consequences of Its Activation during Initiation and the Subsequent Stages of Tumorigenesis. <i>Cancers</i> , 2020, 12, 3609.	3.7	44
1405	A small UTX stabilization domain of Trx is conserved within mammalian MLL3-4/COMPASS and is sufficient to rescue loss of viability in null animals. <i>Genes and Development</i> , 2020, 34, 1493-1502.	5.9	14
1406	Efficacy of neoadjuvant atezolizumab treatment in patients with advanced urothelial bladder cancer according to the BASQ classification: a study protocol for an open-label, two-cohort, phase II trial. <i>BMJ Open</i> , 2020, 10, e035530.	1.9	3
1407	Treatment of muscle-invasive and advanced bladder cancer in 2020. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 404-423.	329.8	507
1408	A compendium of mutational cancer driver genes. <i>Nature Reviews Cancer</i> , 2020, 20, 555-572.	28.4	605
1409	Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 755-763.	2.4	14
1410	Practicability of clinical application of bladder cancer molecular classification and additional value of epithelial-to-mesenchymal transition: prognostic value of vimentin expression. <i>Journal of Translational Medicine</i> , 2020, 18, 303.	4.4	11
1411	Emerging Roles of Urine-Based Tumor DNA Analysis in Bladder Cancer Management. <i>JCO Precision Oncology</i> , 2020, 4, 806-817.	3.0	7
1412	Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma. <i>International Immunopharmacology</i> , 2020, 87, 106818.	3.8	10
1413	PLEKHS1 Over-Expression is Associated with Metastases and Poor Outcomes in Papillary Thyroid Carcinoma. <i>Cancers</i> , 2020, 12, 2133.	3.7	16
1414	An overview on precision therapy in bladder cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 347-361.	0.7	0
1415	DNA Methylation as a Therapeutic Target for Bladder Cancer. <i>Cells</i> , 2020, 9, 1850.	4.1	35
1416	Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5670.	4.1	49
1417	Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. <i>Nature Communications</i> , 2020, 11, 4011.	12.8	198
1418	Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic. <i>Pharmaceutics</i> , 2020, 12, 996.	4.5	6
1419	Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations. <i>Pathology Research and Practice</i> , 2020, 216, 153186.	2.3	11
1420	Development and validation of a novel stem cell subtype for bladder cancer based on stem genomic profiling. <i>Stem Cell Research and Therapy</i> , 2020, 11, 457.	5.5	12
1421	Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7935.	4.1	17

#	ARTICLE	IF	CITATIONS
1422	MutSignatures: an R package for extraction and analysis of cancer mutational signatures. Scientific Reports, 2020, 10, 18217.	3.3	33
1423	Precision oncology in urothelial cancer. ESMO Open, 2020, 5, e000616.	4.5	3
1424	Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Nonâ€Muscle-Invasive Bladder Cancer. Cancer Research, 2020, 80, 4476-4486.	0.9	49
1425	Molecular Characterisation of Canine Osteosarcoma in High Risk Breeds. Cancers, 2020, 12, 2405.	3.7	12
1426	Moving towards Personalized Medicine in Muscle-Invasive Bladder Cancer: Where Are We Now and Where Are We Going?. International Journal of Molecular Sciences, 2020, 21, 6271.	4.1	18
1427	An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas. Expert Opinion on Pharmacotherapy, 2020, 21, 2199-2204.	1.8	3
1428	Potential biomarkers and risk assessment models to enhance the tumor-node-metastasis (TNM) staging classification of urologic cancers. Expert Review of Molecular Diagnostics, 2020, 20, 921-932.	3.1	2
1429	Classification of Muscle-Invasive Bladder Cancer Based on Immunogenomic Profiling. Frontiers in Oncology, 2020, 10, 1429.	2.8	16
1430	Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine. BMC Medical Genomics, 2020, 13, 138.	1.5	4
1431	Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate. Nature Communications, 2020, 11, 4225.	12.8	47
1432	Mutational Landscape and Environmental Effects in Bladder Cancer. International Journal of Molecular Sciences, 2020, 21, 6072.	4.1	30
1433	ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment. Frontiers in Genetics, 2020, 11, 933.	2.3	32
1434	Bladder preservation therapy in muscle-invasive bladder cancer: Current evidence and future perspectives. AME Medical Journal, 0, 5, 16-16.	0.4	5
1435	Identification of glycogene-type and validation of ST3GAL6 as a biomarker predicts clinical outcome and cancer cell invasion in urinary bladder cancer. Theranostics, 2020, 10, 10078-10091.	10.0	26
1436	Human transcription factor and protein kinase gene fusions in human cancer. Scientific Reports, 2020, 10, 14169.	3.3	9
1437	MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets. PLoS ONE, 2020, 15, e0238809.	2.5	5
1438	Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer. Oncologist, 2020, 25, e1711-e1719.	3.7	28
1440	Genomic and epigenetic aberrations of chromosome 1p36.13 have prognostic implications in malignancies. Chromosome Research, 2020, 28, 307-330.	2.2	2

#	ARTICLE	IF	CITATIONS
1441	Activation of PPAR $\beta$ and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells. PLoS ONE, 2020, 15, e0237976.	2.5	4
1442	The impact of histological variants on bladder cancer outcomes. AME Medical Journal, 2020, 5, 4-4.	0.4	5
1443	Long noncoding RNA MIR31HG and its splice variants regulate proliferation and migration: prognostic implications for muscle invasive bladder cancer. Journal of Experimental and Clinical Cancer Research, 2020, 39, 288.	8.6	11
1444	PD-L1 Expression in Muscle-Invasive Urinary Bladder Urothelial Carcinoma According to Basal/Squamous-Like Phenotype. Frontiers in Oncology, 2020, 10, 527385.	2.8	13
1445	Evaluating the Utility of Combined Bladder Cancer Biomarkers, the Molecular Prognostication of Tumor Subtypes, or What Else Is Needed to Illuminate Our Vision?. International Journal of Molecular Sciences, 2020, 21, 9657.	4.1	0
1446	Histology-specific FGFR2 alterations and FGFR2-TACC2 fusion in mixed adenoid cystic and neuroendocrine small cell carcinoma of the uterine cervix. Gynecologic Oncology Reports, 2020, 34, 100668.	0.6	7
1447	Enfortumab vedotin â€“ next game-changer in urothelial cancer. Expert Opinion on Biological Therapy, 2021, 21, 801-809.	3.1	17
1448	Targeting Major Signaling Pathways of Bladder Cancer with Phytochemicals: A Review. Nutrition and Cancer, 2021, 73, 2249-2271.	2.0	22
1449	Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo. , 2020, 8, e001673.		5
1450	Resveratrol, curcumin, paclitaxel and miRNAs mediated regulation of PI3K/Akt/mTOR pathway: go four better to treat bladder cancer. Cancer Cell International, 2020, 20, 560.	4.1	39
1451	A Comparative Meta-Analysis and in silico Analysis of Differentially Expressed Genes and Proteins in Canine and Human Bladder Cancer. Frontiers in Veterinary Science, 2020, 7, 558978.	2.2	9
1452	Targeted Therapy in Metastatic Bladder Cancer: Present Status and Future Directions. Applied Sciences (Switzerland), 2020, 10, 7102.	2.5	5
1453	Analysis of open chromatin regions in bladder cancer links $\beta$ -catenin mutations and Wnt signaling with neuronal subtype of bladder cancer. Scientific Reports, 2020, 10, 18667.	3.3	4
1454	Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discovery, 2020, 10, 1808-1825.	9.4	388
1455	FGFR3 â€“ a Central Player in Bladder Cancer Pathogenesis?. Bladder Cancer, 2020, 6, 403-423.	0.4	7
1456	Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of KRT5, KRT20, and ERBB2 in Muscle-Invasive Bladder Cancer Treated by Adjuvant Chemotherapy. International Journal of Molecular Sciences, 2020, 21, 7420.	4.1	2
1457	Trp53 Mutation in Keratin 5 (Krt5)-Expressing Basal Cells Facilitates the Development of Basal Squamous-Like Invasive Bladder Cancer in the Chemical Carcinogenesis of Mouse Bladder. American Journal of Pathology, 2020, 190, 1752-1762.	3.8	7
1458	Identification of Human Secretome and Membrane Proteome-Based Cancer Biomarkers Utilizing Bioinformatics. Journal of Membrane Biology, 2020, 253, 257-270.	2.1	4

#	ARTICLE	IF	CITATIONS
1459	Renal Cell and Urothelial Carcinoma: Biomarkers for New Treatments. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e197-e206.	3.8	10
1460	CK14 Expression Identifies a Basal/Squamous-Like Type of Papillary Non-Muscle-Invasive Upper Tract Urothelial Carcinoma. Frontiers in Oncology, 2020, 10, 623.	2.8	9
1461	Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation. Molecular Oncology, 2020, 14, 2190-2202.	4.6	17
1462	Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations. International Journal of Molecular Sciences, 2020, 21, 3214.	4.1	11
1463	Tumor-associated Macrophages Facilitate Bladder Cancer Progression by Increasing Cell Growth, Migration, Invasion and Cytokine Expression. Anticancer Research, 2020, 40, 2715-2724.	1.1	11
1464	Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer. Journal of Pathology: Clinical Research, 2020, 6, 238-251.	3.0	9
1465	Dysregulation of Redox Status in Urinary Bladder Cancer Patients. Cancers, 2020, 12, 1296.	3.7	11
1466	Fibroblast growth factor receptors across urothelial carcinoma landscape. Current Opinion in Urology, 2020, 30, 557-565.	1.8	5
1467	Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma. British Journal of Cancer, 2020, 123, 226-239.	6.4	10
1468	Pathological and molecular aspects of urothelial carcinomas. Diagnostic Histopathology, 2020, 26, 330-336.	0.4	2
1469	Critical role of SOX2-IGF2 signaling in aggressiveness of bladder cancer. Scientific Reports, 2020, 10, 8261.	3.3	14
1470	Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC. International Journal of Cancer, 2020, 147, 2293-2302.	5.1	10
1471	Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. Journal of Clinical Oncology, 2020, 38, 2407-2417.	1.6	102
1472	microRNA-324 plays an oncogenic role in bladder cancer cell growth and motility. Translational Cancer Research, 2020, 9, 707-716.	1.0	5
1473	Curcumin: A Viable Agent for Better Bladder Cancer Treatment. International Journal of Molecular Sciences, 2020, 21, 3761.	4.1	21
1474	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. Cancers, 2020, 12, 1449.	3.7	72
1475	Establishment of diagnostic criteria for upper urinary tract urothelial carcinoma based on genome-wide DNA methylation analysis. Epigenetics, 2020, 15, 1289-1301.	2.7	9
1476	Slow N-acetylation as a possible contributor to bladder carcinogenesis. Molecular Carcinogenesis, 2020, 59, 1017-1027.	2.7	13

#	ARTICLE	IF	CITATIONS
1477	Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Scientific Reports, 2020, 10, 9743.	3.3	83
1478	<i>ARID1A</i> mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Science Translational Medicine, 2020, 12, .	12.4	82
1479	Response to Anti-HER2-Based Treatment in a Patient with Bladder Adenocarcinoma Harboring <i>HER2</i> Amplification and S310F Mutation Discovered by Next-Generation Sequencing: A Case Report. OncoTargets and Therapy, 2020, Volume 13, 4249-4255.	2.0	6
1480	Neoadjuvant therapy for muscle-invasive bladder cancer. Expert Review of Anticancer Therapy, 2020, 20, 603-614.	2.4	11
1481	The emerging role of antibody-drug conjugates in urothelial carcinoma. Expert Review of Anticancer Therapy, 2020, 20, 551-561.	2.4	23
1482	Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer. Cancer Immunology, Immunotherapy, 2020, 69, 2305-2317.	4.2	11
1483	<i>Kdm6a</i> Deficiency Activates Inflammatory Pathways, Promotes M2 Macrophage Polarization, and Causes Bladder Cancer in Cooperation with <i>p53</i> Dysfunction. Clinical Cancer Research, 2020, 26, 2065-2079.	7.0	80
1484	TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer. Molecular Cancer Research, 2020, 18, 811-821.	3.4	4
1485	The metabolic landscape of urological cancers: New therapeutic perspectives. Cancer Letters, 2020, 477, 76-87.	7.2	14
1486	RNAseq expression patterns of canine invasive urothelial carcinoma reveal two distinct tumor clusters and shared regions of dysregulation with human bladder tumors. BMC Cancer, 2020, 20, 251.	2.6	16
1487	Searching for the perfect combination of drug, disease, genetic alteration, and screening test to maximize FGFR inhibition in urothelial cancer. Cancer, 2020, 126, 2588-2591.	4.1	1
1488	Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells. Cytometry Part B - Clinical Cytometry, 2020, 98, 355-367.	1.5	10
1489	SNHG16 regulates invasion and migration of bladder cancer through induction of epithelial-to-mesenchymal transition. Human Cell, 2020, 33, 737-749.	2.7	21
1490	Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nature Reviews Urology, 2020, 17, 259-270.	3.8	100
1491	Muscle-invasive Urothelial Cancer: Association of Mutational Status with Metastatic Pattern and Survival. Radiology, 2020, 295, 572-580.	7.3	7
1492	The Influence of Cancer Molecular Subtypes and Treatment on the Mutation Spectrum in Metastatic Breast Cancers. Cancer Research, 2020, 80, 3062-3069.	0.9	8
1493	Genomic Subtyping in Bladder Cancer. Current Urology Reports, 2020, 21, 9.	2.2	18
1494	The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor. Cancer Treatment Reviews, 2020, 86, 102000.	7.7	19



#	ARTICLE	IF	CITATIONS
1495	HDMAC: A Web-Based Interactive Program for High-Dimensional Analysis of Molecular Alterations in Cancer. <i>Scientific Reports</i> , 2020, 10, 3953.	3.3	3
1496	An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 863-870.	1.8	7
1497	Mutation signatures to Pan-Cancer Atlas: Investigation of the genomic landscape of muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, , .	1.6	5
1498	Characterization of Tumor Blood Vasculature Expression of Human Invasive Bladder Cancer by Laser Capture Microdissection and Transcriptional Profiling. <i>American Journal of Pathology</i> , 2020, 190, 1960-1970.	3.8	8
1499	Three-Dimensional Microtumors for Probing Heterogeneity of Invasive Bladder Cancer. <i>Analytical Chemistry</i> , 2020, 92, 8768-8775.	6.5	9
1500	OncotRF: an online resource for exploration of tRNA-derived fragments in human cancers. <i>RNA Biology</i> , 2020, 17, 1081-1091.	3.1	39
1501	A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring <i>HRAS</i> Mutations. <i>Clinical Cancer Research</i> , 2020, 26, 5113-5119.	7.0	27
1502	Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy. <i>Cancers</i> , 2020, 12, 1784.	3.7	28
1503	Emerging biomarkers in urothelial carcinoma: Challenges and opportunities. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100179.	1.7	4
1504	Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. <i>Cells</i> , 2020, 9, 1495.	4.1	8
1505	Evaluation of the effect of synthetic compounds derived from azidothymidine on MDA-MB-231 type breast cancer cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127365.	2.2	5
1506	Antibody-drug conjugates for the treatment of urothelial carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 915-922.	3.1	4
1507	Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer. <i>Scientific Reports</i> , 2020, 10, 10952.	3.3	9
1508	Tumor Heterogeneity and Phenotypic Plasticity in Bladder Carcinoma. <i>Journal of the Indian Institute of Science</i> , 2020, 100, 567-578.	1.9	0
1509	Targeting the Immune system and Epigenetic Landscape of Urological Tumors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 829.	4.1	15
1510	The landscape of chimeric RNAs in non-diseased tissues and cells. <i>Nucleic Acids Research</i> , 2020, 48, 1764-1778.	14.5	47
1511	Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans. <i>Frontiers in Oncology</i> , 2019, 9, 1493.	2.8	51
1512	An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC). <i>Cancer Medicine</i> , 2020, 9, 2774-2790.	2.8	63



#	ARTICLE	IF	CITATIONS
1513	The CUL4B-miR-372/373-PIK3CA-AKT axis regulates metastasis in bladder cancer. <i>Oncogene</i> , 2020, 39, 3588-3603.	5.9	24
1514	The paradox of cancer genes in non-malignant conditions: implications for precision medicine. <i>Genome Medicine</i> , 2020, 12, 16.	8.2	33
1515	Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 346-351.	1.0	40
1516	Immunotherapy for urothelial cancer: from the diagnostic pathologist's point of view. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 539-544.	3.1	9
1517	Genitourinary Pathology (Including Adrenal Gland). , 2020, , 1523-1726.		0
1518	Cancer-derived UTX TPR mutations G137V and D336G impair interaction with MLL3/4 complexes and affect UTX subcellular localization. <i>Oncogene</i> , 2020, 39, 3322-3335.	5.9	19
1519	The applicability and utility of immunohistochemical biomarkers in bladder pathology. <i>Human Pathology</i> , 2020, 98, 32-55.	2.0	21
1520	Clinical and pathological characteristics of bladder cancer in post brachytherapy patients. <i>Pathology Research and Practice</i> , 2020, 216, 152822.	2.3	5
1521	Screening and Identifying Immune-Related Cells and Genes in the Tumor Microenvironment of Bladder Urothelial Carcinoma: Based on TCGA Database and Bioinformatics. <i>Frontiers in Oncology</i> , 2019, 9, 1533.	2.8	53
1522	Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. <i>European Urology</i> , 2020, 77, 548-556.	1.9	41
1523	Competitive glucose metabolism as a target to boost bladder cancer immunotherapy. <i>Nature Reviews Urology</i> , 2020, 17, 77-106.	3.8	91
1524	The top 100 most cited manuscripts in bladder cancer: A bibliometric analysis (review article). <i>International Journal of Surgery</i> , 2020, 75, 130-138.	2.7	37
1525	Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes. <i>Scientific Reports</i> , 2020, 10, 1439.	3.3	35
1526	Bladder cancer genomics. <i>Urologia</i> , 2020, 87, 49-56.	0.7	43
1527	Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 352.	4.1	18
1528	PIK3CA gene aberrancy and role in targeted therapy of solid malignancies. <i>Cancer Gene Therapy</i> , 2020, 27, 634-644.	4.6	22
1530	Sirtuins™ Deregulation in Bladder Cancer: SIRT7 Is Implicated in Tumor Progression through Epithelial to Mesenchymal Transition Promotion. <i>Cancers</i> , 2020, 12, 1066.	3.7	21
1531	Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder. <i>Journal of Clinical Medicine</i> , 2020, 9, 1265.	2.4	18

#	ARTICLE	IF	CITATIONS
1532	Mutational signatures are jointly shaped by DNA damage and repair. <i>Nature Communications</i> , 2020, 11, 2169.	12.8	137
1533	Deep Learning Predicts Molecular Subtype of Muscle-invasive Bladder Cancer from Conventional Histopathological Slides. <i>European Urology</i> , 2020, 78, 256-264.	1.9	96
1534	Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer. <i>Modern Pathology</i> , 2020, 33, 1802-1810.	5.5	7
1535	Urine Endocannabinoids as Novel Non-Invasive Biomarkers for Bladder Cancer at Early Stage. <i>Cancers</i> , 2020, 12, 870.	3.7	16
1536	Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer. <i>Oncologist</i> , 2020, 25, 680-688.	3.7	14
1537	The role and function of PPAR $\delta$ in bladder cancer. <i>Journal of Cancer</i> , 2020, 11, 3965-3975.	2.5	17
1538	Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2825.	4.1	11
1539	Moesin (MSN) as a Novel Proteome-Based Diagnostic Marker for Early Detection of Invasive Bladder Urothelial Carcinoma in Liquid-Based Cytology. <i>Cancers</i> , 2020, 12, 1018.	3.7	10
1540	The genetic landscapes of urological cancers and their clinical implications in the era of high-throughput genome analysis. <i>BJU International</i> , 2020, 126, 26-54.	2.5	5
1541	A randomised Phase II trial of carboplatin and gemcitabine $\pm$ vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin. <i>BJU International</i> , 2020, 126, 292-299.	2.5	4
1542	Comparative genomic profiling of glandular bladder tumours. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 445-454.	2.8	22
1543	Structure-based drug design of 1,3,5-triazine and pyrimidine derivatives as novel FGFR3 inhibitors with high selectivity over VEGFR2. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115453.	3.0	16
1544	Role and efficacy of current biomarkers in bladder cancer. <i>AME Medical Journal</i> , 0, 5, 6-6.	0.4	7
1545	FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy. <i>Journal of Clinical Medicine</i> , 2020, 9, 994.	2.4	14
1546	Pedigree analysis of a POLD1 germline mutation in urothelial carcinoma shows a close association between different mutation burdens and overall survival. <i>Cellular and Molecular Immunology</i> , 2021, 18, 767-769.	10.5	2
1547	Combining two grading systems: the clinical validity and inter-observer variability of the 1973 and 2004 WHO bladder cancer classification systems assessed in a UK cohort with 15 years of prospective follow-up. <i>World Journal of Urology</i> , 2021, 39, 425-431.	2.2	10
1548	Evolutionary Action Score of TP53 Enhances the Prognostic Prediction for Stage I Lung Adenocarcinoma. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2021, 33, 221-229.	0.6	2
1549	Survey and comparative assessments of computational multi-omics integrative methods with multiple regulatory networks identifying distinct tumor compositions across pan-cancer data sets. <i>Briefings in Bioinformatics</i> , 2021, 22, .	6.5	9

#	ARTICLE	IF	CITATIONS
1550	Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC). <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1-18.	4.2	79
1551	Liquid Biopsies to Select Patients for Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: A Systematic Review. <i>European Urology Oncology</i> , 2021, 4, 204-214.	5.4	20
1552	Updates in the management and future landscape of urothelial carcinoma. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 435-444.	0.9	2
1553	Arsenic-induced HER2 promotes proliferation, migration and angiogenesis of bladder epithelial cells via activation of multiple signaling pathways in vitro and in vivo. <i>Science of the Total Environment</i> , 2021, 753, 141962.	8.0	16
1554	Cytologically targeted next-generation sequencing: a synergy for diagnosing urothelial carcinoma. <i>Journal of the American Society of Cytopathology</i> , 2021, 10, 94-102.	0.5	4
1555	Transcriptional and signalling regulation of skin epithelial stem cells in homeostasis, wounds and cancer. <i>Experimental Dermatology</i> , 2021, 30, 529-545.	2.9	15
1556	Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 7.	3.0	6
1557	Sequencing facility and DNA source associated patterns of virus-mappable reads in whole-genome sequencing data. <i>Genomics</i> , 2021, 113, 1189-1198.	2.9	3
1558	Amplification of 8p11.23 in cancers and the role of amplicon genes. <i>Life Sciences</i> , 2021, 264, 118729.	4.3	12
1559	Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2011-2022.	7.0	19
1560	Impact of immunohistochemistry-based molecular subtype on predicting chemotherapy response and survival in patients with T1 stage bladder cancer after bladder-preserving treatment. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 424-433.	1.3	11
1561	Differential Effects of Clinically Relevant N- versus C-Terminal Truncating CDKN1A Mutations on Cisplatin Sensitivity in Bladder Cancer. <i>Molecular Cancer Research</i> , 2021, 19, 403-413.	3.4	5
1563	Nested Variant of Urothelial Carcinoma Is a Luminal Bladder Tumor With Distinct Coexpression of the Basal Marker Cytokeratin 5/6. <i>American Journal of Clinical Pathology</i> , 2021, 155, 588-596.	0.7	10
1565	Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes. <i>Pathology</i> , 2021, 53, 56-66.	0.6	22
1566	Cytotoxic and chemosensitizing effects of glycoalkaloidic extract on 2D and 3D models using RT4 and patient derived xenografts bladder cancer cells. <i>Materials Science and Engineering C</i> , 2021, 119, 111460.	7.3	14
1567	Retinoic acid signaling and bladder cancer: Epigenetic deregulation, therapy and beyond. <i>International Journal of Cancer</i> , 2021, 148, 2364-2374.	5.1	10
1568	Intestinal metaplasia of the urinary tract harbors potentially oncogenic genetic variants. <i>Modern Pathology</i> , 2021, 34, 457-468.	5.5	9
1569	Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer?. <i>European Urology Oncology</i> , 2021, 4, 510-514.	5.4	10

#	ARTICLE	IF	CITATIONS
1570	Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets. <i>Seminars in Cancer Biology</i> , 2021, 68, 59-74.	9.6	64
1571	Comprehensive Gene Expression Analyses of Immunohistochemically Defined Subgroups of Muscle-Invasive Urinary Bladder Urothelial Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 628.	4.1	7
1572	Novel Combination Therapies for the Treatment of Bladder Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 539527.	2.8	24
1573	Diagnostic roles of proliferative markers in pathological Grade of T1 Urothelial Bladder Cancer. <i>Journal of Cancer</i> , 2021, 12, 2498-2506.	2.5	2
1574	Evolving Therapies for Urothelial Carcinoma—Novel Paradigms and Future Directions. <i>Oncology &amp; Hematology Review</i> , 2021, 16, 82.	0.2	1
1575	Characteristics of upper urinary tract urothelial carcinoma in the context of bladder cancer: a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 4036-4050.	1.4	11
1576	Non-Muscle Invasive Bladder Cancer with Variant Histology: Biological Features and Clinical Implications. <i>Oncology</i> , 2021, 99, 345-358.	1.9	18
1577	Ursolic Acid and Its Nanoparticles Are Potentiators of Oncolytic Measles Virotherapy against Breast Cancer Cells. <i>Cancers</i> , 2021, 13, 136.	3.7	11
1578	Combined use of immunohistochemical markers of basal and luminal subtypes in urothelial carcinoma of the bladder: Association with clinicopathological features and outcomes. <i>Clinics</i> , 2021, 76, e2587.	1.5	7
1579	Molecular Pathology. , 2021, , 175-188.		0
1580	Research Progress of Urine Biomarkers in the Diagnosis, Treatment, and Prognosis of Bladder Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1306, 61-80.	1.6	1
1582	Fast mutual exclusivity algorithm nominates potential synthetic lethal gene pairs through brute force matrix product computations. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 4394-4403.	4.1	5
1583	Risk Stratification of Patients: Risk Tables and Assessment — NMIBC and MIBC. , 2021, , 41-52.		1
1584	Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. <i>Cancers</i> , 2021, 13, 131.	3.7	153
1585	Association of immunohistochemical markers of tumor subtype with response to neoadjuvant chemotherapy and survival in patients with muscle-invasive bladder cancer. <i>Investigative and Clinical Urology</i> , 2021, 62, 274.	2.0	13
1586	Pre-clinical investigation of STAT3 pathway in bladder cancer: Paving the way for clinical translation. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111077.	5.6	31
1588	Topsentinol L Trisulfate, a Marine Natural Product That Targets Basal-like and Claudin-Low Breast Cancers. <i>Marine Drugs</i> , 2021, 19, 41.	4.6	3
1589	The Role of Toll-Like Receptor (TLR) Polymorphisms in Urinary Bladder Cancer. , 2021, , 281-317.		7

#	ARTICLE	IF	CITATIONS
1590	Novel Therapies. , 2021, , 315-322.		0
1591	Recurrent ZNF83-E293V Mutation Promotes Bladder Cancer Progression through the NF- $\kappa$ B Pathway via Transcriptional Dysregulation of S100A8. Molecular Therapy, 2021, 29, 275-290.	8.2	8
1592	Bladder Cancer Genomics: Indications for Sequencing and Diagnostic Implications. , 2021, , 193-205.		0
1593	Metabolic regulation in urological tumors: Interplay with epigenetics and epitranscriptomics. , 2021, , 107-145.		0
1594	Urinary Cell-Free DNA in Bladder Cancer Detection. Diagnostics, 2021, 11, 306.	2.6	9
1595	The Development of Antibody-Drug Conjugates for Urothelial Carcinoma Treatment. The Korean Journal of Urological Oncology, 2021, 19, 30-39.	0.1	0
1596	On Urinary Bladder Cancer Diagnosis: Utilization of Deep Convolutional Generative Adversarial Networks for Data Augmentation. Biology, 2021, 10, 175.	2.8	13
1597	A pediatric brain tumor atlas of genes deregulated by somatic genomic rearrangement. Nature Communications, 2021, 12, 937.	12.8	23
1598	PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action. Frontiers in Endocrinology, 2021, 12, 624112.	3.5	167
1599	Clinicopathological and molecular characteristics of patients with hypermutant lung cancer: A retrospective cohort study. Oncology Letters, 2021, 21, 329.	1.8	8
1600	Identification of deregulation mechanisms specific to cancer subtypes. Journal of Bioinformatics and Computational Biology, 2021, 19, 2140003.	0.8	2
1601	Wnt/ $\beta$ -Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma. Cancers, 2021, 13, 889.	3.7	24
1602	Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells. Genes, 2021, 12, 260.	2.4	13
1603	Robust Data Integration Method for Classification of Biomedical Data. Journal of Medical Systems, 2021, 45, 45.	3.6	1
1604	Identification of a ten-long noncoding RNA signature for predicting the survival and immune status of patients with bladder urothelial carcinoma based on the GEO database: a superior machine learning model. Aging, 2021, 13, 6957-6981.	3.1	4
1605	Diagnostic value of a comprehensive, urothelial carcinomaâ€specific nextâ€generation sequencing panel in urine cytology and bladder tumor specimens. Cancer Cytopathology, 2021, 129, 537-547.	2.4	6
1606	Genomic profiling of Chinese patients with urothelial carcinoma. BMC Cancer, 2021, 21, 162.	2.6	5
1607	Tripleâ€marker immunohistochemical assessment of muscleâ€invasive bladder cancer: Is there prognostic significance?. Cancer Reports, 2021, 4, e1313.	1.4	3

#	ARTICLE	IF	CITATIONS
1608	A Urine-Based Liquid Biopsy Method for Detection of Upper Tract Urinary Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 597486.	2.8	10
1609	Low-Coverage Sequencing of Urine Sediment DNA for Detection of Copy Number Aberrations in Bladder Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 1943-1953.	1.9	3
1610	Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI/SNF mutant cancers and tumor microenvironment modulation. <i>Drug Development Research</i> , 2021, 82, 730-753.	2.9	5
1611	Bladder cancer risk associated with family history of cancer. <i>International Journal of Cancer</i> , 2021, 148, 2915-2923.	5.1	7
1612	Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment. <i>Cancers</i> , 2021, 13, 1376.	3.7	4
1613	Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 630773.	4.8	22
1614	Prognostic Value of an Immunohistochemical Signature in Patients With Bladder Cancer Undergoing Radical Cystectomy. <i>Frontiers in Oncology</i> , 2021, 11, 641385.	2.8	1
1615	Synthesis and structure-activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 33, 116019.	3.0	6
1616	Analysis of mRNA expression differences in bladder cancer metastasis based on TCGA datasets. <i>Journal of International Medical Research</i> , 2021, 49, 030006052199692.	1.0	3
1617	Significant benefit of everolimus in a patient with urothelial bladder cancer harboring a rare M1043I mutation of PIK3CA. <i>Investigational New Drugs</i> , 2021, 39, 1197-1199.	2.6	1
1618	Biomarker-Oriented Therapy in Bladder and Renal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2832.	4.1	18
1619	A role of TTI1 in the colorectal cancer by promoting proliferation. <i>Translational Cancer Research</i> , 2021, 10, 1378-1388.	1.0	3
1620	Oxidative Stress and the Intersection of Oncogenic Signaling and Metabolism in Squamous Cell Carcinomas. <i>Cells</i> , 2021, 10, 606.	4.1	3
1621	Tumor Subtyping: Making Sense of Heterogeneity with a Goal Toward Treatment. <i>Bladder Cancer</i> , 2021, 7, 1-11.	0.4	3
1622	Increased expression of urinary exosomal LncRNA TUG-1 in early bladder cancer. <i>Gene Reports</i> , 2021, 22, 101010.	0.8	4
1623	Comprehensive Analysis of Correlations in the Expression of miRNA Genes and Immune Checkpoint Genes in Bladder Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2553.	4.1	3
1625	Role of Previous Malignancy History in Clinical Outcomes in Patients with Initially Diagnosed Non-Muscle Invasive Bladder Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 5349-5359.	1.5	5
1626	HER2 / neu Overexpression in Urothelial Carcinoma and Its Association with Tumour Grading - A Cross Sectional Study from a Tertiary Care Hospital in Kerala. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2021, 8, 497-501.	0.0	0

#	ARTICLE	IF	CITATIONS
1627	Therapeutic and prognostic implications of NOTCH and MAPK signaling in bladder cancer. <i>Cancer Science</i> , 2021, 112, 1987-1996.	3.9	16
1628	SUMO-Modification of Human Nrf2 at K110 and K533 Regulates Its Nucleocytoplasmic Localization, Stability and Transcriptional Activity. <i>Cellular Physiology and Biochemistry</i> , 2021, 55, 141-159.	1.6	21
1629	TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?â€”a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 1541-1552.	1.4	6
1630	The Usefulness of Cell-Based and Liquid-Based Urine Tests in Clarifying the Diagnosis and Monitoring the Course of Urothelial Carcinoma. Identification of Novel, Potentially Actionable, RB1 and ERBB2 Somatic Mutations. <i>Journal of Personalized Medicine</i> , 2021, 11, 362.	2.5	0
1631	RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer. <i>BMC Cancer</i> , 2021, 21, 432.	2.6	21
1632	The ECM Modulator ITIH5 Affects Cell Adhesion, Motility and Chemotherapeutic Response of Basal/Squamous-Like (BASQ) Bladder Cancer Cells. <i>Cells</i> , 2021, 10, 1038.	4.1	11
1633	Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. <i>European Urology Oncology</i> , 2021, 4, 170-179.	5.4	28
1634	Targeted Deep Sequencing of Bladder Tumors Reveals Novel Associations between Cancer Gene Mutations and Mutational Signatures with Major Risk Factors. <i>Clinical Cancer Research</i> , 2021, 27, 3725-3733.	7.0	11
1635	Notch signaling in cancer: Complexity and challenges on the path to clinical translation. <i>Seminars in Cancer Biology</i> , 2022, 85, 95-106.	9.6	17
1637	Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience. <i>Pathology Research and Practice</i> , 2021, 220, 153410.	2.3	1
1638	A combination of ssGSEA and mass cytometry identifies immune microenvironment in muscleâ€”invasive bladder cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23754.	2.1	9
1639	Toward urinary cell-free DNA-based treatment of urothelial carcinoma: a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 1865-1877.	1.4	7
1640	Subtype-associated epigenomic landscape and 3D genome structure in bladder cancer. <i>Genome Biology</i> , 2021, 22, 105.	8.8	29
1641	Liquid biopsy in NSCLC: a new challenge in radiation therapy. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.8	0
1642	Prognostic Impact of APOBEC3B Expression in Metastatic Urothelial Carcinoma and Its Association with Tumor-Infiltrating Cytotoxic T Cells. <i>Current Oncology</i> , 2021, 28, 1652-1662.	2.2	4
1643	Gene Targeting in Disease Networks. <i>Frontiers in Genetics</i> , 2021, 12, 649942.	2.3	11
1644	Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 646874.	4.8	6
1645	Identification of an 11-Autophagy-Related-Gene Signature as Promising Prognostic Biomarker for Bladder Cancer Patients. <i>Biology</i> , 2021, 10, 375.	2.8	10



#	ARTICLE	IF	CITATIONS
1646	Histopathological characteristics and artificial intelligence for predicting tumor mutational burden-high colorectal cancer. <i>Journal of Gastroenterology</i> , 2021, 56, 547-559.	5.1	23
1647	Urologic malignancies: advances in the analysis and interpretation of clinical findings. <i>Future Science OA</i> , 2021, 7, FSO674.	1.9	24
1648	Identification of a Hypoxia-Related Signature for Predicting Prognosis and the Immune Microenvironment in Bladder Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 613359.	3.5	14
1649	Expression and prognostic value of SULT1A2 in bladder cancer. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 779.	1.8	1
1650	Current State of Personalized Genitourinary Cancer Radiotherapy in the Era of Precision Medicine. <i>Frontiers in Oncology</i> , 2021, 11, 675311.	2.8	6
1651	Epigenomic and Metabolomic Integration Reveals Dynamic Metabolic Regulation in Bladder Cancer. <i>Cancers</i> , 2021, 13, 2719.	3.7	8
1652	Molecular Mechanisms of PD-1 and PD-L1 Activity on a Pan-Cancer Basis: A Bioinformatic Exploratory Study. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5478.	4.1	6
1653	<i>h1&gt;TERT&lt;/i&gt; promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor. , 2021, 9, e002127.</i>		24
1654	Frontiers in Bladder Cancer Genomic Research. <i>Frontiers in Oncology</i> , 2021, 11, 670729.	2.8	11
1655	Molecular markers of systemic therapy response in urothelial carcinoma. <i>Asian Journal of Urology</i> , 2021, 8, 376-390.	1.2	22
1656	Can serum matrix metalloproteinaseâ€9 and SMADâ€2 levels predict lamina propria invasion in bladder urothelial carcinoma?. <i>International Journal of Clinical Practice</i> , 2021, 75, e14277.	1.7	0
1658	Identification of a prognostic signature based on immune-related genes in bladder cancer. <i>Genomics</i> , 2021, 113, 1203-1218.	2.9	5
1659	SWI/SNF-deficient neoplasms of the genitourinary tract. <i>Seminars in Diagnostic Pathology</i> , 2021, 38, 212-221.	1.5	5
1660	Identifying the Molecular Mechanisms Contributing to Progression, Metastasis, and Death in Low-grade Nonâ€muscle-invasive Bladder Cancer: A Case Report. <i>European Urology Open Science</i> , 2021, 27, 29-32.	0.4	2
1661	Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3734-3743.	7.0	17
1662	Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5938.	4.1	12
1663	Identification of autophagyâ€related genes signature predicts chemotherapeutic and immunotherapeutic efficiency in bladder cancer (BLCA). <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 5417-5433.	3.6	11
1664	Molecular Biology of Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 457-468.	2.2	4

#	ARTICLE	IF	CITATIONS
1665	Oncogenetic network estimation with disjunctive Bayesian networks. Computational and Systems Oncology, 2021, 1, e1027.	1.5	5
1666	Polyisoprenylated Cysteinyl Amide Inhibitors: A Novel Approach to Controlling Cancers with Hyperactive Growth Signaling. Current Medicinal Chemistry, 2021, 28, 3476-3489.	2.4	2
1667	Genome-Wide Transcriptomic Analysis of Non-Tumorigenic Tissues Reveals Aging-Related Prognostic Markers and Drug Targets in Renal Cell Carcinoma. Cancers, 2021, 13, 3045.	3.7	10
1668	Identification of the Functions and Prognostic Values of RNA Binding Proteins in Bladder Cancer. Frontiers in Genetics, 2021, 12, 574196.	2.3	19
1669	Deletion of Lats1/2 in adult kidney epithelia leads to renal cell carcinoma. Journal of Clinical Investigation, 2021, 131, .	8.2	12
1670	Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy—A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin. Cancers, 2021, 13, 3206.	3.7	6
1671	Reappraisal of HER2 Amplification in High-Grade Urothelial Carcinoma Based on 2018 ASCO/CAP Clinical Practice Guidelines. American Journal of Clinical Pathology, 2021, 156, 1130-1141.	0.7	4
1672	Oncogenic FGFR Fusions Produce Centrosome and Cilia Defects by Ectopic Signaling. Cells, 2021, 10, 1445.	4.1	6
1673	A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer. Frontiers in Oncology, 2021, 11, 660273.	2.8	6
1674	Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell, 2021, 39, 793-809.e8.	16.8	65
1675	Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?. Translational Andrology and Urology, 2021, 10, 2787-2808.	1.4	7
1676	Current Therapy for Metastatic Urothelial Carcinoma. Hematology/Oncology Clinics of North America, 2021, 35, 469-493.	2.2	4
1677	Integrative analysis of immune molecular subtypes and microenvironment characteristics of bladder cancer. Cancer Medicine, 2021, 10, 5375-5391.	2.8	6
1678	Characterizing the molecular and immune landscape of canine bladder cancer. Veterinary and Comparative Oncology, 2022, 20, 69-81.	1.8	10
1679	Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell, 2021, 39, 845-865.e7.	16.8	503
1680	Emerging Targeted Therapy for Bladder Cancer. Hematology/Oncology Clinics of North America, 2021, 35, 585-596.	2.2	4
1681	The Evolving Landscape of Antibody–Drug Conjugates for Urothelial Carcinoma. Clinical Genitourinary Cancer, 2021, 19, 183-193.	1.9	6
1682	Gene Expression Profiling of Muscle-Invasive Bladder Cancer With Secondary Variant Histology. American Journal of Clinical Pathology, 2021, 156, 895-905.	0.7	5

#	ARTICLE	IF	CITATIONS
1683	<scp>TDO2</scp> overexpression correlates with poor prognosis, cancer stemness, and resistance to cetuximab in bladder cancer. Cancer Reports, 2021, 4, e1417.	1.4	8
1684	Cohesin Mutations in Cancer: Emerging Therapeutic Targets. International Journal of Molecular Sciences, 2021, 22, 6788.	4.1	22
1685	The emerging role of somatic tumor sequencing in the treatment of urothelial cancer. Asian Journal of Urology, 2021, 8, 391-399.	1.2	6
1686	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. Advances in Anatomic Pathology, 2021, 28, 196-208.	4.3	20
1687	Three-antibody classifier for muscle invasive urothelial carcinoma and its correlation with p53 expression. Journal of Clinical Pathology, 2022, 75, 766-771.	2.0	9
1689	Activation of the DDR Pathway Leads to the Down-Regulation of the TGFÎ² Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma. Frontiers in Immunology, 2021, 12, 634741.	4.8	20
1690	Developing Precision Medicine for Bladder Cancer. Hematology/Oncology Clinics of North America, 2021, 35, 633-653.	2.2	9
1691	Decoding human cancer with whole genome sequencing: a review of PCAWG Project studies published in February 2020. Cancer and Metastasis Reviews, 2021, 40, 909-924.	5.9	10
1692	Molecular Classification of Bladder Cancer. , 0, , .		0
1693	Distinctive morphological and molecular features of urothelial carcinoma with an inverted growth pattern. Journal of Pathology and Translational Medicine, 2021, 55, 239-246.	1.1	3
1694	A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibodyâ€“drug conjugate, in patients with advanced or metastatic cancer. Investigational New Drugs, 2021, 39, 1613-1623.	2.6	8
1695	Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder. PLoS ONE, 2021, 16, e0241766.	2.5	4
1696	Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives. International Journal of Molecular Sciences, 2021, 22, 7201.	4.1	8
1697	Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 436.e1-436.e10.	1.6	4
1699	Machine learning analysis of TCGA cancer data. PeerJ Computer Science, 2021, 7, e584.	4.5	13
1700	p53 mitigates the effects of oncogenic HRAS in urothelial cells via the repression of MCOLN1. IScience, 2021, 24, 102701.	4.1	5
1701	Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort. World Journal of Urology, 2021, 39, 4011-4019.	2.2	22
1702	Molecular pathology of urothelial carcinoma. Human Pathology, 2021, 113, 67-83.	2.0	24

#	ARTICLE	IF	CITATIONS
1703	Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. <i>British Journal of Cancer</i> , 2021, 125, 1251-1260.	6.4	77
1704	High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 63.e9-63.e18.	1.6	5
1706	A Prognostic Signature Constructed by CTHRC1 and LRFN4 in Stomach Adenocarcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 646818.	2.3	4
1707	Integrative Transcriptomic, Lipidomic, and Metabolomic Analysis Reveals Potential Biomarkers of Basal and Luminal Muscle Invasive Bladder Cancer Subtypes. <i>Frontiers in Genetics</i> , 2021, 12, 695662.	2.3	3
1708	Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 3199-3206.	1.6	5
1709	Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions. <i>Cancers</i> , 2021, 13, 4341.	3.7	8
1710	Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003732.	8.4	38
1711	Thioredoxin-Interacting Protein in Cancer and Diabetes. <i>Antioxidants and Redox Signaling</i> , 2022, 36, 1001-1022.	5.4	19
1712	Repurposing RNA sequencing for discovery of RNA modifications in clinical cohorts. <i>Science Advances</i> , 2021, 7, .	10.3	12
1713	The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 6567-6578.	1.9	10
1714	Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives. <i>Cancers</i> , 2021, 13, 4411.	3.7	31
1715	Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 498.e1-498.e11.	1.6	3
1717	Robust Prognostic Subtyping of Muscle-Invasive Bladder Cancer Revealed by Deep Learning-Based Multi-Omics Data Integration. <i>Frontiers in Oncology</i> , 2021, 11, 689626.	2.8	10
1720	Plasmacytoid urothelial carcinoma (UC) are luminal tumors with similar CD8+ Tcell density and PD-L1 protein expression on immune cells as compared to conventional UC. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 12.e1-12.e11.	1.6	6
1721	mTOR pathway and DNA damage response: A therapeutic strategy in cancer therapy. <i>DNA Repair</i> , 2021, 104, 103142.	2.8	14
1722	A qPCR based method for molecular subtype classification of urinary bladder cancer stromal gene expressions show higher prognostic values than intrinsic tumor genes. <i>International Journal of Cancer</i> , 2021, , .	5.1	6
1723	Novel Mouse Models of Bladder Cancer Identify a Prognostic Signature Associated with Risk of Disease Progression. <i>Cancer Research</i> , 2021, 81, 5161-5175.	0.9	7
1724	Effects of Concurrent Chemoradiotherapy on the Metastasis and the Mesenchymal Transition of Bladder Urothelial Carcinoma Cells. <i>Anticancer Research</i> , 2021, 41, 4957-4968.	1.1	0

#	ARTICLE	IF	CITATIONS
1725	SRT1720 inhibits the growth of bladder cancer in organoids and murine models through the SIRT1-HIF axis. <i>Oncogene</i> , 2021, 40, 6081-6092.	5.9	24
1726	Models of pancreatic ductal adenocarcinoma. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 803-818.	5.9	9
1727	Identification of Immune Function-Related Subtypes in Cutaneous Melanoma. <i>Life</i> , 2021, 11, 925.	2.4	2
1728	Molecular Pathology of Urothelial Carcinoma. <i>Surgical Pathology Clinics</i> , 2021, 14, 403-414.	1.7	4
1729	Blood-based protein biomarkers in bladder urothelial tumors. <i>Journal of Proteomics</i> , 2021, 247, 104329.	2.4	10
1730	HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells. <i>Cells</i> , 2021, 10, 2371.	4.1	41
1731	Current Advances and Outlook in Gastric Cancer Chemoresistance: A Review. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2022, 17, 26-41.	1.6	15
1732	STC1 is a Novel Biomarker Associated with Immune Characteristics and Prognosis of Bladder Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5505-5516.	1.8	12
1733	Characterization of hypoxia response patterns identified prognosis and immunotherapy response in bladder cancer. <i>Molecular Therapy - Oncolytics</i> , 2021, 22, 277-293.	4.4	19
1734	A 25 year perspective on advances in the pathologic assessment and diagnosis of urologic cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 582-594.	1.6	4
1735	Current Development and Application of Anaerobic Glycolytic Enzymes in Urothelial Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10612.	4.1	7
1736	Mutational landscape of primary pulmonary salivary gland-type tumors through targeted next-generation sequencing. <i>Lung Cancer</i> , 2021, 160, 1-7.	2.0	11
1737	Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies. , 2021, 9, e003001.		8
1738	Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 457-465.	1.9	8
1739	MDM2 amplification in malignant Brenner tumors may play a role in progression to malignancy and aid in separation from urothelial and other ovarian carcinomas. <i>Human Pathology</i> , 2021, 117, 42-50.	2.0	3
1740	Pathogenesis and Diagnosis of Genitourinary Cancer. <i>Cancers</i> , 2021, 13, 347.	3.7	2
1741	Contemporary Molecular Classification of Urinary Bladder Cancer. <i>In Vivo</i> , 2021, 35, 75-80.	1.3	3
1742	Role of Bladder Cancer Metabolic Reprogramming in the Effectiveness of Immunotherapy. <i>Cancers</i> , 2021, 13, 288.	3.7	12

#	ARTICLE	IF	CITATIONS
1743	The Differential Diagnosis of Medullary-Based Renal Masses. Archives of Pathology and Laboratory Medicine, 2021, 145, 1148-1170.	2.5	11
1744	Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nature Communications, 2021, 12, 184.	12.8	85
1745	Metastatic Urothelial Cancer: a rapidly changing treatment landscape. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110473.	3.2	19
1746	Environmental and Genetic Factors Contributing to Bladder Carcinogenesis. , 2021, , 13-44.		1
1747	Somatic data usage for classification of germ line variants. , 2021, , 169-192.		0
1749	Cell-Intrinsic Tumorigenic Functions of PPAR $\gamma$ in Bladder Urothelial Carcinoma. Molecular Cancer Research, 2021, 19, 598-611.	3.4	7
1750	Emerging agents for the treatment of metastatic urothelial cancer. Investigative and Clinical Urology, 2021, 62, 243.	2.0	8
1751	Cross-Talk between STYK1 and EGFR in Autophagy Regulation and EGFR-TKIs Sensitivity in Non-Small Cell Lung Cancer. SSRN Electronic Journal, 0, , .	0.4	0
1752	SLC35F2, a Transporter Sporadically Mutated in the Untranslated Region, Promotes Growth, Migration, and Invasion of Bladder Cancer Cells. Cells, 2021, 10, 80.	4.1	12
1753	Emerging Roles of Urine-Derived Components for the Management of Bladder Cancer: One Man's Trash Is Another Man's Treasure. Cancers, 2021, 13, 422.	3.7	15
1755	Nanopore Sequencing and Its Clinical Applications. Methods in Molecular Biology, 2020, 2204, 13-32.	0.9	12
1756	Taking Bioinformatics to Systems Medicine. Methods in Molecular Biology, 2016, 1386, 17-41.	0.9	9
1757	Mechanisms of Environmental and Occupational Carcinogenesis. , 2020, , 39-55.		1
1758	Current Landscape of Immunotherapy in Genitourinary Malignancies. Advances in Experimental Medicine and Biology, 2020, 1244, 107-147.	1.6	3
1759	Selected protein expression in a new prognostic model for patients with non-muscle-invasive bladder cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2099-2108.	2.5	6
1760	Antibody-Drug Conjugates in Urothelial Carcinomas. Current Oncology Reports, 2020, 22, 13.	4.0	21
1761	The Genomics, Epigenomics, and Transcriptomics of HPV-Associated Oropharyngeal Cancer—Understanding the Basis of a Rapidly Evolving Disease. Advances in Genetics, 2016, 93, 1-56.	1.8	27
1762	Non-coding RNA in bladder cancer. Cancer Letters, 2020, 485, 38-44.	7.2	86

#	ARTICLE	IF	CITATIONS
1763	The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e269-e276.	1.9	39
1764	Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. <i>European Urology Focus</i> , 2021, 7, 1339-1346.	3.1	58
1765	The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. <i>Nature Genetics</i> , 2019, 51, 506-516.	21.4	166
1766	Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy. <i>Communications Biology</i> , 2020, 3, 784.	4.4	21
1767	Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 503-512.	2.4	11
1768	Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA. <i>Journal of Urology</i> , 2020, 203, 62-72.	0.4	33
1769	Aligner optimization increases accuracy and decreases compute times in multi-species sequence data. <i>Microbial Genomics</i> , 2017, 3, e000122.	2.0	13
1788	Targeted therapy for upper gastrointestinal tract cancer: current and future prospects. <i>Histopathology</i> , 2021, 78, 148-161.	2.9	17
1789	Extensive heterogeneity in somatic mutation and selection in the human bladder. <i>Science</i> , 2020, 370, 75-82.	12.6	195
1790	The Analysis of PTPN6 for Bladder Cancer: An Exploratory Study Based on TCGA. <i>Disease Markers</i> , 2020, 2020, 1-8.	1.3	10
1791	Notch controls urothelial integrity in the mouse bladder. <i>JCI Insight</i> , 2020, 5, .	5.0	9
1792	Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. <i>JCI Insight</i> , 2016, 1, e85902.	5.0	179
1793	ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. <i>Journal of Clinical Investigation</i> , 2017, 127, 2916-2929.	8.2	176
1794	Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 2951-2965.	8.2	36
1795	Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition. <i>Cancer Control</i> , 2020, 27, 107327482097666.	1.8	25
1796	New discoveries in the molecular landscape of bladder cancer. <i>F1000Research</i> , 2016, 5, 2875.	1.6	5
1797	The INO80 chromatin remodeler sustains metabolic stability by promoting TOR signaling and regulating histone acetylation. <i>PLoS Genetics</i> , 2018, 14, e1007216.	3.5	23
1798	Amygdalin Blocks Bladder Cancer Cell Growth In Vitro by Diminishing Cyclin A and cdk2. <i>PLoS ONE</i> , 2014, 9, e105590.	2.5	64



#	ARTICLE	IF	CITATIONS
1799	Molecular Analysis of Upper Tract and Bladder Urothelial Carcinoma: Results from a Microarray Comparison. PLoS ONE, 2015, 10, e0137141.	2.5	36
1800	Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer. PLoS ONE, 2016, 11, e0149756.	2.5	66
1801	Clinicopathological and Prognostic Value of Ki-67 Expression in Bladder Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0158891.	2.5	57
1802	Protein Profiling of Bladder Urothelial Cell Carcinoma. PLoS ONE, 2016, 11, e0161922.	2.5	9
1803	Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples. PLoS ONE, 2016, 11, e0165109.	2.5	18
1804	Genomic Landscape of Experimental Bladder Cancer in Rodents and Its Application to Human Bladder Cancer: Gene Amplification and Potential Overexpression of Cyp2a5/CYP2A6 Are Associated with the Invasive Phenotype. PLoS ONE, 2016, 11, e0167374.	2.5	6
1805	A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable. PLoS ONE, 2017, 12, e0174039.	2.5	7
1806	Immunohistochemical subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis. PLoS ONE, 2017, 12, e0179602.	2.5	24
1807	Copy number gains at chr3p25 and chr11p11 are associated with lymph node involvement and survival in muscle-invasive bladder tumors. PLoS ONE, 2017, 12, e0187975.	2.5	4
1808	The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site. Histology and Histopathology, 2015, 30, 503-21.	0.7	26
1809	Piceatannol inhibits proliferation and induces apoptosis of bladder cancer cells through regulation of the PTEN/AKT signal pathway. Cellular and Molecular Biology, 2020, 66, 181-184.	0.9	2
1810	Small RNAs inhibit bladder cancer by up-regulating tumor suppressor genes. RNA & Disease (Houston,) Tj ETQq1 1 0.784314 1gBT /Over	1.0	1
1811	Sulfated polysaccharide of Sepiella maindroni ink targets Akt and overcomes resistance to the FGFR inhibitor AZD4547 in bladder cancer. Aging, 2019, 11, 7780-7795.	3.1	4
1812	Nucleotide excision repair (NER) alterations as evolving biomarkers and therapeutic targets in epithelial cancers. Oncoscience, 2015, 2, 942-943.	2.2	14
1813	Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion. Oncotarget, 2016, 7, 51626-51639.	1.8	8
1814	Foxp3 enhances HIF-1 $\alpha$ target gene expression in human bladder cancer through decreasing its ubiquitin-proteasomal degradation. Oncotarget, 2016, 7, 65403-65417.	1.8	12
1815	Roles of SPARC in urothelial carcinogenesis, progression and metastasis. Oncotarget, 2016, 7, 67574-67585.	1.8	14
1816	Positive association of collagen type I with non-muscle invasive bladder cancer progression. Oncotarget, 2016, 7, 82609-82619.	1.8	58

#	ARTICLE	IF	CITATIONS
1817	Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup. <i>Oncotarget</i> , 2016, 7, 71429-71439.	1.8	23
1818	RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation. <i>Oncotarget</i> , 2016, 7, 69159-69172.	1.8	23
1819	Prognostic value of vascular mimicry in patients with urothelial carcinoma of the bladder after radical cystectomy. <i>Oncotarget</i> , 2016, 7, 76214-76223.	1.8	5
1820	MCM10 overexpression implicates adverse prognosis in urothelial carcinoma. <i>Oncotarget</i> , 2016, 7, 77777-77792.	1.8	34
1821	DDR2 overexpression in urothelial carcinoma indicates an unfavorable prognosis: a large cohort study. <i>Oncotarget</i> , 2016, 7, 78918-78931.	1.8	11
1822	Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts. <i>Oncotarget</i> , 2016, 7, 76374-76389.	1.8	32
1823	Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. <i>Oncotarget</i> , 2016, 7, 80164-80174.	1.8	40
1824	E-cadherin downregulation sensitizes PTEN-mutant tumors to PI3K <sup>Î²</sup> silencing. <i>Oncotarget</i> , 2016, 7, 84054-84071.	1.8	10
1825	High throughput estimation of functional cell activities reveals disease mechanisms and predicts relevant clinical outcomes. <i>Oncotarget</i> , 2017, 8, 5160-5178.	1.8	66
1826	Opposing roles of <i>PIK3CA</i> gene alterations to EZH2 signaling in non-muscle invasive bladder cancer. <i>Oncotarget</i> , 2017, 8, 10531-10542.	1.8	11
1827	Increased lncRNA ABHD11-AS1 represses the malignant phenotypes of bladder cancer. <i>Oncotarget</i> , 2017, 8, 28176-28186.	1.8	42
1828	MicroRNAs in biofluids are novel tools for bladder cancer screening. <i>Oncotarget</i> , 2017, 8, 32370-32379.	1.8	43
1829	Identification of long non-coding RNAs that stimulate cell survival in bladder cancer. <i>Oncotarget</i> , 2017, 8, 34442-34452.	1.8	12
1830	HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts. <i>Oncotarget</i> , 2017, 8, 48905-48914.	1.8	35
1831	Synthetic lethal interaction between the tumour suppressor <i>STAG2</i> and its paralog <i>STAG1</i> . <i>Oncotarget</i> , 2017, 8, 37619-37632.	1.8	61
1832	Insights from animal models of bladder cancer: recent advances, challenges, and opportunities. <i>Oncotarget</i> , 2017, 8, 57766-57781.	1.8	45
1833	Increased expression of long non-coding RNA CCEPR is associated with poor prognosis and promotes tumorigenesis in urothelial bladder carcinoma. <i>Oncotarget</i> , 2017, 8, 44326-44334.	1.8	19
1834	Environment and bladder cancer: molecular analysis by interaction networks. <i>Oncotarget</i> , 2017, 8, 65240-65252.	1.8	39

#	ARTICLE	IF	CITATIONS
1835	Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies. <i>Oncotarget</i> , 2017, 8, 67684-67695.	1.8	16
1836	Human papillomavirus dysregulates the cellular apparatus controlling the methylation status of H3K27 in different human cancers to consistently alter gene expression regardless of tissue of origin. <i>Oncotarget</i> , 2017, 8, 72564-72576.	1.8	24
1837	Long non-coding RNA HNF1A-AS1 promotes proliferation and suppresses apoptosis of bladder cancer cells through upregulating Bcl-2. <i>Oncotarget</i> , 2017, 8, 76656-76665.	1.8	39
1838	Inflammatory microenvironment in the initiation and progression of bladder cancer. <i>Oncotarget</i> , 2017, 8, 93279-93294.	1.8	61
1839	HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells. <i>Oncotarget</i> , 2017, 8, 110016-110028.	1.8	17
1840	Suppression of FGFR3- and MYC-dependent oncogenesis by tubacin: association with HDAC6-dependent and independent activities. <i>Oncotarget</i> , 2018, 9, 3172-3187.	1.8	5
1841	Potential therapeutic targets of <i>TP53</i> gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer. <i>Oncotarget</i> , 2018, 9, 16234-16247.	1.8	24
1842	Acquired resistance to temsirolimus is associated with integrin $\alpha 7$ driven chemotactic activity of renal cell carcinoma <i>in vitro</i> . <i>Oncotarget</i> , 2018, 9, 18747-18759.	1.8	3
1843	microRNA profiles in urine by next-generation sequencing can stratify bladder cancer subtypes. <i>Oncotarget</i> , 2018, 9, 20658-20669.	1.8	63
1844	“Two hits - one stone” increased efficacy of cisplatin-based therapies by targeting PCNA’s role in both DNA repair and cellular signaling. <i>Oncotarget</i> , 2018, 9, 32448-32465.	1.8	35
1845	Dual targeting of HSP70 does not induce the heat shock response and synergistically reduces cell viability in muscle invasive bladder cancer. <i>Oncotarget</i> , 2018, 9, 32702-32717.	1.8	17
1846	Targeting Hsp90 in urothelial carcinoma. <i>Oncotarget</i> , 2015, 6, 8454-8473.	1.8	31
1847	MicroRNA-155 promotes bladder cancer growth by repressing the tumor suppressor DMTF1. <i>Oncotarget</i> , 2015, 6, 16043-16058.	1.8	48
1848	Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. <i>Oncotarget</i> , 2015, 6, 21522-21532.	1.8	39
1849	Degradation of the cancer genomic DNA deaminase APOBEC3B by SIV Vif. <i>Oncotarget</i> , 2015, 6, 39969-39979.	1.8	17
1850	Combined inhibition of heat shock proteins 90 and 70 leads to simultaneous degradation of the oncogenic signaling proteins involved in muscle invasive bladder cancer. <i>Oncotarget</i> , 2015, 6, 39821-39838.	1.8	22
1851	Beyond proliferation: KLF5 promotes angiogenesis of bladder cancer through directly regulating VEGFA transcription. <i>Oncotarget</i> , 2015, 6, 43791-43805.	1.8	53
1852	MEF2 transcription factors: developmental regulators and emerging cancer genes. <i>Oncotarget</i> , 2016, 7, 2297-2312.	1.8	132

#	ARTICLE	IF	CITATIONS
1853	Novel variants in <i>MLL</i> confer to bladder cancer recurrence identified by whole-exome sequencing. <i>Oncotarget</i> , 2016, 7, 2629-2645.	1.8	25
1854	Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition <i>via</i> LSD1 targeting. <i>Oncotarget</i> , 2016, 7, 17616-17630.	1.8	62
1855	The essential role of methylthioadenosine phosphorylase in prostate cancer. <i>Oncotarget</i> , 2016, 7, 14380-14393.	1.8	29
1856	Mapping of deletion breakpoints at the <i>CDKN2A</i> locus in melanoma: detection of <i>MTAP-ANRIL</i> fusion transcripts. <i>Oncotarget</i> , 2016, 7, 16490-16504.	1.8	22
1857	The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation. <i>Oncotarget</i> , 2016, 7, 21618-21630.	1.8	26
1858	Identification of extracellular vesicle-borne periostin as a feature of muscle-invasive bladder cancer. <i>Oncotarget</i> , 2016, 7, 23335-23345.	1.8	45
1859	Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 26374-26387.	1.8	18
1860	Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma. <i>Oncotarget</i> , 2016, 7, 52442-52449.	1.8	6
1861	Suppression of progranulin expression inhibits bladder cancer growth and sensitizes cancer cells to cisplatin. <i>Oncotarget</i> , 2016, 7, 39980-39995.	1.8	26
1862	Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells. <i>Oncotarget</i> , 2016, 7, 40362-40376.	1.8	50
1863	Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurrence and prognostic significance. <i>Oncotarget</i> , 2016, 7, 39293-39301.	1.8	45
1864	Alterations of DNA damage repair in cancer: from mechanisms to applications. <i>Annals of Translational Medicine</i> , 2020, 8, 1685-1685.	1.7	44
1865	Ezh2-dependent therapies in bladder cancer: synthetic lethality. <i>Annals of Translational Medicine</i> , 2017, 5, 494-494.	1.7	3
1866	Emerging biomarkers and targeted therapies in urothelial carcinoma. <i>Annals of Translational Medicine</i> , 2018, 6, 250-250.	1.7	33
1867	High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer. <i>Translational Andrology and Urology</i> , 2018, 7, S738-S740.	1.4	4
1868	Perioperative immunotherapy for muscle-invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2020, 9, 2976-2985.	1.4	5
1869	UroSEEK gene panel for bladder cancer surveillance. <i>Translational Andrology and Urology</i> , 2019, 8, S546-S549.	1.4	6
1870	Tumor heterogeneity in muscle-invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2020, 9, 2866-2880.	1.4	11

#	ARTICLE	IF	CITATIONS
1871	Perioperative immunotherapy in muscle-invasive bladder cancer. Translational Cancer Research, 2020, 9, 6546-6553.	1.0	8
1872	A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer. SSRN Electronic Journal, 0, , .	0.4	9
1873	Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications. Current Drug Targets, 2019, 20, 852-870.	2.1	19
1874	In Vitro and In Vivo Antimetastatic Effects of ZSTK474 on Prostate Cancer DU145 Cells. Current Cancer Drug Targets, 2019, 19, 321-329.	1.6	7
1875	Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer. Current Topics in Medicinal Chemistry, 2020, 20, 1535-1563.	2.1	22
1876	The Genomic Alterations of 5 $\alpha$ -Reductases and Their Inhibitor Finasteride's Effect in Bladder Cancer. Anticancer Research, 2017, 37, 6893-6898.	1.1	14
1877	Bladder-sparing treatment in MIBC: where do we stand?. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 101-112.	3.9	17
1878	Mediator kinase module and human tumorigenesis. Critical Reviews in Biochemistry and Molecular Biology, 2015, 50, 393-426.	5.2	88
1879	Mutational Analysis of Field Cancerization in Bladder Cancer. Bladder Cancer, 2020, 6, 253-264.	0.4	12
1880	Genomic Landscape of Young-Onset Bladder Cancer and Its Prognostic Implications on Adult Bladder Cancer. Cancers, 2020, 12, 307.	3.7	3
1881	Immune Checkpoint Inhibitors in Uro-Oncology: Urgent Call for Biomarkers. Cancers, 2020, 12, 2768.	3.7	2
1882	Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?. Cancers, 2015, 7, 1925-1958.	3.7	51
1883	ITIHS and ECRG4 DNA Methylation Biomarker Test (EI-BLA) for Urine-Based Non-Invasive Detection of Bladder Cancer. International Journal of Molecular Sciences, 2020, 21, 1117.	4.1	18
1885	Ki-67 Expression as a Predictive Factor of Muscle Invasion in Bladder Cancer. Open Access Macedonian Journal of Medical Sciences, 2018, 6, 260-262.	0.2	5
1886	Functional network analysis of gene's phenotype connectivity based on pioglitazone. Experimental and Therapeutic Medicine, 2019, 18, 4790-4798.	1.8	1
1887	Distinct expression and prognostic value of OTU domain-containing proteins in non-small cell lung cancer. Oncology Letters, 2019, 18, 5417-5427.	1.8	16
1888	Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options. Korean Journal of Internal Medicine, 2020, 35, 834-853.	1.7	10
1889	Molecular subtyping bladder cancer: Is it ready for clinical practice?. Turkish Journal of Medical Sciences, 2020, 50, 1677-1678.	0.9	4

#	ARTICLE	IF	CITATIONS
1890	MiR-608 rs4919510 C&Atilde%>â&Atilde%G polymorphism increased the risk of bladder cancer in an Iranian population. AIMS Genetics, 2016, 03, 212-218.	1.9	5
1891	Genomic-Glycosylation Aberrations in Tumor Initiation, Progression and Management. AIMS Medical Science, 2016, 3, 386-416.	0.4	3
1892	Understanding the molecular pathogenesis and prognostics of bladder cancer: an overview. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 92-8.	2.2	23
1893	Bacille-Calmette-Guerin non-responders: how to manage. Translational Andrology and Urology, 2015, 4, 244-53.	1.4	5
1894	Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer. Translational Andrology and Urology, 2015, 4, 273-82.	1.4	4
1895	Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise. Indian Journal of Urology, 2015, 31, 273.	0.6	19
1896	Bladder cancer: Micro RNAs as biomolecules for prognostication and surveillance. Indian Journal of Urology, 2017, 33, 127.	0.6	13
1897	Systemic therapy in bladder cancer. Indian Journal of Urology, 2017, 33, 118.	0.6	9
1898	Holistic cancer genome profiling for every patient. Swiss Medical Weekly, 2020, 150, w20158.	1.6	5
1899	PICOT promotes T lymphocyte proliferation by down-regulating cyclin D2 expression. World Journal of Immunology, 2020, 10, 1-12.	0.5	2
1900	Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 329-354.	4.9	383
1901	Integration of Immunotherapy Into the Treatment of Advanced Urothelial Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 355-361.	4.9	8
1902	Epigenetic regulation of mammalian Hedgehog signaling to the stroma determines the molecular subtype of bladder cancer. ELife, 2019, 8, .	6.0	19
1903	Transcriptional control of subtype switching ensures adaptation and growth of pancreatic cancer. ELife, 2019, 8, .	6.0	66
1904	A pan-cancer analysis of prognostic genes. PeerJ, 2015, 3, e1499.	2.0	32
1905	Prioritisation of structural variant calls in cancer genomes. PeerJ, 2017, 5, e3166.	2.0	17
1906	Tumor-infiltrating CD8+ lymphocytes predict different clinical outcomes in organ- and non-organ-confined urothelial carcinoma of the bladder following radical cystectomy. PeerJ, 2017, 5, e3921.	2.0	11
1907	Characterization of bidirectional gene pairs in The Cancer Genome Atlas (TCGA) dataset. PeerJ, 2019, 7, e7107.	2.0	8

#	ARTICLE	IF	CITATIONS
1908	Significance of TP53 mutation in bladder cancer disease progression and drug selection. PeerJ, 2019, 7, e8261.	2.0	30
1909	The effect of S427F mutation on RXR $\alpha$ activity depends on its dimeric partner. Chemical Science, 2021, 12, 14700-14710.	7.4	2
1910	Development of a radiomic signature for predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Canadian Urological Association Journal, 2021, 16, .	0.6	1
1911	Current status of organoid culture in urological malignancy. International Journal of Urology, 2021, , .	1.0	3
1912	Urothelial cancer organoids: a tool for bladder cancer research. Der Pathologe, 2021, 42, 165-169.	1.6	2
1913	Pparg signaling controls bladder cancer subtype and immune exclusion. Nature Communications, 2021, 12, 6160.	12.8	28
1914	KDM6A mutations promote acute cytoplasmic DNA release, DNA damage response and mitosis defects. BMC Molecular and Cell Biology, 2021, 22, 54.	2.0	5
1915	Association Between Estrogen Receptors and GATA3 in Bladder Cancer: A Systematic Review and Meta-Analysis of Their Clinicopathological Significance. Frontiers in Endocrinology, 2021, 12, 684140.	3.5	4
1916	Differences in genomic profile of high-grade urothelial carcinoma according to tumor location. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 109.e1-109.e9.	1.6	2
1917	Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer. Journal of Pathology, 2022, 256, 108-118.	4.5	12
1918	Tumor Heterogeneity and Consequences for Bladder Cancer Treatment. Cancers, 2021, 13, 5297.	3.7	13
1919	Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer. Scientific Reports, 2021, 11, 21186.	3.3	12
1920	Comparative Cancer Cell Signaling in Muscle-Invasive Urothelial Carcinoma of the Bladder in Dogs and Humans. Biomedicines, 2021, 9, 1472.	3.2	7
1921	Emerging biomarkers in metastatic urothelial carcinoma: tumour mutational burden, PD-L1 expression and APOBEC polypeptide-like signature in a patient with complete response to anti-programmed cell death protein-1 inhibitor. Ecancermedicalscience, 2021, 15, 1306.	1.1	2
1924	Genetic and Epigenetic Alterations in Urothelial Carcinoma. , 2015, , 253-259.		0
1933	Systemic Treatment for Metastatic Bladder Cancer. Korean Journal of Medicine, 2015, 89, 515-521.	0.3	0
1934	Urinary Bladder. , 2016, , 1681-1735.		0
1935	Urothelial Carcinoma. , 2016, , 8-148-8-153.		0



#	ARTICLE	IF	CITATIONS
1936	Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?. Journal of Research in Pharmacy Practice, 2016, 5, 227.	0.7	0
1940	Targeted Therapies and ImmunotherapyImmunotherapy in bladder cancer in Bladder Cancer. , 2017, , 111-122.		0
1941	Urethra. , 2017, , 353-361.		0
1942	Urothelial Carcinoma. , 2017, , 4741-4747.		0
1943	Bladder. , 2017, , 321-336.		0
1944	Systemic Therapy for Bladder Cancer. , 2017, , 103-109.		0
1945	Molecular Carcinogenesis of Urinary Bladder Cancer. , 2017, , 191-205.		0
1954	Identification of FGFR3-TACC3 gene fusion in metastatic gastric cancer. Precision and Future Medicine, 2017, 1, 168-172.	1.6	2
1956	APOBEC3B Signature Mutations Benefit BK Polyomavirus. SSRN Electronic Journal, 0, , .	0.4	0
1958	Clinical, morphological and molecular genetic prognostic factors for survival rates in non-muscle-invasive bladder cancer. Onkologiya Zhurnal Imeni P A Gertsena, 2018, 7, 49.	0.2	2
1959	INO80 Chromatin Remodelling Coordinates Metabolic Homeostasis with Cell Division. SSRN Electronic Journal, 0, , .	0.4	0
1960	Developments in the area of bladder cancer genomics and its importance in the treatment selection. , 2018, 02, .		2
1965	INFLUENCE OF P16 GENE METHYLATION ON THE RISK OF PROGRESSION OF NON-MUSCLE INVASIVE BLADDER CANCER. , 2018, 62, 322-328.	0.1	0
1967	ASSESSMENT OF A PROGNOSTIC VALUE OF CDKN2A AND TIMP3 GENE METHYLATION IN BLADDER CANCER. Proceedings of the National Academy of Sciences of Belarus, Medical Series, 2018, 15, 263-275.	0.1	0
1971	Transcriptomics within the Exposome Paradigm. , 2019, , 183-214.		1
1972	Molecular Pathology of Genitourinary Cancers: Translating the Cancer Genome to the Clinic. , 2019, , 419-443.		0
1973	Epidemiology, Etiology, and Histopathology. , 2019, , 3-7.		0
1974	Profiling MicroRNA Markers in Plasma: Looking into Better Approaches and Recommendations. Methods in Molecular Biology, 2019, 2054, 93-103.	0.9	1

#	ARTICLE	IF	CITATIONS
1976	Notch signaling pathway: dual role in tumour progression and therapeutic opportunities for bladder cancer. <i>Onkourologiya</i> , 2019, 15, 108-116.	0.3	0
1978	A retrospective analysis of the correlation between AXL expression and clinical outcomes of patients with urothelial bladder carcinoma. <i>Translational Cancer Research</i> , 2019, 8, 976-984.	1.0	0
1980	Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A. <i>Oncotarget</i> , 2019, 10, 5168-5180.	1.8	7
1982	Tumor Sequencing: Enabling Personalized Targeted Treatments with Informatics. <i>Computers in Health Care</i> , 2020, , 161-174.	0.3	0
1983	Surgical Management for Transitional Cell Carcinoma of theÂUpper Tract. , 2020, , 325-343.		0
1985	Molekulare Grundlagen der Karzinogenese und molekularbiologische Untersuchungsmethoden. <i>Springer Reference Medizin</i> , 2020, , 1-20.	0.0	0
1986	The bladder cancer: the risk factors and prognostic markers. <i>Klinichna Khirurgiia</i> , 2019, 86, 78-84.	0.2	1
1988	MappingÂthe Radiogenome of Human Cancers. <i>Cancer Drug Discovery and Development</i> , 2020, , 35-61.	0.4	0
1989	Pathogenicity of BK virus on the urinary system. <i>Central European Journal of Urology</i> , 2020, 73, 94-103.	0.3	12
1992	MOLECULAR SUBTYPES OF MUSCULAR INVASIVE BLADDER CANCER. <i>Proceedings of the Shevchenko Scientific Society Medical Sciences</i> , 2020, 59, .	0.3	0
1993	Molecular subtypes of a bladder cancer: evolution of classifications and clinical significance. <i>Klinichna Khirurgiia</i> , 2020, 87, 92-99.	0.2	0
1994	GENOMICS OF BLADDER CANCER. <i>Fiziologichnyi Zhurnal (Kiev, Ukraine)</i> , 1994, 2020, 66, 83-92.	0.6	0
1996	Identification of potential therapeutic targets in urothelial bladder carcinoma of Chinese population by targeted next-generation sequencing. <i>Cancer Biology and Therapy</i> , 2020, 21, 709-716.	3.4	6
1997	Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 412-417.	0.4	1
2000	Assembling a network to promote translational bladder cancer research in Canada. <i>Canadian Urological Association Journal</i> , 2020, 14, E475-E481.	0.6	1
2001	The Tumor Microenvironment of Bladder Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1296, 275-290.	1.6	18
2002	Urethral Carcinoma. , 2020, , 395-399.		0
2003	Proteomic profiling of bladder cancer for precision medicine in the clinical setting: A review for the busy urologist. <i>Investigative and Clinical Urology</i> , 2020, 61, 539.	2.0	3

#	ARTICLE	IF	CITATIONS
2005	Molecular pathology of urothelial carcinoma: prognostic and predictive biomarkers. Practical Oncology, 2020, 2, 2-10.	0.1	2
2006	Developing Biomarkers and New Therapeutic Targets in Muscle Invasive Bladder Cancer. The Korean Journal of Urological Oncology, 2020, 18, 1-10.	0.1	1
2008	Molecular subtypes of bladder cancer and first success in personalized treatment. Onkourologiya, 2020, 16, 106-113.	0.3	1
2009	DNA Methylation Profiling: An Emerging Paradigm for Cancer Diagnosis. Annual Review of Pathology: Mechanisms of Disease, 2022, 17, 295-321.	22.4	83
2010	Expression Analysis and Mutational Status of Histone Methyltransferase KMT2D at Different Upper Tract Urothelial Carcinoma Locations. Journal of Personalized Medicine, 2021, 11, 1147.	2.5	1
2011	Differential Gene Expression in Bladder Tumors from Workers Occupationally Exposed to Arylamines. BioMed Research International, 2021, 2021, 1-7.	1.9	3
2012	Proteomics as a Complementary Technique to Characterize Bladder Cancer. Cancers, 2021, 13, 5537.	3.7	4
2013	Semantic Segmentation of Urinary Bladder Cancer Masses from CT Images: A Transfer Learning Approach. Biology, 2021, 10, 1134.	2.8	6
2014	Systematic Pan-Cancer Characterization of Nuclear Receptors Identifies Potential Cancer Biomarkers and Therapeutic Targets. Cancer Research, 2022, 82, 46-59.	0.9	3
2016	Bladder Pathology. , 2021, , 87-115.		0
2017	MEK is a promising target in the basal subtype of bladder cancer. Oncotarget, 2020, 11, 3921-3932.	1.8	2
2021	Urinary-Based Markers for Bladder Cancer Detection. Soci��t�� Internationale D'urologie Journal, 2020, 1, 49-61.	0.4	3
2022	Dysregulated Expression of Long Intergenic Non-coding RNAs (LincRNAs) in Urothelial Bladder Carcinoma. International Journal of Molecular and Cellular Medicine, 2017, 6, 212-221.	1.1	10
2023	Prognostic significance of mucin expression in urothelial bladder cancer. International Journal of Clinical and Experimental Pathology, 2014, 7, 4945-58.	0.5	16
2024	Biomarkers for bladder cancer management: present and future. American Journal of Clinical and Experimental Urology, 2014, 2, 1-14.	0.4	36
2025	Expression and function of SIRT6 in muscle invasive urothelial carcinoma of the bladder. International Journal of Clinical and Experimental Pathology, 2014, 7, 6504-13.	0.5	10
2026	Will the 40-gene expression classifier predict responders to EGFR targeted chemotherapy for the invasive bladder cancer patients?. Annals of Translational Medicine, 2015, 3, 18.	1.7	0
2027	Clinicopathologic and prognostic significance of p21 (Cip1/Waf1) expression in bladder cancer. International Journal of Clinical and Experimental Pathology, 2015, 8, 4999-5007.	0.5	17

#	ARTICLE	IF	CITATIONS
2029	Papillary urothelial carcinoma with squamous differentiation in association with human papilloma virus: case report and literature review. American Journal of Clinical and Experimental Urology, 2016, 4, 12-6.	0.4	3
2030	Rs401681 polymorphism in TERT-CLPTM1L was associated with bladder cancer risk: A meta-analysis. Iranian Journal of Basic Medical Sciences, 2015, 18, 1130-6.	1.0	1
2031	ONE-CLASS DETECTION OF CELL STATES IN TUMOR SUBTYPES. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2016, 21, 405-16.	0.7	38
2032	Androgen receptor expands the population of cancer stem cells in upper urinary tract urothelial cell carcinoma cells. American Journal of Cancer Research, 2016, 6, 238-48.	1.4	4
2033	Androgen receptor facilitates the recruitment of macrophages in tumor microenvironment to promote upper urinary tract urothelial cell carcinoma progression. American Journal of Cancer Research, 2016, 6, 1922-1934.	1.4	0
2035	Deep Learning data integration for better risk stratification models of bladder cancer. AMIA Summits on Translational Science Proceedings, 2018, 2017, 197-206.	0.4	18
2036	2018 CUA Abstracts. Canadian Urological Association Journal, 2018, 12, S51-S136.	0.6	0
2037	Genomics of adult and pediatric solid tumors. American Journal of Cancer Research, 2018, 8, 1356-1386.	1.4	14
2038	From genome to phenome: Predicting multiple cancer phenotypes based on somatic genomic alterations via the genomic impact transformer. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2020, 25, 79-90.	0.7	7
2039	Improving survival prediction using a novel feature selection and feature reduction framework based on the integration of clinical and molecular data. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2020, 25, 415-426.	0.7	2
2040	Identification and validation of an immune-related gene-based prognostic index for bladder cancer. American Journal of Translational Research (discontinued), 2020, 12, 5188-5204.	0.0	6
2041	Identification of a tumor microenvironment-associated prognostic gene signature in bladder cancer by integrated bioinformatic analysis. International Journal of Clinical and Experimental Pathology, 2021, 14, 551-566.	0.5	1
2042	Expression of Spred2 in the urothelial tumorigenesis of the urinary bladder. PLoS ONE, 2021, 16, e0254289.	2.5	2
2045	Intratumoral Heterogeneity Promotes Collective Cancer Invasion through NOTCH1 Variation. Cells, 2021, 10, 3084.	4.1	9
2046	Hypoxic Characteristic Genes Predict Response to Immunotherapy for Urothelial Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 762478.	3.7	8
2047	Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy. Cancer Research and Treatment, 2022, 54, 894-906.	3.0	6
2048	Construction of diagnostic and subtyping models for renal cell carcinoma by genome-wide DNA methylation profiles. Translational Andrology and Urology, 2021, 10, 4161-4172.	1.4	3
2050	Morphological predictors for microsatellite instability in urothelial carcinoma. Diagnostic Pathology, 2021, 16, 106.	2.0	5

#	ARTICLE	IF	CITATIONS
2051	Rearrangement-mediated cis-regulatory alterations in advanced patient tumors reveal interactions with therapy. <i>Cell Reports</i> , 2021, 37, 110023.	6.4	8
2054	Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial). <i>BMC Cancer</i> , 2021, 21, 1292.	2.6	8
2055	Landscape of Immunotherapy in Genitourinary Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 143-192.	1.6	2
2056	Oxidative Stress in Genitourinary Cancer. , 2021, , 1-11.		0
2058	A Pan-Cancer Analysis of Tumor-Infiltrating B Cell Repertoires. <i>Frontiers in Immunology</i> , 2021, 12, 790119.	4.8	7
2060	A genomic mutation spectrum of collecting duct carcinoma in the Chinese population. <i>BMC Medical Genomics</i> , 2022, 15, 1.	1.5	7
2061	Introduction. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	1.6	0
2063	Role of immunotherapy in <i>Bacillus Calmette-Guérin</i> unresponsive: non-muscle invasive bladder cancer. <i>Translational Cancer Research</i> , 2020, 9, 6537-6545.	1.0	5
2064	The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma. <i>Translational Cancer Research</i> , 2020, 9, 6609-6623.	1.0	1
2065	Gene regulatory networks analysis of muscle-invasive bladder cancer subtypes using differential graphical model. <i>BMC Genomics</i> , 2021, 22, 863.	2.8	6
2066	Subcategorization of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens for Predicting Progression. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, , .	2.5	4
2067	Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 497.	2.4	3
2069	Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive review. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1097-1105.	2.5	5
2071	CpG Island Methylator Phenotypeâ€”A Hope for the Future or a Road to Nowhere?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 830.	4.1	8
2072	Evaluation of exosomal non-coding RNAs in cancer using high-throughput sequencing. <i>Journal of Translational Medicine</i> , 2022, 20, 30.	4.4	22
2073	Oxidative Stress in Genitourinary Cancer. , 2022, , 87-97.		0
2074	Applications of artificial intelligence in the diagnosis and prediction of erectile dysfunction: a narrative review. <i>International Journal of Impotence Research</i> , 2023, 35, 95-102.	1.8	4
2075	Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway. <i>Nutrients</i> , 2022, 14, 369.	4.1	4

#	ARTICLE	IF	CITATIONS
2076	Neurofibromin and suppression of tumorigenesis: beyond the GAP. <i>Oncogene</i> , 2022, 41, 1235-1251.	5.9	13
2077	The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives. <i>Cancer Treatment Reviews</i> , 2022, 104, 102351.	7.7	34
2078	Proteomic cellular signatures of kinase inhibitor-induced cardiotoxicity. <i>Scientific Data</i> , 2022, 9, 18.	5.3	2
2079	Canine models of human cancer: Bridging the gap to improve precision medicine. <i>Progress in Molecular Biology and Translational Science</i> , 2022, , 67-99.	1.7	8
2081	Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1133.	4.1	31
2082	Roles and drug development of METTL3 (methyltransferase-like 3) in anti-tumor therapy. <i>European Journal of Medicinal Chemistry</i> , 2022, 230, 114118.	5.5	31
2083	CD47-targeted optical molecular imaging and near-infrared photoimmunotherapy in the detection and treatment of bladder cancer. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 319-330.	4.4	4
2084	Heterozygous loss of Dip2B enhances tumor growth and metastasis by altering immune microenvironment. <i>International Immunopharmacology</i> , 2022, 105, 108559.	3.8	3
2085	Liquid biopsy in bladder tumors. , 2022, , 45-65.		1
2086	Pathogenesis of Urothelial Carcinoma. , 2022, , 1-5.		1
2087	Intravesical delivery of <i>KDM6A</i> mRNA via mucoadhesive nanoparticles inhibits the metastasis of bladder cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	87
2088	Identification and Validation of an Annexin-Related Prognostic Signature and Therapeutic Targets for Bladder Cancer: Integrative Analysis. <i>Biology</i> , 2022, 11, 259.	2.8	7
2089	Discovery of ASP5878: Synthesis and structure-activity relationships of pyrimidine derivatives as pan-FGFRs inhibitors with improved metabolic stability and suppressed hERG channel inhibitory activity. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 59, 116657.	3.0	4
2090	Adjuvant immunotherapy for muscle-invasive urothelial carcinoma of the bladder. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 259-267.	2.4	1
2091	Review of the Bladder Cancer Molecular Classification Proposed: a New Era – New Taxonomy. <i>Acta Clinica Croatica</i> , 2021, 60, 519-524.	0.2	1
2092	Celecoxib Synergistically Enhances MLN4924-Induced Cytotoxicity and EMT Inhibition Via AKT and ERK Pathways in Human Urothelial Carcinoma. <i>Cell Transplantation</i> , 2022, 31, 096368972210779.	2.5	4
2093	Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies. <i>Current Oncology</i> , 2022, 29, 1390-1407.	2.2	11
2094	Early Breast Cancer Evolution by Autosomal Broad Copy Number Alterations. <i>International Journal of Genomics</i> , 2022, 2022, 1-17.	1.6	1

#	ARTICLE	IF	CITATIONS
2095	Detection of Cancer Mutations by Urine Liquid Biopsy as a Potential Tool in the Clinical Management of Bladder Cancer Patients. <i>Cancers</i> , 2022, 14, 969.	3.7	2
2096	Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside. <i>Cells</i> , 2022, 11, 803.	4.1	19
2097	Clinicopathological Review of Micropapillary Urothelial Carcinoma. <i>Current Oncology Reports</i> , 2022, 24, 603.	4.0	3
2098	Identification of the gene expression changes and gene regulatory aspects in ELF3 mutant bladder cancer. <i>Molecular Biology Reports</i> , 2022, 49, 3135-3147.	2.3	3
2099	Role of Chromatin Modifying Complexes and Therapeutic Opportunities in Bladder Cancer. <i>Bladder Cancer</i> , 2022, 8, 101-112.	0.4	4
2100	Circulating tumor cells and cell-free tumor DNA analyses in urothelial cancer using the LiquidBiopsy platform. <i>Current Urology</i> , 2022, Publish Ahead of Print, .	0.6	1
2101	Immune Infiltration in Gastric Cancer Microenvironment and Its Clinical Significance. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 762029.	3.7	10
2102	Two Faces of Nrf2 in Cancer. , 0, , .		0
2103	KIX domain determines a selective tumor-promoting role for EP300 and its vulnerability in small cell lung cancer. <i>Science Advances</i> , 2022, 8, eabl4618.	10.3	15
2104	Bacillus Calmette-Guérin Treatment Changes the Tumor Microenvironment of Non-Muscle-Invasive Bladder Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 842182.	2.8	2
2105	Comprehensive Analysis of the Carcinogenic Process, Tumor Microenvironment, and Drug Response in HPV-Positive Cancers. <i>Frontiers in Oncology</i> , 2022, 12, 842060.	2.8	5
2106	PARP inhibitors chemopotentialize and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth. <i>BMC Cancer</i> , 2022, 22, 312.	2.6	3
2107	The multifaceted roles of cohesin in cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 96.	8.6	11
2108	Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy. <i>Cancers</i> , 2022, 14, 1555.	3.7	18
2109	Molecular classification of patients with NMIBC predicts the efficacy of intravesical chemotherapy with pirarubicin, pharmorubicin and gemcitabine-immunohistochemistry-based classification. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 642-649.	1.3	2
2110	The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Cancers</i> , 2022, 14, 1640.	3.7	3
2111	SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021). <i>Clinical and Translational Oncology</i> , 2022, 24, 613-624.	2.4	8
2112	Development and Validation of Ferroptosis-Related LncRNA Biomarker in Bladder Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 809747.	3.7	5



#	ARTICLE	IF	CITATIONS
2113	Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific region. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, .	1.1	5
2114	Comparative Analysis of Differentially Mutated Genes in Non-Muscle and Muscle-Invasive Bladder Cancer in the Chinese Population by Whole Exome Sequencing. <i>Frontiers in Genetics</i> , 2022, 13, 831146.	2.3	5
2115	Anatomic position determines oncogenic specificity in melanoma. <i>Nature</i> , 2022, 604, 354-361.	27.8	44
2117	Conflicting Roles of ZFP36L1 in Regulating the Progression of Muscle Invasive Bladder Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 687786.	3.5	0
2118	Molecular Subtypes as a Basis for Stratified Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer—A Narrative Review. <i>Cancers</i> , 2022, 14, 1692.	3.7	8
2119	New Directions and Challenges in Targeted Therapies of Advanced Bladder Cancer: The Role of FGFR Inhibitors. <i>Cancers</i> , 2022, 14, 1416.	3.7	7
2120	Combined miRNA and SERS urine liquid biopsy for the point-of-care diagnosis and molecular stratification of bladder cancer. <i>Molecular Medicine</i> , 2022, 28, 39.	4.4	26
2121	Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer. <i>Cancers</i> , 2022, 14, 1795.	3.7	15
2123	Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain <i>FGFR</i> genetic alterations. <i>Future Oncology</i> , 2022, 18, 2455-2464.	2.4	4
2124	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. <i>Nature Communications</i> , 2022, 13, 1878.	12.8	3
2125	Arid1a regulates bladder urothelium formation and maintenance. <i>Developmental Biology</i> , 2022, 485, 61-69.	2.0	5
2126	Improving the role of immune checkpoint inhibitors in the management of advanced urothelial carcinoma, where do we stand?. <i>Translational Oncology</i> , 2022, 19, 101387.	3.7	2
2127	Therapeutic targeting m6A-guided miR-146a-5p signaling contributes to the melittin-induced selective suppression of bladder cancer. <i>Cancer Letters</i> , 2022, 534, 215615.	7.2	29
2128	The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis. <i>Translational Oncology</i> , 2022, 20, 101375.	3.7	15
2129	The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 629-635.	1.0	8
2130	Overexpression of the PPAR $\gamma$ 3 protein in primary Ta/T1 non-muscle-invasive urothelial carcinoma. <i>Molecular and Clinical Oncology</i> , 2021, 16, 36.	1.0	2
2131	Immune Signature-Based Risk Stratification and Prediction of Immunotherapy Efficacy for Bladder Urothelial Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 673918.	3.5	2
2132	Identification of Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer by Fourier-Transform Infrared Micro-Imaging. <i>Cancers</i> , 2022, 14, 21.	3.7	0

#	ARTICLE	IF	CITATIONS
2133	Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 689076.	4.8	21
2135	PKM2 Is Essential for Bladder Cancer Growth and Maintenance. <i>Cancer Research</i> , 2022, 82, 571-585.	0.9	24
2136	Classification of bladder cancer cell lines according to regulon activity. <i>Turkish Journal of Biology</i> , 2021, 45, 656-666.	0.8	3
2137	Immunohistochemical Assays for Bladder Cancer Molecular Subtyping: Optimizing Parsimony and Performance of Lund Taxonomy Classifiers. <i>Journal of Histochemistry and Cytochemistry</i> , 2022, 70, 357-375.	2.5	5
2138	Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4173.	4.1	40
2139	Loss of PBRM1 Alters Promoter Histone Modifications and Activates ALDH1A1 to Drive Renal Cell Carcinoma. <i>Molecular Cancer Research</i> , 2022, 20, 1193-1207.	3.4	7
2140	Tumor microenvironment-aware, single-transcriptome prediction of microsatellite instability in colorectal cancer using meta-analysis. <i>Scientific Reports</i> , 2022, 12, 6283.	3.3	5
2141	New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine?. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103682.	4.4	5
2167	A functional genomic approach to actionable gene fusions for precision oncology. <i>Science Advances</i> , 2022, 8, eabm2382.	10.3	9
2168	A Preclinical Study to Repurpose Spironolactone for Enhancing Chemotherapy Response in Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 786-798.	4.1	3
2170	Identification of hub genes and pathways in bladder cancer using bioinformatics analysis.. <i>American Journal of Clinical and Experimental Urology</i> , 2022, 10, 13-24.	0.4	0
2171	Patient-derived organoids as a model for tumor research. <i>Progress in Molecular Biology and Translational Science</i> , 2022, , 259-326.	1.7	2
2172	Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial. <i>Cancers</i> , 2022, 14, 2275.	3.7	0
2173	Genomics and Immunomics in the Treatment of Urothelial Carcinoma. <i>Current Oncology</i> , 2022, 29, 3499-3518.	2.2	6
2174	New Prognostic Gene Signature and Immune Escape Mechanisms of Bladder Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	3.7	3
2175	Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?. <i>Cells</i> , 2022, 11, 1614.	4.1	1
2176	Androgen Receptor Expression Is a Predictor of Poor Outcome in Urothelial Carcinoma. <i>Frontiers in Urology</i> , 2022, 2, .	0.5	1
2177	Cytokeratin 5/6 expression in pT1 bladder cancer predicts intravesical recurrence in patients treated with bacillus Calmetteâ€GuÃ©rin instillation. <i>Pathology</i> , 2022, 54, 700-706.	0.6	0

#	ARTICLE	IF	CITATIONS
2178	Urinary Markers for Bladder Cancer Diagnosis and Monitoring. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 892067.	3.7	8
2179	Benchmarking weakly-supervised deep learning pipelines for whole slide classification in computational pathology. <i>Medical Image Analysis</i> , 2022, 79, 102474.	11.6	64
2180	Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5154.	4.1	5
2181	Wnt/ $\beta$ 2-Catenin Signalling and Its Cofactor BCL9L Have an Oncogenic Effect in Bladder Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5319.	4.1	4
2182	PD-L1 Expression in Bladder Cancer and Correlation with Tumor Grade, Stage and Outcome. <i>Oman Medical Journal</i> , 0, , .	1.0	1
2183	Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways. <i>Nature Communications</i> , 2022, 13, 2669.	12.8	78
2184	Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab.. <i>Cold Spring Harbor Molecular Case Studies</i> , 2022, 8, .	1.0	6
2185	Non-muscle-invasive bladder cancer with metastasis to cervical lymph nodes without local recurrence or progression: A case report. <i>Asian Journal of Surgery</i> , 2022, , .	0.4	0
2186	Molecular Diagnostic and Prognostication Assays for the Subtyping of Urinary Bladder Cancer Are on the Way to Illuminating Our Vision. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5620.	4.1	0
2187	<sc>PD&#x2D;L1</sc> expression and <sc>FGFR</sc>â&#x2013;mutations among Danish patients diagnosed with metastatic urothelial carcinoma: A retrospective and descriptive study. <i>Apmis</i> , 2022, 130, 498-506.	2.0	2
2188	A novel strategy for treatment of bladder cancer: Antibody-drug conjugates. <i>Investigative and Clinical Urology</i> , 2022, 63, 373.	2.0	5
2189	Emerging treatment landscape of non-muscle invasive bladder cancer. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 717-734.	3.1	8
2190	Validation of a Liquid Biopsy Protocol for Canine BRAFV595E Variant Detection in Dog Urine and Its Evaluation as a Diagnostic Test Complementary to Cytology. <i>Frontiers in Veterinary Science</i> , 0, 9, .	2.2	1
2191	Molecular Oncology of Bladder Cancer from Inception to Modern Perspective. <i>Cancers</i> , 2022, 14, 2578.	3.7	9
2192	HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature. <i>Current Oncology</i> , 2022, 29, 3748-3758.	2.2	7
2193	Uroplakin II as a single marker for luminal versus basal molecular subtypes in muscle invasive urothelial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 397-403.	2.8	2
2194	Can Oncogenic Driver Alterations be Responsible for the Lack of Immunotherapy Efficacy in First-line Advanced Urothelial Carcinoma?. <i>European Urology</i> , 2023, 83, 1-2.	1.9	1
2195	Overexpression of long intergenic noncoding RNAs in bladder cancer: A new insight to cancer diagnosis. <i>Pathology Research and Practice</i> , 2022, 235, 153961.	2.3	1

#	ARTICLE	IF	CITATIONS
2198	A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an <i>in situ</i> vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial. <i>Future Oncology</i> , 2022, 18, 2771-2781.	2.4	2
2199	Precursors of urinary bladder cancer: molecular alterations and biomarkers. <i>Human Pathology</i> , 2023, 133, 5-21.	2.0	2
2200	PTIP-Associated Protein 1: More Than a Component of the MLL3/4 Complex. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	1
2201	Implications of Chromatin Modifier Mutations in Epigenetic Regulation of Bladder Cancer. , 0, , 45-60.		1
2202	High Expression of a Cancer Stemness-Related Gene, Chromobox 8 (CBX8), in Normal Tissue Adjacent to the Tumor (NAT) Is Associated with Poor Prognosis of Colorectal Cancer Patients. <i>Cells</i> , 2022, 11, 1852.	4.1	0
2203	Histone H3K36me2 demethylase KDM2A promotes bladder cancer progression through epigenetically silencing RARRES3. <i>Cell Death and Disease</i> , 2022, 13, .	6.3	10
2204	The CDK1/TFCP2L1/ID2 cascade offers a novel combination therapy strategy in a preclinical model of bladder cancer. <i>Experimental and Molecular Medicine</i> , 2022, 54, 801-811.	7.7	11
2205	Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. <i>JCO Precision Oncology</i> , 2022, , .	3.0	6
2206	Recurrent exon-deleting activating mutations in AHR act as drivers of urinary tract cancer. <i>Scientific Reports</i> , 2022, 12, .	3.3	2
2208	The origin of bladder cancer from mucosal field effects. <i>IScience</i> , 2022, 25, 104551.	4.1	12
2209	A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188751.	7.4	1
2210	Therapeutic significance of ARID1A mutation in bladder cancer. <i>Neoplasia</i> , 2022, 31, 100814.	5.3	7
2211	Clinical implications and practical considerations for poly-ADP-ribose polymerase inhibitors as a new horizon for the management of urothelial carcinoma of the bladder. <i>Investigative and Clinical Urology</i> , 2022, 63, 369.	2.0	1
2212	Neurexophilin 4 is a prognostic biomarker correlated with immune infiltration in bladder cancer. <i>Bioengineered</i> , 2022, 13, 13986-13999.	3.2	6
2213	Alternative splicing patterns reveal prognostic indicator in muscle-invasive bladder cancer. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	1.9	2
2214	Characterization of novel small non-coding RNAs and their modifications in bladder cancer using an updated small RNA-seq workflow. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	3
2215	Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene Assessment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7898.	4.1	5
2216	Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7819.	4.1	7

#	ARTICLE	IF	CITATIONS
2217	<scp>FOXP4</scp> inhibits squamous differentiation of atypical cells in cervical intraepithelial neoplasia via an <scp>ELF3</scp>-dependent pathway. <i>Cancer Science</i> , 2022, 113, 3376-3389.	3.9	4
2218	ANXA10 Expression Is Inversely Associated with Tumor Stage, Grade, and TP53 Expression in Upper and Lower Urothelial Carcinoma. <i>Pathobiology</i> , 2023, 90, 94-103.	3.8	4
2219	Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7844.	4.1	3
2220	Mechanism of Sex Differences in Bladder Cancer: Evident and Elusive Sex-biasing Factors. <i>Bladder Cancer</i> , 2022, 8, 241-254.	0.4	5
2221	A Diagnostic Gene Expression Signature for Bladder Cancer Can Stratify Cases into Prescribed Molecular Subtypes and Predict Outcome. <i>Diagnostics</i> , 2022, 12, 1801.	2.6	2
2222	Whole-exome sequencing identified mutational profiles of urothelial carcinoma post kidney transplantation. <i>Journal of Translational Medicine</i> , 2022, 20, .	4.4	2
2223	Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: A review on therapeutic implications. <i>International Journal of Biological Macromolecules</i> , 2022, 218, 394-408.	7.5	13
2224	Pozotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer. <i>Cancer Research</i> , 2022, 82, 2928-2939.	0.9	7
2225	Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	7
2226	Aristolochic acid-associated cancers: a public health risk in need of global action. <i>Nature Reviews Cancer</i> , 2022, 22, 576-591.	28.4	23
2227	Radiotherapy in Metastatic Urothelial Carcinoma: Rationale and Clinical Applications. <i>Anticancer Research</i> , 2022, 42, 3767-3778.	1.1	4
2228	Integrative Multi-Omics Analysis for the Determination of Non-Muscle Invasive vs. Muscle Invasive Bladder Cancer: A Pilot Study. <i>Current Oncology</i> , 2022, 29, 5442-5456.	2.2	5
2229	The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors. <i>European Urology</i> , 2022, 82, 469-482.	1.9	71
2230	Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. <i>Biomedicines</i> , 2022, 10, 2005.	3.2	0
2231	Risk Stratification for Breast Cancer Patient by Simultaneous Learning of Molecular Subtype and Survival Outcome Using Genetic Algorithm-Based Gene Set Selection. <i>Cancers</i> , 2022, 14, 4120.	3.7	0
2232	The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma. <i>British Journal of Clinical Pharmacology</i> , 0, , .	2.4	1
2233	Prognostic Value and Clinical Significance of FGFR Genomic Alterations (GAs) in Metastatic Urothelial Cancer Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 4483.	2.4	5
2234	Genetic, metabolic and immunological features of cancers with <scp>NRF2</scp> addiction. <i>FEBS Letters</i> , 2022, 596, 1981-1993.	2.8	5

#	ARTICLE	IF	CITATIONS
2235	Neoadjuvant therapy for muscle-invasive bladder cancer: Current clinical scenario, future perspectives, and unsolved questions. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 178, 103795.	4.4	5
2236	Prioritizing potential circRNA biomarkers for bladder cancer and bladder urothelial cancer based on an ensemble model. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	0
2237	The research status of adjuvant therapy for non-muscular invasive bladder cancer. <i>AIP Conference Proceedings</i> , 2022, , .	0.4	0
2238	Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492211262.	1.3	6
2239	Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimens. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 538.e15-538.e24.	1.6	1
2240	DNMT3A/miR-129-2-5p/Rac1 Is an Effector Pathway for SNHG1 to Drive Stem-Cell-like and Invasive Behaviors of Advanced Bladder Cancer Cells. <i>Cancers</i> , 2022, 14, 4159.	3.7	4
2241	The Molecular Predictive and Prognostic Biomarkers in Metastatic Breast Cancer: The Contribution of Molecular Profiling. <i>Cancers</i> , 2022, 14, 4203.	3.7	5
2242	Biomarkers in Urological Cancers. , 2022, , 37-76.		0
2243	omicsGAT: Graph Attention Network for Cancer Subtype Analyses. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10220.	4.1	1
2244	Analysis of the Relationship between Bladder Cancer Gene Mutation and Clinical Prognosis by High-Throughput Sequencing. <i>Laboratory Medicine</i> , 2023, 54, 142-152.	1.2	1
2245	Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor. <i>Cell Genomics</i> , 2022, 2, 100179.	6.5	74
2246	Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt-mTOR and Cyclin-CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10996.	4.1	3
2247	Biochemical and structural basis for the pharmacological inhibition of nuclear hormone receptor PPAR $\gamma$ by inverse agonists. <i>Journal of Biological Chemistry</i> , 2022, , 102539.	3.4	2
2248	Identification of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with bladder cancer. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	2
2249	Prognostic significance of HER2 status evaluation using immunohistochemistry in patients with urothelial carcinoma of the bladder: A retrospective single-center experience. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	1.8	2
2250	The evolution of modern notions about bladder cancer. <i>Russian Journal of Oncology</i> , 2022, 26, 57-64.	0.1	0
2251	Novel <sc>NRF2</sc>-activated cancer treatments utilizing synthetic lethality. <i>IUBMB Life</i> , 2022, 74, 1209-1231.	3.4	7
2252	Emerging photodynamic/sonodynamic therapies for urological cancers: progress and challenges. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	9.1	9

#	ARTICLE	IF	CITATIONS
2253	Epistasis and evolutionary dependencies in human cancers. <i>Current Opinion in Genetics and Development</i> , 2022, 77, 101989.	3.3	3
2254	Structural or functional defects of PTEN in urothelial cells lacking P53 drive basal/squamous-subtype muscle-invasive bladder cancer. <i>Cancer Letters</i> , 2022, 550, 215924.	7.2	2
2255	Immunohistochemical expression of AMACR and Cyclin D1 in bladder urothelial carcinoma in correlation to the histopathological characteristics. <i>Egyptian Journal of Pathology</i> , 2021, 41, 175.	0.0	0
2256	TFAP2C Knockdown Sensitizes Bladder Cancer Cells to Cisplatin Treatment via Regulation of EGFR and NF- $\kappa$ B. <i>Cancers</i> , 2022, 14, 4809.	3.7	6
2257	Urinary Comprehensive Genomic Profiling Correlates Urothelial Carcinoma Mutations with Clinical Risk and Efficacy of Intervention. <i>Journal of Clinical Medicine</i> , 2022, 11, 5827.	2.4	6
2258	Development of a Clinically Applicable NanoString-Based Gene Expression Classifier for Muscle-Invasive Bladder Cancer Molecular Stratification. <i>Cancers</i> , 2022, 14, 4911.	3.7	1
2259	Chronic Arsenic Exposure Upregulates the Expression of Basal Transcriptional Factors and Increases Invasiveness of the Non-Muscle Invasive Papillary Bladder Cancer Line RT4. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12313.	4.1	4
2260	Molecular Taxonomy and Immune Checkpoint Therapy in Bladder Cancer. <i>Surgical Pathology Clinics</i> , 2022, 15, 681-694.	1.7	2
2261	Prognostic Signature GXYLT2 Is Correlated with Immune Infiltration in Bladder Cancer. <i>Disease Markers</i> , 2022, 2022, 1-14.	1.3	2
2262	Immune Checkpoint Inhibitors in Urothelial Carcinoma (Literature Review). <i>Kreativna i Hirurgi i Onkologija</i> , 2022, 12, 205-216.	0.3	0
2264	Patient Selection Approaches in FGFR Inhibitor Trials – Many Paths to the Same End?. <i>Cells</i> , 2022, 11, 3180.	4.1	8
2265	Advanced Bladder Cancer: Changing the Treatment Landscape. <i>Journal of Personalized Medicine</i> , 2022, 12, 1745.	2.5	13
2266	LINC00958 Inhibits Autophagy of Bladder Cancer Cells via Sponge Adsorption of miR-625-5p to Promote Tumor Angiogenesis and Oxidative Stress. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-14.	4.0	5
2267	Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT. <i>Health Technology Assessment</i> , 2022, 26, 1-144.	2.8	11
2269	Powerful and interpretable control of false discoveries in two-group differential expression studies. <i>Bioinformatics</i> , 2022, 38, 5214-5221.	4.1	1
2271	The targets of aspirin in bladder cancer: bioinformatics analysis. <i>BMC Urology</i> , 2022, 22, .	1.4	0
2272	Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 211-218.	1.6	3
2273	Cytokeratin 13 (<sc>CK13</sc>) expression in cancer: a tissue microarray study on 10,439 tumors. <i>Apmis</i> , 2023, 131, 77-91.	2.0	3



#	ARTICLE	IF	CITATIONS
2274	Multiregional Sequencing Analysis Reveals Extensive Genetic Heterogeneity in Gastric Tumors from Latinos. Cancer Research Communications, 2022, 2, 1487-1496.	1.7	2
2275	Discovery of novel analogs of KHS101 as transforming acidic coiled coil containing protein 3 (TACC3) inhibitors for the treatment of glioblastoma. European Journal of Medicinal Chemistry, 2022, 244, 114874.	5.5	1
2276	Translational proteomics and phosphoproteomics: Tissue to extracellular vesicles. Advances in Clinical Chemistry, 2023, , 119-153.	3.7	1
2277	Evaluation of molecular signatures in the urinary bladder and upper tract urothelial carcinomas: a prospective controlled clinical study. Journal of the Egyptian National Cancer Institute, 2022, 34, .	1.5	1
2278	The global research of bladder cancer immunotherapy from 2012 to 2021: A bibliometric analysis. Frontiers in Oncology, 0, 12, .	2.8	5
2279	Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer. Frontiers in Immunology, 0, 13, .	4.8	1
2280	Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma. Cancers, 2022, 14, 5431.	3.7	8
2281	Repression of the PRELP gene is relieved by histone deacetylase inhibitors through acetylation of histone H2B lysine 5 in bladder cancer. Clinical Epigenetics, 2022, 14, .	4.1	3
2282	Accurate Characterization of Bladder Cancer Cells with Intraoperative Flow Cytometry. Cancers, 2022, 14, 5440.	3.7	7
2283	Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nature Communications, 2022, 13, .	12.8	14
2284	Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer, 2023, 21, 69-75.	1.9	3
2285	Higher Expression of Annexin A2 in Metastatic Bladder Urothelial Carcinoma Promotes Migration and Invasion. Cancers, 2022, 14, 5664.	3.7	1
2286	The Many Faces of Muscle-Invasive Bladder Cancer: Histopathological and Molecular Characterization. Seminars in Radiation Oncology, 2023, 33, 1-11.	2.2	0
2287	Recent Progress in Urothelial Bladder Carcinoma: Basic Biology, Molecular Characterization, Conventional and Innovative Therapies and Tumour-Stroma Interactions. , 2022, , .		0
2288	PAIP1 is a novel oncogene in human hepatocellular carcinoma. Discover Oncology, 2022, 13, .	2.1	1
2289	TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced Urothelial carcinoma. BMC Cancer, 2022, 22, .	2.6	6
2290	The Somatic Mutation Landscape of UDP-Glycosyltransferase (UGT) Genes in Human Cancers. Cancers, 2022, 14, 5708.	3.7	1
2291	PD-L1 immunoexpression and molecular characterization of histological subtypes in urothelial carcinoma. Revista Espanola De Patologia, 2022, , .	0.2	0

#	ARTICLE	IF	CITATIONS
2292	The coming decade in precision oncology: six riddles. <i>Nature Reviews Cancer</i> , 2023, 23, 43-54.	28.4	52
2293	Therapeutic Landscape Beyond Immunotherapy in Advanced Urothelial Carcinoma: Moving Past the Checkpoint. <i>Drugs</i> , 2022, 82, 1649-1662.	10.9	5
2294	Integrated analysis of racial disparities in genomic architecture identifies a trans-ancestry prognostic subtype in bladder cancer. <i>Molecular Oncology</i> , 2023, 17, 564-581.	4.6	0
2295	Article Review: Biochemical Aspect of Survivin Hormone. , 2022, 1, 1-15.		0
2296	CPPA: A Web Tool for Exploring Proteomic and Phosphoproteomic Data in Cancer. <i>Journal of Proteome Research</i> , 2023, 22, 368-373.	3.7	1
2297	Identification and validation of a novel cuproptosis-related lncRNA gene signature to predict prognosis and immune response in bladder cancer. <i>Discover Oncology</i> , 2022, 13, .	2.1	4
2298	Multimodal Learning for Multi-omics: A Survey. , 2023, 01, .		1
2299	The Roles of miRNAs in Predicting Bladder Cancer Recurrence and Resistance to Treatment. <i>International Journal of Molecular Sciences</i> , 2023, 24, 964.	4.1	2
2300	Complete Response to Sequential Human Epidermal Growth Factor Receptor 2-Targeted Strategies in a Heavily Pretreated Patient With Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Bladder Cancer. <i>JCO Precision Oncology</i> , 2023, , .	3.0	1
2301	Mutational Landscape of Bladder Cancer in Mexican Patients: KMT2D Mutations and chr11q15.5 Amplifications Are Associated with Muscle Invasion. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1092.	4.1	1
2302	Increasing Biomarker Guidance in the Treatment of Urothelial Carcinoma: Systematic Review of International Clinical Trials. <i>Urologia Internationalis</i> , 2023, 107, 480-488.	1.3	2
2303	Influence of luminal and basal subtype in prognosis of high-grade non muscle invasive urothelial carcinoma. <i>Annals of Diagnostic Pathology</i> , 2023, , 152081.	1.3	0
2304	TERT promoter mutations and methylation for telomerase activation in urothelial carcinomas: New mechanistic insights and clinical significance. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
2305	CircHGS enhances the progression of bladder cancer by regulating the miR-513a-5p/VEGFC axis and activating the AKT/mTOR signaling pathway. <i>Cell Cycle</i> , 2023, 22, 919-938.	2.6	3
2306	Multimodal investigation of bladder cancer data based on computed tomography, whole slide imaging, and transcriptomics. <i>Quantitative Imaging in Medicine and Surgery</i> , 2023, 13, 1023-1035.	2.0	3
2307	Identifying Tumor-Associated Genes from Bilayer Networks of DNA Methylation Sites and RNAs. <i>Life</i> , 2023, 13, 76.	2.4	1
2308	Immunohistochemical Study of Bladder Cancer Molecular Subtypes and Their Association with PD-L1 Expression. <i>Cancers</i> , 2023, 15, 188.	3.7	3
2309	Cancer Antigen 125 Expression Enhances the Gemcitabine/Cisplatin-Resistant Tumor Microenvironment in Bladder Cancer. <i>American Journal of Pathology</i> , 2023, 193, 350-361.	3.8	3

#	ARTICLE	IF	CITATIONS
2310	Molecular Subtyping in Muscle-Invasive Bladder Cancer on Predicting Survival and Response of Treatment. <i>Biomedicines</i> , 2023, 11, 69.	3.2	1
2311	Recent advances in high-risk human papillomavirus genotype relationship with bladder cancer tumor genesis. , 2023, , 141-152.		0
2314	Identification and validation of immunohistochemical marker panels to predict the prognosis of muscle invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2023, 12, 176-186.	1.4	1
2315	Expression of epidermal growth factor receptor and human epidermal growth factor receptor 2 in urothelial bladder carcinoma in an Egyptian cohort: Clinical implication and prognostic significance. <i>Urologia</i> , 0, , 039156032211509.	0.7	0
2316	Mint3â€targeted therapy: A novel therapeutic strategy for urothelial carcinoma. <i>Clinical and Translational Discovery</i> , 2023, 3, .	0.5	0
2317	Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients. <i>Npj Precision Oncology</i> , 2023, 7, .	5.4	15
2318	Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival. <i>Diagnostic Pathology</i> , 2023, 18, .	2.0	3
2319	Role of FGFR3 in bladder cancer: Treatment landscape and future challenges. <i>Cancer Treatment Reviews</i> , 2023, 115, 102530.	7.7	37
2320	Significance of RB Loss in Unlocking Phenotypic Plasticity in Advanced Cancers. <i>Molecular Cancer Research</i> , 2023, 21, 497-510.	3.4	4
2322	Acoustic Printing of Patientâ€Derived Organoids That Preserve Tumor Microenvironment for Personalized Drug Screening. <i>Advanced Materials Technologies</i> , 2023, 8, .	5.8	0
2323	Targeted Next-Generation Sequencing of Flat Urothelial Lesions Reveals Putative Pathobiological Pathways, Potential Biomarkers, and Rational Therapeutic Targets. <i>Modern Pathology</i> , 2023, 36, 100120.	5.5	1
2324	Microsatellite Instability: A Review of Molecular Epidemiology and Implications for Immune Checkpoint Inhibitor Therapy. <i>Cancers</i> , 2023, 15, 2288.	3.7	2
2325	Immunotherapy in Genitourinary Cancers: Role of Surgical Pathologist for Detection of Immuno-oncologic Predictive Factors. <i>Advances in Anatomic Pathology</i> , 2023, 30, 203-210.	4.3	0
2326	Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
2327	Recent Advances in the Classification of Bladder Cancer â€“ Updates from the 5th Edition of the World Health Organization Classification of the Urinary and Male Genital Tumors. <i>Bladder Cancer</i> , 2023, 9, 1-14.	0.4	1
2328	Characterization of the tumor-infiltrating immune repertoire in muscle invasive bladder cancer. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
2329	Glucose Metabolism Reprogramming in Bladder Cancer: Hexokinase 2 (HK2) as Prognostic Biomarker and Target for Bladder Cancer Therapy. <i>Cancers</i> , 2023, 15, 982.	3.7	6
2330	FLI1 and FRA1 transcription factors drive the transcriptional regulatory networks characterizing muscle invasive bladder cancer. <i>Communications Biology</i> , 2023, 6, .	4.4	4

#	ARTICLE	IF	CITATIONS
2331	Characteristics and Prognosis of 8p11.23-Amplified Squamous Lung Carcinomas. Journal of Clinical Medicine, 2023, 12, 1711.	2.4	1
2333	Epigenetics in cancer development, diagnosis and therapy. Progress in Molecular Biology and Translational Science, 2023, , 73-92.	1.7	3
2334	Low expression of ZSCAN4 predicts unfavorable outcome in urothelial carcinoma of upper urinary tract and urinary bladder. World Journal of Surgical Oncology, 2023, 21, .	1.9	1
2335	Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer. Journal of the National Cancer Center, 2023, 3, 121-128.	7.4	1
2336	Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma. Expert Opinion on Emerging Drugs, 2023, 28, 17-26.	2.4	0
2337	In vivo detection of circulating tumor cells predicts high-risk features in patients with bladder cancer. , 2023, 40, .		0
2338	FAM193A is a positive regulator of p53 activity. Cell Reports, 2023, 42, 112230.	6.4	2
2339	Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nature Reviews Clinical Oncology, 2023, 20, 287-304.	27.6	34
2340	Kawain Inhibits Urinary Bladder Carcinogenesis through Epigenetic Inhibition of LSD1 and Upregulation of H3K4 Methylation. Biomolecules, 2023, 13, 521.	4.0	2
2341	The Hurdle of Precision Medicine in Cancer Immunotherapy: Personalization Now or Then?. , 2023, , 1-32.		0
2342	A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy. Clinical Cancer Research, 2023, 29, 2052-2065.	7.0	8
2344	Mutations in genes encoding innate immune molecules identified in bladder cancer samples as potential biomarkers for immunotherapy with BCG and agonists. Frontiers in Urology, 0, 3, .	0.5	0
2345	Androgen promotes squamous differentiation of atypical cells in cervical intraepithelial neoplasia via an <sc>ELF3</sc>-dependent pathway. Cancer Medicine, 2023, 12, 10816-10828.	2.8	3
2346	Evidence for virus-mediated oncogenesis in bladder cancers arising in solid organ transplant recipients. ELife, 0, 12, .	6.0	6
2347	Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networks. Oncogene, 2023, 42, 1524-1542.	5.9	5
2348	Circulating and urinary tumour DNA in urothelial carcinoma“ upper tract, lower tract and metastatic disease. Nature Reviews Urology, 2023, 20, 406-419.	3.8	6
2349	Identifying novel biomarkers associated with bladder cancer treatment outcomes. Frontiers in Oncology, 0, 13, .	2.8	5
2350	Risk Classification of Bladder Cancer by Gene Expression and Molecular Subtype. Cancers, 2023, 15, 2149.	3.7	4

#	ARTICLE	IF	CITATIONS
2351	Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
2352	LncRNA Phosphatase and Tensin Homolog Induced Kinase 1-AS Promotes Insulin Like Growth Factor 1 Receptor Expression Through Sponge miR-98-5p and Contributes to Bladder Cancer Progression. <i>Journal of Biomaterials and Tissue Engineering</i> , 2023, 13, 334-341.	0.1	0
2353	The DNA Damage Response and Inflammation in Cancer. <i>Cancer Discovery</i> , 2023, 13, 1521-1545.	9.4	18
2354	Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward. <i>Expert Opinion on Biological Therapy</i> , 2023, 23, 407-418.	3.1	2
2355	Bladder cancer organoids as a functional system to model different disease stages and therapy response. <i>Nature Communications</i> , 2023, 14, .	12.8	11
2356	Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption. <i>PLoS Genetics</i> , 2023, 19, e1010575.	3.5	6
2358	Correlation between fibroblast growth factor receptor mutation, programmed death ligand-1 expression and survival in urinary bladder cancer based on real-world data. <i>Pathology and Oncology Research</i> , 0, 29, .	1.9	1
2359	H3 histone methylation landscape in male urogenital cancers: from molecular mechanisms to epigenetic biomarkers and therapeutic targets. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	3.7	2
2360	Major hurdles to the use of tyrosine kinase inhibitors in clinical prevention/interception studies: Do preclinical studies with EGFR inhibitors suggest approaches to overcome some of the limitations. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	3.7	0
2361	Mutation Hotspots Found in Bladder Cancer Aid Prediction of Carcinogenic Risk in Normal Urothelium. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7852.	4.1	0
2362	Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 8418.	4.1	0
2363	The utilisation of digital droplet <scp>PCR</scp> to enhance the diagnosis of bladder and pancreaticobiliary tumours in cytology specimens. <i>Diagnostic Cytopathology</i> , 0, , .	1.0	0
2364	Anna Karenina principle in personalized treatment of bladder cancer according to oncogram: which drug for which patient?. <i>Personalized Medicine</i> , 0, , .	1.5	0
2365	Inhibiting WEE1 Augments the Antitumor Efficacy of Cisplatin in Urothelial Carcinoma by Enhancing the DNA Damage Process. <i>Cells</i> , 2023, 12, 1471.	4.1	2
2366	Characterization of the metabolic alteration-modulated tumor microenvironment mediated by TP53 mutation and hypoxia. <i>Computers in Biology and Medicine</i> , 2023, 163, 107078.	7.0	7
2367	Epigenetic and Immunological Features of Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 9854.	4.1	1
2368	Cancers du rein et des voies urinaires. , 2023, , 207-209.		0
2369	Transcriptome profiling research in urothelial cell carcinoma. , 0, , .		0

#	ARTICLE	IF	CITATIONS
2370	Large, Nested Variant of Urothelial Carcinoma Is Enriched with Activating Mutations in Fibroblast Growth Factor Receptor-3 among Other Targetable Mutations. <i>Cancers</i> , 2023, 15, 3167.	3.7	0
2371	Knockdown of pyruvate kinase M2 suppresses bladder cancer progression. <i>Oncologie</i> , 2023, 25, 37-50.	0.7	0
2373	Construction and validation of a cuproptosis-related lncRNA prognosis signature in bladder carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 11207-11221.	2.5	0
2374	Physician-reported treatment patterns and outcomes in metastatic bladder cancer in the USA: the CancerMPact <sup>®</sup> Survey 2020. <i>Future Oncology</i> , 2024, 20, 613-622.	2.4	0
2375	Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer. <i>Cancer Discovery</i> , 2023, 13, 1998-2011.	9.4	5
2376	Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18. <i>ESMO Open</i> , 2023, 8, 101588.	4.5	2
2377	Therapeutic responses to chemotherapy or immunotherapy by molecular subtype in bladder cancer patients: A meta-analysis and systematic review. <i>Investigative and Clinical Urology</i> , 2023, 64, 229.	2.0	0
2378	The molecular-morphologic correlates of bladder cancer. <i>Diagnostic Histopathology</i> , 2023, 29, 299-307.	0.4	0
2379	Precision Medicine in Bladder Cancer: Present Challenges and Future Directions. <i>Journal of Personalized Medicine</i> , 2023, 13, 756.	2.5	3
2380	Single-cell RNA sequencing reveals the cellular and molecular characteristics of high-grade and metastatic bladder cancer. <i>Cellular Oncology (Dordrecht)</i> , 2023, 46, 1415-1427.	4.4	2
2381	Cadherins and catenins in cancer: connecting cancer pathways and tumor microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	3.7	1
2382	Accurate Detection of Urothelial Bladder Cancer Using Targeted Deep Sequencing of Urine DNA. <i>Cancers</i> , 2023, 15, 2868.	3.7	2
2384	Deregulated Expression of IL-37 in Patients with Bladder Urothelial Cancer: The Diagnostic Potential of the IL-37e Isoform. <i>International Journal of Molecular Sciences</i> , 2023, 24, 9258.	4.1	2
2385	DriverGenePathway: Identifying driver genes and driver pathways in cancer based on MutSigCV and statistical methods. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 3124-3135.	4.1	0
2386	Upregulation of dihydropyrimidinase-like 3 (DPYSL3) protein predicts poor prognosis in urothelial carcinoma. <i>BMC Cancer</i> , 2023, 23, .	2.6	0
2387	Epigenetic Priming and Development of New Combination Therapy Approaches. <i>Methods in Molecular Biology</i> , 2023, , 259-281.	0.9	1
2388	Using Sister Chromatid Exchange Assay to Detect Homologous Recombination Deficiency in Epigenetically Deregulated Urothelial Carcinoma Cells. <i>Methods in Molecular Biology</i> , 2023, , 133-144.	0.9	0
2389	Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations. <i>JCO Precision Oncology</i> , 2023, , .	3.0	2

#	ARTICLE	IF	CITATIONS
2390	Predictive Biomarkers of Response to Neoadjuvant Therapy in Muscle Invasive Bladder Cancer. <i>Methods in Molecular Biology</i> , 2023, , 229-247.	0.9	0
2391	S100A5 Attenuates Efficiency of Anti-PD-L1/PD-1 Immunotherapy by Inhibiting CD8 <sup>+</sup> T Cell-Mediated Anti-Cancer Immunity in Bladder Carcinoma. <i>Advanced Science</i> , 2023, 10, .	11.2	12
2392	TRAIL-mediated signaling in bladder cancer: realization of clinical efficacy of TRAIL-based therapeutics in medical oncology. , 2023, 40, .		1
2393	Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study). <i>Oncologist</i> , 2023, 28, 790-798.	3.7	1
2394	Cancer-keeper genes as therapeutic targets. <i>IScience</i> , 2023, 26, 107296.	4.1	1
2395	Development and Multicenter Case-Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction. <i>Clinical Cancer Research</i> , 2023, 29, 3668-3680.	7.0	1
2396	Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection. <i>Cancer Prevention Research</i> , 2023, 16, 561-570.	1.5	1
2397	Microtubule Dynamics Deregulation Induces Apoptosis in Human Urothelial Bladder Cancer Cells via a p53-Independent Pathway. <i>Cancers</i> , 2023, 15, 3730.	3.7	1
2399	Cancer Vaccines. , 2023, , 191-210.e9.		0
2400	U-CHANGE Project: a multidimensional consensus on how clinicians, patients and caregivers may approach together the new urothelial cancer scenario. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
2401	Molecular classification of urothelial bladder carcinoma. <i>Molecular Biology Reports</i> , 2023, 50, 7867-7877.	2.3	3
2402	Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma. <i>Current Oncology</i> , 2023, 30, 7398-7411.	2.2	1
2403	Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
2404	Cross-species oncogenomics offers insight into human muscle-invasive bladder cancer. <i>Genome Biology</i> , 2023, 24, .	8.8	2
2405	Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials. <i>Translational Oncology</i> , 2023, 37, 101763.	3.7	1
2406	The sex gap in bladder cancer survival – a missing link in bladder cancer care?. <i>Nature Reviews Urology</i> , 2024, 21, 181-192.	3.8	0
2407	Bioinformatics in urology – molecular characterization of pathophysiology and response to treatment. <i>Nature Reviews Urology</i> , 0, , .	3.8	0
2408	Betapapillomaviruses in p16-Negative Vulvar Intraepithelial Lesions Associated with Squamous Cell Carcinoma. <i>Viruses</i> , 2023, 15, 1950.	3.3	0



#	ARTICLE	IF	CITATIONS
2409	Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia. Asia-Pacific Journal of Clinical Oncology, 0, , .	1.1	0
2410	The APC/C E3 ligase subunit ANAPC11 mediates FOXO3 protein degradation to promote cell proliferation and lymph node metastasis in urothelial bladder cancer. Cell Death and Disease, 2023, 14, .	6.3	0
2411	Loss of Paip1 causes translation reduction and induces apoptotic cell death through ISR activation and Xrp1. Cell Death Discovery, 2023, 9, .	4.7	0
2412	The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer. Scientific Reports, 2023, 13, .	3.3	2
2413	Biomarkers determining treatment tactics in metastatic urothelial cancer. Onkourologiya, 2023, 19, 111-126.	0.3	0
2414	Use of cutting-edge RNA-sequencing technology to identify biomarkers and potential therapeutic targets in canine and feline cancers and other diseases. Journal of Veterinary Science, 2023, 24, .	1.3	0
2415	GPX3 rs8177412 Polymorphism Modifies Risk of Upper Urothelial Tumors in Patients with Balkan Endemic Nephropathy. Medicina (Lithuania), 2023, 59, 1421.	2.0	1
2416	Urothelium-Specific Expression of Mutationally Activated Pik3ca Initiates Early Lesions of Noninvasive Bladder Cancer. American Journal of Pathology, 2023, 193, 2133-2143.	3.8	1
2417	Current and Emerging Strategies to Treat Urothelial Carcinoma. Cancers, 2023, 15, 4886.	3.7	1
2418	Global impact of somatic structural variation on the cancer proteome. Nature Communications, 2023, 14, .	12.8	5
2419	The role of SOD2 and NOS2 genes in the molecular aspect of bladder cancer pathophysiology. Scientific Reports, 2023, 13, .	3.3	0
2422	Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience. Clinical Cancer Research, 2023, 29, 4586-4595.	7.0	3
2423	BK polyomavirus: latency, reactivation, diseases and tumorigenesis. Frontiers in Cellular and Infection Microbiology, 0, 13, .	3.9	0
2424	Sulforaphane and bladder cancer: a potential novel antitumor compound. Frontiers in Pharmacology, 0, 14, .	3.5	0
2425	A glycosylation risk score comprehensively assists the treatment of bladder neoplasm in the real-world cohort, including the tumor microenvironment, molecular and clinical prognosis. Frontiers in Pharmacology, 0, 14, .	3.5	1
2426	Urinary comprehensive genomic profiling predicts urothelial carcinoma recurrence and identifies responders to intravesical therapy. Molecular Oncology, 2024, 18, 291-304.	4.6	0
2428	Invasive urothelial carcinoma with chordoid features or abundant myxoid stroma: A reappraisal of morphologic spectrum and risk stratification based on molecular classification. Pathology Research and Practice, 2023, 251, 154839.	2.3	0
2429	PKMYT1 induced by YAP/TEAD1 gives rise to the progression and worse prognosis of bladder cancer. Molecular Carcinogenesis, 2024, 63, 160-172.	2.7	0

#	ARTICLE	IF	CITATIONS
2430	Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer. European Journal of Cancer, 2023, , 113368.	2.8	0
2431	Pathology and Staging. , 2023, , 79-87.		0
2432	Pathology and Staging. , 2023, , 125-140.		0
2434	Integrative approach for classifying male tumors based on DNA methylation 450K data. Mathematical Biosciences and Engineering, 2023, 20, 19133-19151.	1.9	0
2435	Artificial Intelligence Reveals Distinct Prognostic Subgroups of Muscle-Invasive Bladder Cancer on Histology Images. Cancers, 2023, 15, 4998.	3.7	0
2437	How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma?. Molecular Diagnosis and Therapy, 2024, 28, 37-51.	3.8	1
2438	Ipsilateral synchronous papillary renal neoplasm with reverse polarity and urothelial carcinoma in a renal transplant recipient: a rare case report with molecular analysis and literature review. Diagnostic Pathology, 2023, 18, .	2.0	0
2439	Reconstructing disease dynamics for mechanistic insights and clinical benefit. Nature Communications, 2023, 14, .	12.8	0
2440	The urothelial gene regulatory network: understanding biology to improve bladder cancer management. Oncogene, 2024, 43, 1-21.	5.9	0
2441	Multi-omics analysis reveals critical metabolic regulators in bladder cancer. International Urology and Nephrology, 2024, 56, 923-934.	1.4	0
2442	Rethinking cancer initiation: The role of large-scale mutational events. Genes Chromosomes and Cancer, 2024, 63, .	2.8	0
2443	Molecular Pathology of Urinary Bladder Tumors. , 2023, , 401-422.		0
2445	HER2 overexpression predicts pathological T2 stage and improved survival in de novo muscle-invasive bladder cancer after immediate radical cystectomy: a retrospective cohort study. International Journal of Surgery, 2024, 110, 847-858.	2.7	0
2446	Screening for a practical method to monitor the status of patients with metastatic bladder cancer at the circulating cell-gene level. Scientific Reports, 2023, 13, .	3.3	0
2447	Frequency of next-generation sequencing, prevalence of targetable mutations and response to targeted therapies amongst patients with metastatic urothelial cancer in Ireland: a multi-centre retrospective study of real-world data. Irish Journal of Medical Science, 0, , .	1.5	0
2448	Stem Cell Theory of Cancer: Clinical Implications of Epigenomic versus Genomic Biomarkers in Cancer Care. Cancers, 2023, 15, 5533.	3.7	0
2449	The efficacy and safety of chemotherapy with or without <sc>antiâ€PD</sc>â€1 for the firstâ€line treatment of advanced urothelial carcinoma. Cancer Medicine, 2023, 12, 21129-21137.	2.8	0
2450	Genomic Alterations of Signaling and DNA Damage Repair Pathways in Non-Muscle Invasive Bladder Cancer. Cancer Investigation, 2023, 41, 848-857.	1.3	0

#	ARTICLE	IF	CITATIONS
2451	Central Nervous System Disease Progression Among Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Case Series. Clinical Genitourinary Cancer, 2024, 22, 315-321.	1.9	0
2452	Contemporary Issues in Urothelial Carcinoma of Upper Urinary Tract. Advances in Anatomic Pathology, 2024, 31, 80-87.	4.3	1
2453	<scp>CD271</scp> promotes proliferation and migration in bladderÂcancer. Genes To Cells, 0, , .	1.2	0
2454	Establishment of bladder cancer spheroids and cultured in microfluidic platform for predicting drug response. Bioengineering and Translational Medicine, 2024, 9, .	7.1	0
2455	The Genomic Landscape of Urothelial Carcinoma with High and Low ERBB2 Expression. Cancers, 2023, 15, 5721.	3.7	1
2456	Molecular classification of high-grade, muscle-invasive urothelial carcinomas and the relationship with CTLA-4 and PD-L1 expression. Surgical and Experimental Pathology, 2023, 6, .	0.6	0
2457	Non-Small Cell Lung Carcinoma With Clear Cell Features and FGFR3::TACC3 Gene Rearrangement. American Journal of Surgical Pathology, 2024, 48, 284-291.	3.7	2
2458	Targeted therapies in bladder cancer: signaling pathways, applications, and challenges. MedComm, 2023, 4, .	7.2	0
2459	Novel immunotherapeutic options for BCGâ€unresponsive highâ€risk nonâ€muscleâ€invasive bladder cancer. Cancer Medicine, 2023, 12, 21944-21968.	2.8	2
2460	Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation. British Journal of Cancer, 2024, 130, 369-379.	6.4	1
2461	Gender disparities in clinical outcomes of urothelial carcinoma linked to X chromosome gene<i>KDM6A</i>mutation. , 2023, 2, e000199.		0
2462	Transcriptional state dynamics lead to heterogeneity and adaptive tumor evolution in urothelial bladder carcinoma. Communications Biology, 2023, 6, .	4.4	2
2463	The Potential of Congo Red Supplied Aggregates of Multitargeted Tyrosine Kinase Inhibitor (Sorafenib,) Tj ETQq0 0 0 rgBT /Overlock 10 Sciences, 2024, 25, 269.	4.1	0
2464	Therapeutic importance and diagnostic function of circRNAs in urological cancers: from metastasis to drug resistance. Cancer and Metastasis Reviews, 0, , .	5.9	0
2465	Retinoids and EZH2 inhibitors cooperate to orchestrate anti-oncogenic effects on bladder cancer cells. Cancer Gene Therapy, 2024, 31, 537-551.	4.6	0
2466	Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma. Cancer Research, 2024, 84, 725-740.	0.9	1
2467	Associations of <i>TACSTD2</i></scp>TROP2</scp> and <i>NECTINâ€4</i></scp>NECTIN</scp>â€4 with molecular subtypes, <scp>PDâ€L1</scp> expression, and <i>FGFR3</i> mutational status in two advanced urothelial bladder cancer cohorts. Histopathology, 2024, 84, 863-876.	2.9	0
2468	Shaping the future of men's sexual health: How artificial intelligence can assist in the management and treatment of erectile dysfunction. , 0, , .		0

#	ARTICLE	IF	CITATIONS
2469	FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression. Journal of Clinical Investigation, 2024, 134, .	8.2	1
2471	Precision medicine for urothelial carcinoma: An international perspective. Urologic Oncology: Seminars and Original Investigations, 2024, , .	1.6	0
2472	Multi-omics reveals the role of ENO1 in bladder cancer and constructs an epithelial-related prognostic model to predict prognosis and efficacy. Scientific Reports, 2024, 14, .	3.3	0
2474	Mini-Review: Current Bladder Cancer Treatment—The Need for Improvement. International Journal of Molecular Sciences, 2024, 25, 1557.	4.1	1
2476	Tumour tissue-derived small extracellular vesicles reflect molecular subtypes of bladder cancer. Journal of Extracellular Vesicles, 2024, 13, .	12.2	0
2477	Research Progress of New Urine Markers in the Diagnosis of Bladder Cancer. Annals of Urologic Oncology, 2024, , .	0.1	0
2478	Molecular profile of bladder cancer progression to clinically aggressive subtypes. Nature Reviews Urology, 0, , .	3.8	0
2479	NRF2 Activation in Trp53;p16-deficient Mice Drives Oral Squamous Cell Carcinoma. Cancer Research Communications, 2024, 4, 487-495.	1.7	0
2480	Outcomes of intravesical Bacillus Calmette-Guerin in patients with non-muscle invasive bladder cancer: a retrospective study in Australia. Frontiers in Urology, 0, 4, .	0.5	0
2481	The co-expression of antigen targets as a rationale for ADC combination in urothelial cancer. Annals of Oncology, 2024, 35, 477-478.	1.2	0
2482	The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer. Nature Communications, 2024, 15, .	12.8	0
2483	Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer, 2024, 22, 102054.	1.9	0
2484	The synergism of SMC1A cohesin gene silencing and bevacizumab against colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2024, 43, .	8.6	0
2485	Targeting histone modifiers in bladder cancer therapy — preclinical and clinical evidence. Nature Reviews Urology, 0, , .	3.8	0
2486	TP53 disruptive mutation predicts platinum-based chemotherapy and PD-L1 blockade response in urothelial carcinoma. Journal of Pathology, 0, , .	4.5	0
2487	Integration of CD4 <sup>+</sup> T cells and molecular subtype predicts benefit from PD-L1 blockade in muscle-invasive bladder cancer. Cancer Science, 2024, 115, 1306-1316.	3.9	0
2488	Potential molecular biomarkers for the diagnosis and prognosis of bladder cancer. Biomedicine and Pharmacotherapy, 2024, 173, 116312.	5.6	0
2489	Tumor Predisposing Post-Zygotic Chromosomal Alterations in Bladder Cancer—Insights from Histologically Normal Urothelium. Cancers, 2024, 16, 961.	3.7	0

#	ARTICLE	IF	CITATIONS
2490	MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation. Nature Communications, 2024, 15, .	12.8	0
2491	Role of chromosomal cohesion and separation in aneuploidy and tumorigenesis. Cellular and Molecular Life Sciences, 2024, 81, .	5.4	0
2492	Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer. Cancer Immunology, Immunotherapy, 2024, 73, .	4.2	0
2493	Dual role of <scp>GRHL3</scp> in bladder carcinogenesis depending on histological subtypes. Molecular Oncology, 0, , .	4.6	0
2494	Establishment and validation of nomograms to predict the overall survival and cancer-specific survival for non-metastatic bladder cancer patients: A large population-based cohort study and external validation. Medicine (United States), 2024, 103, e37492.	1.0	0
2495	Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review. International Journal of Molecular Sciences, 2024, 25, 3347.	4.1	0
2496	Glycoprotein nonmetastatic melanoma protein B impacts the malignant potential of bladder cancer cells through its hemâ€immunoreceptor tyrosineâ€based activation motif. Pathology International, 0, , .	1.3	0